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ABSTRACT
The endothelin (ET) family consists of three structurally-related peptides
(ET-1, ET-2 and ET-3) which interact with two populations of receptors
(ETa-R and ETb-R). ETs and their receptors are expressed by a variety of
tissues in which they may be involved in a multiplicity of functions
including regulation of mitogenesis. ETs may also be expressed by cancer
cell lines and may be present in tumours at concentrations much higher
than those in normal tissues. Despite this, the involvement of ETs in
cancer is largely undefined.
The aim of this project was to investigate the potential involvement of
endothelins in the breast and ovarian cancer by (i) measuring the
expression and secretion of endothelin by epithelial and fibroblast cell
lines derived from ovarian and breast cancers, (ii) determining the
expression of specific receptors for endothelins in the same cell lines, (iii)
monitoring the effects of exogenous additions of endothelins on the
growth of the cell lines in culture, (iv) measuring the expression of
endothelins and their receptors in a series of primary ovarian and breast
cancers.
To investigate endothelin production by ovarian and breast carcinoma
and fibroblast cell lines, ET-l-like material was detected by
radioimmunoassay in conditioned media collected from two ovarian
(PE04 and PE014) and three breast carcinoma (MDA-MB-231, T47D, ZR-
75-1) cell lines. Addition of either bombesin or IL-6 to the culture media
increased production of immunoreactive ET from the cell lines. In
contrast, ET-like material was not found in the conditioned media from
three ovarian (PE012F, PE014F, PE027F) and two breast (Sharlow,
Dunbar) human fibroblast cell lines. Expression of mRNA for
endothelins was investigated using RT-PCR analysis, and by this
methodology, mRNA for ET-1 and ET-3 were detected in ovarian and
breast carcinoma cell lines. Hybridisation of the RT-PCR products with
specific oligonucleotides designed for each ET confirmed their nature.
This suggests that the major source of ET in breast and ovarian tumours
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is from the epithelial cells rather than the stromal compartment.
Immunohistochemical staining of ovarian and breast tumours with an
antibody specific for ET-1 indicated the presence of the protein in these
tumours. RT-PCR analysis demonstrated not only the presence of ET-1
but also ET-3 mRNA.
ET receptors were measured using a ligand binding assay and expression
of ET receptor mRNA was detected by RT-PCR. Binding studies using
125I-ET-1 failed to indicate the presence of specific ET receptors in breast
epithelial cancer cell lines but ET receptors were detected in the two
ovarian carcinoma cell lines. Scatchard analysis indicated the presence of
two binding sites in one ovarian carcinoma cell line (PE04) and a single
binding site in another line (PE014). Competition experiments using 125I-
ET-1 in the presence of increasing concentrations of ET-1, ET-3, an ETa-R
antagonist (BQ123) and an ETb-R antagonist (BQ788) indicated the
expression of specific receptor subtypes in the carcinoma and fibroblast
lines. RT-PCR analysis detecting mRNA for ETa-R and ETb-R receptor
subtypes provided further identification of the receptor subtypes.
The growth of breast carcinoma cell lines was unaffected by the exogenous
addition of ETs while ET-1 and ET-2 but not ET-3 addition stimulated the
growth of ovarian carcinoma cells. Exogenous addition of ET-1, ET-2 and
ET-3 stimulated the growth of both ovarian and breast fibroblast cell lines.
The antagonists BQ123 (ETa-R antagonist) and BQ788 (ETb-R antagonist)
inhibited ET-stimulated growth in a manner consistent with the receptor
subtypes present in each cell line. In the absence of exogenous ET, the
antagonists produced small inhibitory effects of growth in the ovarian
carcinoma cell lines. This may be caused by the antagonism of ETs
secreted by the same cells and could be consistent with autocrine
stimulation of growth by endothelins.
Co-culture of epithelial and fibroblast cells produced increased growth of
both cell types relative to that when individual cell types were cultured
separately. This indication, that increased growth could be blocked by
addition of ET antagonists, suggests possible paracrine regulation of
iv
growth by ETs.
These results support the view that endothelins may affect the growth of
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The scope of this study was to investigate the potential role of
endothelins in breast and ovarian cancer. The first two section of this
introductory chapter are concerned with general features of ovarian and
breast cancer. In the third section, the latest information about the
structures and biology of endothelins and their receptors is reviewed and
what is known so far of their roles in ovarian and breast cancer. Finally,
at the end of the chapter, the main aims of this study are described.
1.2 Ovarian cancer
1.2.1 Introduction/epidemiology
Ovarian cancer is a major gynaecological disease being the fifth most
common cause of cancer in women. On average one woman in 70 will
develop ovarian cancer and almost one in 100 will die from the disease.
Ovarian cancer is most common in women of age 70-80 years of age and
very rare in women under 45 years of age. The five year survival rate is
low at approximately 30% due to the generally advanced stage of disease
at diagnosis.
1.2.2 Origins of ovarian cancer
Ovarian cancer presents in a variety of histologically different forms the
existence of which can be explained by the range of epithelial tissue types.
The latter are generated during embryological development and reflect
the physiology of the ovaries (Young et al., 1992). Thus, neoplasms may
originate from the epithelial cells of the surface of the ovaries, the germ
cells or the stroma of the ovary (Serov and Scully 1973). Epithelial
ovarian carcinomas represent more than 90% of the malignant
neoplasms of the ovaries. Histological studies have suggested that these
types of neoplasms show close resemblance to the Miillerian epithelium
which during development has formed the fallopian tubes, the uterine
body and the uterine cervix, which are lined with distinctive epithelia.
The differentiated epithelium of serous tumours is similar to the
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epithelium of the fallopian tubes; that of mucinous tumours similar to
the endocervical epithelium and that of endometroid and clear cell
tumours, similar to the epithelia of the endometrium. The extent of
progression of this disease can be detected by surgery. Thus, the stage of
the disease is defined by the extent of the spread which is reported at
laparotomy (the stages of the disease as defined by the International
federation of gynaecology and obstetrics (FIGO, 1988, Rio de Janeiro) are
shown on table 1.1).
Stage Definition
I Growth limited to the ovaries
IA Growth limited to the ovary; no ascites; no tumour on the external
surface; capsule intact
IB Growth limited to both ovaries; no ascites; no tumour on the
external surfaces; capsule intact
IC* Tumour either stage la or lb, but with tumour on surface of
one or both ovaries; or with capsule ruptured; or with ascites
present containing malignant cells or with positive peritoneal washings
II Growth involving one or both ovaries with pelvic extension
IIA Extension and/or metastasis to the uterus and/or tubes
IIB Extension to other pelvic tissues
IIC* Tumour either stage Ila or lib but with tumour on surface of
one or both ovaries; or with capsule(s) ruptured; or with
ascites present containing malignant cells or with positive
peritoneal washings
III Tumour involving one or both ovaries with peritoneal implants outside the
pelvis and/or positive retroperitoneal or inguinal nodes; superficial liver
metastases; tumour is limited to the true pelvis but with histologically
proven malignant extension to small bowel or omentum
IIIA Tumour grossly limited to the true pelvis with negative
nodes but with histologically confirmed microscopic seeding of abdominal
peritoneal surfaces
IIIB Tumour involving one or both ovaries with histologically
confirmed implants of abdominal peritoneal surfaces none
exceeding 2 cm in diameter; nodes are negative
IIIC Abdominal implants greater than 2 cm in diameter and/or
positive retroperitoneal or inguinal nodes
IV Growth involving one or both ovaries with distant
metastases. If pleural effusion present, there must be positive cytology to
assign a case to Stage IV; parenchymal liver metastasis
* To assess the impact on prognosis of the different criteria for assigning cases to Stage IC
or IIC, it would be of value to know whether the source of malignant cells was (I)
peritoneal washings, or (ii) ascites, and whether rupture of the capsule was spontaneous or
caused by the surgeon
Table 1.1: FIGO stages for primary carcinoma of the ovary (International Federation of
Gynaecology and Obstetrics 1988, Rio de Janeiro).
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1.2.3 Aetiology/risk factors
More than 90% of ovarian cancer patients have no family history of the
disease, suggesting no major familial determinant in the majority of
cases. Therefore, most cases are likely to arise as a result of spontaneous
or environmentally induced carcinogenesis. Some risk factors associated
with the disease are presented here.
i) Environmental factors
A strong geographical variation of the disease has been observed. In
general industrialised or "Westernised" countries have a higher
incidence than other countries (Parazzini et al., 1991). Interestingly,
immigrants from a country of low incidence (Japan) to a country of high
incidence (USA) and especially second generation immigrants show
levels of incidence comparable to those found in their new country (USA)
(Herrinton et al., 1994).
ii) Hereditary factors
The ovarian cancer cases which are thought to be caused by clearly
defined hereditary factors account only for a small percentage of the cases.
Women with one first degree relative with ovarian cancer have a 5%
increase in risk while women with 2 first degree relatives suffering from
the disease have a 7% increase in risk . However, women with defined
genetic syndromes run a 40-50% level of risk for developing the disease
(Narod., 1994). These syndromes, can be (a) hereditary syndromes, where
patients appear with bilateral and multifocal tumours (b) hereditary
breast/ovarian cancer, where patients develop breast and ovarian cancer
and in which tumour suppressor genes such as BRCA1 seem to be
involved in these cancers, (c) hereditary site-specific ovarian cancer, and
(d) Lynch syndrome II , which are characterised by the association of
hereditary colorectal cancer with endometrial, ovarian, gastrointestinal or
breast cancer (Lynch et al., 1985,1993).
ill) Reproductive factors
About 10-20% of ovarian cancer patients respond to anti-oestrogens and
about 36% to progestins. In post-menopausal women, PR positivity is
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associated with well differentiated ovarian tumours while most
endometroid tumours contain relatively high amounts of PR. PR content
in tumours has been linked with prognosis but there is not complete
agreement on these results. ER levels have also been investigated in
tumours and the evidence that they might be linked with prognosis of
the disease is conflicting. The aetiology of ovarian cancer can be related to
the endocrine hormonal system. Fathala (1971) proposed the 'Incessant
ovulation" theory, according to which repeated ovulatory cycles drive the
ovarian cancer surface epithelium to repeated proliferative repair cycles
which might cause genetic damage and lead to ovarian cancer. Factors
which reduce the number of ovulatory cycles also seem to decrease the
levels of risk. For example, nulliparous women have an increased risk of
ovarian cancer compared to women with children. Lactation seems to
decrease the risk even further. Women with early menarche or late
menopause have an increased risk of ovarian cancer. Women who
undergo fertility treatment with gonadotrophins and stimulants of the
pituitary gonadotrophins, also have an increased risk for developing
ovarian and endometrial cancer. On the other hand the use of oral
contraceptives seems to decrease the rate of risk of the disease by 30-60%
and the effect seems to last for a number of years after the use of the drug
has been stopped (Ron et al., 1987; Whittemore et al., 1992, 1993; Spirtas et
al., 1993; Rossing et al., 1994).
iv) Dietary factors
One of the strongest risk factors concerning diet is the consumption of
saturated fat. Every 10 g of saturated fat consumption increases the risk of
ovarian cancer by 20% while consumption of the same amount of
vegetable fibre reduces the risk by 37% (Risch et al., 1994). Although no
relation has been demonstrated between oestrogen ingestion and
increased ovarian cancer risk a considerable amount of oestrogen and
related compounds are present in saturated animal fat as well as a
number of different products associated with "Westernised" societies in
the form of preservatives, and other ingredients (Risch et al., 1994;
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Adlercreutz et al., 1994). Other dietary factors such as consumption of
coffee, alcohol and fish have been associated with increased risk but
experimental data have not proven strong (Whittemore et al., 1988; Byers
et al., 1983).
1.2.4 Prognosis
Extent of disease spread at the time of diagnosis is the most powerful
prognostic factor in ovarian cancer (Griffiths et al., 1975). Because of the
extremely health threatening nature of the disease when diagnosed at a
late stage, there is an increased need for better prognostic factors. One
example of a biological factor, which has already been correlated with
survival, is the level of CA-125 protein in serum (Sevelda et al., 1989).
CA-125 is a glycoprotein expressed by a number of different epithelia,
including mullerian derived epithelia. CA-125 is expressed at higher
levels in almost 80% of ovarian cancers. The fall of CA-125 levels after
therapy, correlates well with the response of the patient to treatment.




In order to establish diagnosis and evaluate the stage of ovarian cancer
accurately, surgery must be undertaken. Surgery is the standard
treatment for stage I disease with removal of the tumour, the uterus
(hysterectomy), the fallopian tubes and contralateral ovary (bilateral
salpingo-oophorectomy). In about 50% of cases in more advanced stages,
surgery is necessary for the patients comfort, and wherever possible,
cytoreduction of the tumour is performed. This is because (i) maximum
possible tumour size reduction increases chances of responding to
adjuvant therapy and (ii) during the progression of the disease there is
increasing tumour growth in the peritoneal cavity which can lead to the
development of intestinal obstructions. In such cases surgical removal of
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these obstructions can provide comfort for the patients. Most accurate
assessment of the response to any therapy, is by repeated laparotomy.
ii) Radiotherapy
Radiotherapy remains a controversial method of treatment. Because of
the complicated spread of the disease, effective radiotherapy must cover
the entire abdominal cavity. However, such practice is limited because of
the sensitivity of the surrounding organs (liver, kidneys) to radiation.
Radiotherapy is used mainly for cases with poor prognostic features and
in patients at a more advanced stage of the disease.
iii) Chemotherapy
Cytotoxic chemotherapy is now commonly used in patients with
advanced disease as first line adjuvant therapy. Combination
chemotherapy improves the 5 year survival of this disease by 20%
(Omura et al., 1986). Most of the standard chemotherapeutic treatments
consist of platinum containing compounds with alkylating agents. A
number of possible new chemotherapeutic agents have been discovered
and are already in clinical trials. Some of these new agents are members
of the family of Taxans. Taxans are natural and semi-synthetic
diterpenoids based on the structure of the natural productTaxo/ which
was first isolated from the western yew tree in 1971. The use of such
compounds alone or in combination with cisplatin have shown
promising results in clinical trials (Einzig et al., 1992; Thigpen et al., 1994).
1.2.6 Growth regulation of ovarian cancer
i) Hormones
Oestrogen can stimulate growth of ovarian cancer cell lines which express
oestrogen receptor (ER) at levels between 20 and 30 fmol/mg of protein
(Langdon et al., 1990; Chien et al., 1994) while such an effect is not seen in
cell lines expressing lower ER levels (Langdon et al., 1990, 1994). It has
also been shown that oestrogens induce a number of other factors which
are thought to play a role in growth of normal and tumour cells. In ER
positive ovarian cancers 17fi-oestradiol (E2) has been shown to
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downregulate ER and EGF receptor content and to increase the levels of
TGF-a mRNA and the secretion of procathepsin D (Nash et al., 1989;
Galtier-Dereure et al., 1992; Crew et al., 1992; Rowlands et al., 1993).
Addition of anti-oestrogens to ER positive cell lines can block the effect of
E2 on the growth of these cells and tamoxifen can be effective in ER
positive ovarian primary tumours (Lazo et al., 1984; Nash et al., 1989;
Langdon et al., 1990,1992).
ii) Growth factors
A number of studies using ovarian cancer cell lines and xenografts, have
suggested possible involvement of several growth factors in the
development of ovarian cancer. Epidermal growth factor (EGF) has been
most extensively studied. This growth factor demonstrates considerable
similarity with transforming growth factor-a, (TGF-a) amphiregulin and
cripto. Studies in ovarian tumours and ovarian cancer cell lines have
demonstrated the presence of EGF and TGF-a (30 to 70% and 50 to 100% of
cases respectively) (Morishige et al., 1991; Kohler et al., 1992; Stromberg et
al., 1994). Exogenous addition of these two growth factors in ovarian
cancer cell lines in vitro demonstrated their ability to exert mitogenic
effects (Scambia et al ., 1991; Zhou and Lenng 1992; Crew et al., 1994)
through binding and activation of the same receptor, the EGF receptor
(EGFR). EGFR is a 170 kD glycosylated transmembrane protein, present in
33 to 70% of ovarian cancers (Morishige et al., 1991; Henzen-Logmans et
al., 1992). Investigations in ovarian carcinoma cell lines have confirmed
the presence of EGFR and secretion of EGF and TGF-a suggesting a
possible autocrine control of growth (Kurachi et al., 1991; Jindal et al.,
1994). EGF receptor levels may relate to poor prognosis in ovarian cancer
(Bataglia et al., 1989; Owens et al., 1991). The EGF receptor (also known as
c-erbB-1) has similarities with the c-erbB-2, c-erbB-3 and c-erbB-4 receptors.
C-erbB-2 and c-erbB-3 proteins are overexpressed in ovarian tumours (20 -
30% and 89% respectively) and their overexpression associated with poor
survival (c-erbB-2) or with borderline and early invasive lesions (c-erbB-
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3) (Slamon et al., 1989; Berchuck et al., 1990; Simpson et al., 1995). TGF-6
peptides (TGF-61, TGF-62 and TGF-63) exert growth inhibitory effects in
normal ovarian epithelial cultures, ovarian cancer cultures and almost
50% of ovarian carcinoma cell lines (Berchuck et al., 1990, 1992; Marth et
al., 1990; Bartlett et al., 1992;). The proposed role for TGF-fi peptides is that
of controlling the growth of normal ovarian epithelium and such control
might be lost at an early stage of malignant transformation in the ovary
(Havrilesky et al., 1995). Insulin-like growth factors I and II (IGF-I, IGF-II)
are, as the name implies, structurally related to insulin. Both IGFs and
their receptors (insulin receptor, IGF receptors) have been identified in
ovarian cancer cell lines (Yee et al., 1991; Bartlett et al., 1995) and ovarian
tumours (Foekens et al., 1990; Beck et al., 1994) Exogenous addition of
IGFs to the same cell lines may stimulate growth suggesting a possible
autocrine control of growth (Resnicoff et al., 1993). Other growth factors
such as fibroblast growth factor (FGF) and platelet derived growth factor
(PDGF) and their receptors are also expressed in ovarian tumours and are
associated with effects on the surrounding stromal components (Sariban
et al., 1988; Versnel et al., 1994; Di Blassio et al., 1993; Crickard et al., 1994).
iii) Cytokines
Cytokines families include the interleukins, interferons and tumour
necrosis factor (TNF). Cytokines are believed to regulate the growth of
many tumours, as well as being able to regulate oestrogen and growth
factor effects.
A number of cytokines are thought to be involved in ovarian cancer
pathogenesis. Interleukins 1 a (IL-la) and 16 (IL-16) are both produced by
ovarian cancer cell lines in vitro. IL-la has been shown to stimulate
proliferation of ovarian cancer cells in culture and it is thought to
stimulate the expression of tumour necrosis factor (TNF) (Wu et al.,
1992). Interleukin 6 (IL-6) concentrations are elevated in women with
ovarian cancer (Watson et al., 1990; Berek et al., 1991) and experiments in
which the autocrine IL-6 control system was blocked in ovarian cancer
cell lines, resulted in decreased growth of the ovarian cancer cells
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(Watson et al., 1993). Other cytokines are also thought to be involved in
the inhibition of growth of ovarian cancer cells (IL-4) and in the
inhibition of the cytokines involved in the system (IL-10) (Berek et al.,
1994). TNF is expressed in 70% of ovarian tumours (Naylor et al., 1993)
and addition of recombinant TNF-a to ovarian cancer cell lines has been
shown to stimulate growth and also expression of TNF-a mRNA (Wu et
al., 1992). Interferons (IFN) are members of another family of cytokines
that are thought to be cytotoxic and to inhibit the growth of ovarian
cancer cells (Malik et al., 1991). a-IFN, fi-IFN and y-IFN are already used in
clinical trials and these have shown good activity against minimal
residual disease (Willemse et al., 1990; Cappelli et al., 1992; Colombo et al.,
1992; Markman et al., 1993).
1.2.7 Oncogenes and tumour suppressor genes in ovarian cancer
i) Oncogenes
Mutations in normal cellular genes which control cell growth and
proliferation can produce malignant transformation. Such mutations
may convert normal proto-oncogenes into oncogenes. A number of
oncogenes have been associated with ovarian cancer. The c-myc proto-
oncogene is responsible for the expression of a protein which controls the
proliferation, differentiation and programmed cell death (apoptosis) of
the cell and seems to be overexpressed mainly in serous ovarian cancers
(Yokota et al., 1986; Kikuchi et al., 1994).
Studies have revealed that 20% of ovarian cancers show amplification of
the erbB-2 gene and overexpression of the encoded protein (Slamon et al.,
1989; Berchuck et al., 1990a). Overexpression of K-ras gene is usually
associated with advanced ovarian cancers (Chien and Chiau, 1993; Park et
al., 1995). The extensive study of such oncogenes and their role in normal
and malignant cells could potentially lead to valuable information
regarding the prognosis and/or development of cancer.
ii)Tumour suppressor genes
Tumour suppressor genes are defined as genes involved in the control of
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normal cell growth and whose loss or inactivation is associated with the
development of malignancy. Tumour suppressor genes include the
retinoblastoma (RB-1) gene which is involved in the regulation of
normal cell growth by restricting cell cycle progression into the Gi phase
of the cell cycle (Borg et al., 1992; Bowcock et al., 1990) and the p53 gene
which encodes for p53 protein and is overexpressed as a result of DNA
damage driving the cells to cell cycle arrest at the Gi-S phase or into
apoptosis (Levine et al., 1992; Prives et al., 1993).
A recent study by Zhang et al., (1995) has suggested that p53 mutations
may be found in almost 50% of ovarian cancer cases studied whereas no
mutations in the same gene have been detected in benign tumours. In
the benign regions surrounding the ovarian tumours containing the
alteration of the p53 gene, the same mutation was observed. In many
ovarian tumours the wild type BRCA1 allele appears to be lost either due
to a germ-like mutation or (most commonly in ovarian cancer) through
loss of heterozygosity on 17q chromosome (Eccles et al., 1990; Cornells et
al., 1995; Takahashi et al., 1995). There is a high risk of development of
ovarian cancer in women with BRCA1 gene mutations, this ranging
between 20 and 80% (Easton et al., 1993).
1.3 Breast cancer
1.3.1 Introduction/epidemiology
Breast cancer is the second most common female malignancy, after lung
cancer, in the majority of developed countries and the most common
female malignancy in the UK. It is also the predominant cause of death
for women between the age of 35 and 55 in Western societies. Each year
about 150,000 women are treated for the disease in the UK with 30,000
new cases and over 15,000 deaths, while in the USA it has been estimated
that one woman dies from breast cancer every 13 minutes (Washington
Post, 1990). According to a 1975 estimation, more than 500,000 breast
cancer cases are diagnosed worldwide each year, and clearly still
represents one of the greatest dangers for the health of women (Boyle,
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1988).
1.3.2 Origins of breast cancer
The normal human mammary gland is a secretory organ, which consists
of a number of ductules, separated by fibrous bands of connective and
adipose tissues. The nipple comprises the ending of a branching system
of lactiferous ducts which are formed by the coalescing system of terminal
duct lobular units (TDLU), created by the interfusion of smaller groups of
terminal ductules. The surface of all the duct systems, with the exception
of the lactiferous ducts, is lined by a single epithelial cell layer, and it is
from this layer that most breast cancers develop. During tumourigenesis,
it is thought that epithelial cells proliferate without control, resulting in a
multi-layered epithelium (hyperplasia), and as the disease progresses, the
epithelium becomes even more abnormal (atypical hyperplasia) and
eventually proliferates to fill the spaces. Because at this stage the lesion is
restricted to the lobule and tumour cells have not penetrated the
basement membrane it is referred to as "in situ cancer". Ductal carcinoma
in situ (DCIS) consists of solid malignant cells in the lumen or cribriform
(cells growing into the duct lumen) and is detectable by mammography.
DCIS represents the last step before breast cancer becomes invasive. The
stages of the progression of the disease are summarized in table 1.2 and
involve the breaching of the basement membrane.
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T-Tumour
T1 Tumour 2 cm or less in greatest dimension
T1 a 0.5 cm or less in greater dimension
Tib More than 05 cm but notmore than 1 cm in greatest dimension
Tic More than 1 cm but not more than 2 cm in greatest dimension
T2 Tumourmore than 2 cm but notmore than 5 cm in greatest dimension
T3 Tumourmore than 5 cm in greatest dimension
T4 Tumour of any size with direct extension to chest wall or skin
N- Regional lymph nodes
NX Regional lymph nodes can not be assessed (e.g. Previously removed)
NO No regional lymph nodes metastasis
N1 Metastasis to moveable ipsilateral axillary node(s)
N2 Metastasis to ipsilateral axillary node(s) fixed to one another or to other
structures
N3 Metastasis to ipsilateral internal mammary lymph node(s)
M- Distant metastasis
MX Presence of distant metastasis cannot be assessed
MO No distant metastasis
Ml Distant metastasis (includes metastasis to supraclavicular lymph nodes)
Stage grouping
Stage I I T1 NO MO
Stage IIA TO N1 MO
T1 N1 MO
T2 NO MO
Stage IIB T2 N1 MO
T3 NO MO




Stage IIIB T4 Any N MO
Any T N3 MO
Stage IV Any T Any N Ml
Table 1-2: TNM (tumour, node metastasis classification). Abbreviation from Hermanek P,
Sodin LH (Eds). In: TNM Classification of Malignant Tumors. UICC International Union
Against Cancer. Springer-Verlag Ed. (4th Ed.), Berlin, 1987; 93-99.
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1.3.3 Aetiology/risk factors
A number of factors have been associated with an increased risk of
developing breast cancer disease. These may be summarised in the
following categories:
i) Gender
Breast cancer can affect both men and women. However, the incidence of
breast cancer in women is a hundred times greater than in men
suggesting that gender is an important risk factor.
ii) Environmental factors
The incidence of breast cancer in different geographical regions seems to
vary substantially (Waterhouse 1982; Muir et al., 1987). More
industrialised or "Westernised" countries seem to have significantly
higher incidence (incidence in the USA is 5-fold higher than in Japan)
(Henderson et al., 1993). Populations which have migrated from
countries with low risk to countries with higher risk show increased
incidence with successive generations (Stemmerman et al., 1970; Locke
and King 1980). Substantial regional variations may also be seen within
individual countries.
iii) Ionizing radiation
Ionizing radiation is the only definite cause of breast cancer. Studies have
shown that exposure to high levels of radiation (Nagasaki, Hiroshima)
resulted in increased development of the disease (MacGregor et al., 1977).
iv) Hereditary factors
Only 7% of the total breast cancer patient population show true hereditary
aetiology which has been determined by medical genetic scrutiny.
Increased risk of the disease seems to be associated with women who had
a first degree relative with breast cancer (1.5 to 2-fold risk), but there is a 5
to 6-fold risk for those with two affected relatives. Premenopausal
women with an affected first degree relative have a 3 to 5-fold increased
risk or a 6 to 7-fold risk if that relative was identified with bilateral cancer.
v) Benign breast disease *"
There is controversy as to whether women who have been diagnosed
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with benign breast disease have an increased risk of developing breast
cancer and that risk seems to be quite variable but generally modest.
However, women with ductal or lobular hyperplasia may have a 5-fold
increased risk, which could be doubled if they also have a family history
of the disease.
vi) Reproductive life/childbearing
Multiple studies have suggested that an extended reproductive life
increases the risk of developing breast cancer (MacMahon et al., 1973).
These, in association with the observation that the menopause decreases
risk of developing breast cancer, suggest that steroid hormones may play
an important role in breast cancer. Thus women with late menarche and
menopause before the age of 45 show a decreased risk of developing breast
cancer in comparison to women with early menarche and late
menopause (Trichopoulos et al., 1972). A possible explanation for such
observations could be the extended exposure of women with prolonged
reproductive life, to ovarian hormones such as oestrogen and
progesterone which can effect the proliferation rate of hormone sensitive
breast cells.
Childbearing, which disrupts the menstrual cycle, seems to protect against
the overexposure of women to such hormones. Prolonged lactation
together with a high number of pregnancies reduce the risk. It has been
shown that nulliparity increases the risk of breast cancer by 1.4-fold,
women who had their first pregnancy within a few years of menarche,
compared to women who had their first pregnancy after 30 years of age
seem to have a 50% decreased risk for the development of the disease.
vii) Body weight
In post-menopausal women there is a positive association between body
weight and risk and an even higher association with mortality, perhaps
because obese women are usually diagnosed at a later stage (de Waard and
Baander-van Halewijn 1974).
viii) Other factors
The exogenous administration of oestrogens to women during
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pregnancy, after the menopause or as a form of contraceptive may
influence the risk of the disease. The use of oestrogens and progestogens
as oral contraceptives has not appeared to increase the incidence of breast
cancer in general however there is some concern about the use of oral
contraceptives before first pregnancy, or before the age of 25 (Pike et al.,
1981; MacPherson et al., 1987).
1.3.4 Prognosis
The prognosis of breast cancer varies quite dramatically among
individuals and very much depends on the stage at which the disease was
diagnosed (Table 1.2). Some patients live for more than 20 years and are
then cured while others die very shortly after they had been diagnosed
and despite heavy treatment. In general, patients with metastatic disease
have a low survival rate in comparison with patients with tumours
restricted to the breast. Because of the severity of the disease and the great
variability between patients, the need for better prognostic methods is
obvious (Tobar et al., 1992).
1.3.5 Treatment
i) Surgery
Surgery is still the main treatment for invasive breast cancer which is
confined to the breast. In the last years, the general practice is to reduce
the extent of surgery only to local excision of the tumour rather than
radical mastectomy.
ii) Radiotherapy
In breast cancer, radiotherapy has been used for localised lesions as it has
not been effective and cannot be used for widespread disease due to its
potentially harmful side-effects. For a number of years, radiotherapy has
been used in combination with local surgery to eradicate malignant cells
in residual breast tissue.
iii) Chemotherapy
Breast cancer, is moderately sensitive to chemotherapy. Adjuvant
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systemic therapy, is routinely offered to women with early signs of the
disease and especially to those with invaded axillary lymph nodes.
However, the relapse of the disease in these patients is associated with
lowering of the responsiveness to systemic treatment. The basic
endocrine treatment in breast cancer consists of drugs that reduce the
oestrogenic effects on growth. Tamoxifen has been the major drug used
to block the binding of oestrogen to its receptor (Rubens et al., 1988) and
has also been shown to induce the production of TGF-fi which may play
an inhibitory role in the growth of tumours (Butta et al., 1992). However,
resistance to tamoxifen has been shown in many tumours possibly as a
result of mutations to oestrogen receptors (Jiang and Yordan 1992; Fuqua
et al., 1993). A number of chemotherapeutic drugs have also been used
against breast cancer including doxorubicin, methotrexate, mitomycin C
and adriamycin. Although adriamycin has been the most effective single
agent (Henderson et al., 1989), it has been suggested that several drugs
need to be used in the treatment of breast tumours and to cope with drug
resistance (Gregory et al., 1993). In cases where patients are at very
advanced stages, systemic therapy is used to relieve symptoms.
1.3.6 Growth regulation of breast cancer
The growth of breast cancer cells appears to be under the regulation of a
variety of hormones, growth factors and cytokines. Oncogenes and
tumour suppressor genes may produce dys-regulated growth and allow
malignant transformation. These effects are described below,
i) Hormones
Studies on the effects of steroids on breast cancer cells growing in vitro
have shown that these hormones are involved in the growth control of
the malignant cells in the breast. ER-positive breast cancer cell lines such
as MCF-7 can be stimulated by 17fi-oestradiol while ER negative cell lines
such as MDA-MB-231 are not (CHrk et al., 1989). In hormone-sensitive
breast cancer cell lines, it has also been suggested that steroid hormones
induce proteins such as cathepsin D and TGF-a which may be important
17
regarding tumour spread (Lippman and Dickson 1989). Steroid
hormones appear to have no effects on the growth of ER-negative (or low
ER) cell lines (Engle et al., 1978).
ii) Growth factors
The development of the normal breast may be influenced by growth
factors (Lippman and Dickson 1989) such as epidermal growth factor
(EGF) and TGF-a which increase proliferation of normal breast cells in
culture (Perushinge et al., 1992); TGF-a can also be detected in
proliferating human mammary epithelium. Anti-EGF receptor
antibodies block the effects of TGF-a suggesting that it acts through the
EGF receptor (Bates et al., 1990). The EGF receptor and a related protein
(pl85) which is encoded by the c-erbB2 oncogene are over-expressed in a
minority (20-30%) of breast cancers (Klijn et al., 1992; Fox et al., 1994). IGF-
I receptor expression is also over-expressed in a number of breast cancers
(Pekonen et al., 1988) and may therefore be associated with malignant
transformation. The TGF-6 family consists of 3 isoforms which are able
to inhibit growth of epithelial cells (Knabbe and Zugmaier 1994).
However, recent studies have associated TGF-fi expression with rate of
the disease progression and modulation of angiogenesis as well as
neovascularization and progression of tumours towards hormone
independence (Dickson et al., 1986). In general, breast cancer cells appear
to produce and secrete higher amounts of growth factors and over-express
receptors for such factors. Such effects may result in unregulated
proliferation of tumour cells (autocrine action) but may also induce
mitogenesis and other effects on surrounding cells (paracrine action).
iii) Cytokines
Some cytokines are differentially expressed in tumours compared to
normal breast tissue. IL-6 expression is high in normal tissue but low in
almost all tumours while TNFa which is absent in normal breast
epithelium is widely expressed in breast cancers (Basolo et al., 193; Pusztai
et al., 1994).
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1.3.7 Oncogenes and tumour suppressor genes in breast cancer
i) Oncogenes
In human breast carcinomas, alterations in c-myc were found in 25% of
tumours (Escot et al., 1986; Berns et al., 1992) and have been associated
with increased aggressiveness and poor prognosis. Mutations in the
oncogenes H-ras and K-ras, have been identified in breast cancer cell lines
(Bradbury et al., 1991; Kraus et al., 1984) but only rarely found in breast
carcinomas. Amplification of the c-erbB-2 gene is found in 20-30% of
breast cancers and has been shown to correlate with aggressive features in
invasive tumours (Slamon et al., 1987). Another proto-oncogene, CCND1
encodes for cyclin D, a protein regulating progression in the Gi phase of
the cell cycle. Amplification of this gene leads to overexpression of cyclin
D-l seen in many breast cancers (Bartkora et al., 1994; Gillet et al., 1994).
ii) Tumour suppressor genes
Alterations in RB-1 have been found in breast carcinomas and breast
cancer cell lines while mutations in the p53 gene have been reported in a
number of cancers and in about 60% of breast cancers (Mackay et al., 1988;
Varley et al., 1991) and have been associated with aggressive tumours.
Other studies have suggested that mutations in the genes responsible for
genetic stability, DNA replication, or DNA repair found in many breast
cancer can account for damage of the genome (Loeb, 1994). BRCA-1 and
BRCA-2 are tumour suppressor genes (Friedman et al., 1994) linked with




In the 1980s, it was shown for the first time that the endothelium was
involved in the contraction of smooth muscle. The discovery of a
peptidergic endothelium-derived contracting factor (EDCF) with, until
that point, unknown properties was made when cultured medium from
bovine endothelial aortic cells was added to porcine smooth muscle cells
from isolated pig coronary arteries (Hickey et al., 1985). The experimental
data suggested a slowly developing, long-lasting contraction of the
smooth muscle, an observation which was later confirmed by a number
of other groups (Gillesbie et al., 1986; O'Brien et al., 1987). The EDCF
peptide was later isolated, purified, cloned and named endothelin-1
(Yanagisawa et al., 1988 a,b) and was characterised as the most potent
vasoconstrictor known. Since then, a number of studies have more
clearly defined the biological role of the endothelin peptide family, and
provided a better understanding of its involvement in the
pathomechanisms of disease.
1.4.2 Structures of the endothelin peptides
Recently, three different ET genes have been identified in distinct
chromosomal locations expressing 3 different endothelin isopeptides (ET-
1, ET-2, ET-3) in animals and humans (figure 1.1). The endothelin
isoforms are initially synthesised as larger preproendothelins which are
cleaved to 37-41 amino acid peptides ("big" endothelins) by specific
endopeptidases (figure 1.2). The mature endothelins are products of the
proteolytic cleavage of big endothelins. However, such cleavage is not
performed in all big endothelin propeptides since they have been
identified in plasma (Miyauchi et al., 1989) and in the conditioned media
of cultured cells (Parker et al., 1992). All endothelins show marked
homologies to a family of peptides known as Sarafotoxins (SRTXs) found
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Figure 1.1: The primary sequences of endothelins (ETM, -2 and -3 showing the positions of
the disulphide bonds and residues that differ from those of endothelin-1 (shaded). The













Figure 1.2: The biosynthesis and processing of endothelin from preproendothelin (original
illustration in Gandhi et al., 1994).
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in the venom of a rare snake, Atractaspis-engaddensis. Four SRTXs have
been identified and together with the three endothelin peptides form the
endothelin family. All the family members consist of 21 amino acid
residues and are identical at 10 amino acid positions. The COOH region
of the peptides is highly hydrophobic and shows extensive homology
between different members of the family. The amino acids that differ
between members of the family are, with very few exceptions, still similar
in terms of charge and hydrophobicity. The four Cys residues in the
sequence of all endothelins have important structural roles, forming two
disulphide bonds (S-S bonds between Cys1-Cys15 and Cys3- Cys11) which
fold the peptide and are vital for the affinity of binding with at least one
type of endothelin receptors (ETa-R)- The S-S bonds found in
endothelins are different from the common S-S bonds present in other
biological molecules. Studies on the physical properties of the ET
peptides using proton NMR measurements and distance geometry
calculations (Dalgarno et al., 1992; Endo et al., 1989; Munro et al., 1991;
Reily and Dunbar 1991) have suggested that ETs have a very compact
formation when in solution, exhibiting little solubility in aqueous
solutions at neutral pH as well as low partition into ether/water
interfaces (Spinella et al., 1989) and form micelles at 22 (iM concentrations
(Bennes et al., 1990). Most of the NMR studies have been performed in
the presence of organic solvents or at non-physiological pH ranges and in
aqueous/organic solvent mixtures. Although there have been different
suggestions about the tertiary structure of the peptides, such studies have
come to some common conclusions. The central part of the peptide
forms a helix structure which is not of the regular a-helix type. There is
some controversy as to whether the helical region is between residues
Leu6 and Cys11 with both S-S bonds incorporated into the structure (Endo
et al., 1989; Saudek et al., 1991) or between Leu6 and Cys15 (Munro et al.,
1991) thus including only one S-S bond. According to an extended study
on the N-terminus of the endothelin peptides, it has been proposed that it
constitutes the area including the key structural region for the
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differentiation of the binding activity at the ETa-R and ETb-R receptor
sites. No common conclusions have been drawn regarding the COOH
terminal region of the ET peptides. Two models with distinct differences
have been suggested. The first, suggests that the tail folds back towards
the helical region (Saudek et al., 1991) and the second that the COOH tail
is flexible and can form a number of different conformations (Endo et al.,
1989; Munro et al., 1991). During the last two years a study by Janes et al.,
(1994) determined the crystal structure of human ET-1 at 2.18A resolution
in a purely aqueous medium. According to this study, the peptide
consists of an N-terminal fi-strand which is extended, followed by a loop
of hydrogen bonds involving the carbonyl oxygen of residue 7 and the
amide proton of residue 11. According to the same study, the region
following the loop of hydrogen bonds forms an ordered but irregular
helix which is stabilised by main chain to main chain and main chain to
side chain hydrogen interactions and the two S-S bonds between Cys1-
Cys15 and Cys3-Cys11. That helix may represent a recognition site for
endothelin converting enzyme (ECE) resulting in the binding of the
converting enzyme and the cleavage of "big" ET to the mature ET
polypeptide. According to the final NMR structure, the COOH terminus
of the molecule is helical in its crystal structure. The question however
remains as to whether the X-ray crystallographic conformation represents
the natural biological form of the molecule or whether the peptide is
different in solution. The structure of the COOH terminal region,
responsible for the binding and biological activity remains to be clarified.
1.4.3 Endothelin genes
Three distinct ET related genes in humans and other mammalian species
have been identified using ET-1 gene fragments in order to screen
genomic libraries (Itoh et al., 1988; Kimura et al., 1989a; Inoue et al., 1989
a,b; Onda et al., 1991). Human ET-1, ET-2 and ET-3 genes have been
mapped on chromosomes 6 (Arimori et al., 1991a; Bloch et al., 1989a,b),
KArimari et al., 1991; Bloch et al., 1989a; Hoehe et al., 1993) and 20
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(Arimari et al., 1991; Bloch et al., 1989a; Rao et al., 1991) respectively.
Considering the structure of the human ET genes, more information is
known regarding the ET-1 gene than the ET-2 and ET-3 genes. The 6.8 Kb
coding region of the ET-1 gene consists of five exons which are
interrupted by four introns. The primary transcript mRNA is 2.3 Kb in
length and directs the translation of the prepro-ET-1 peptide. Each exon
encodes a portion of the prepro-ET-1 which includes the sequences of
"big" ET-1 and ET-1 peptide. The ET-1 promoter was located at 9 bp
downstream of a CAAT box and includes a number of regulating
sequences [TATAA box, binding sites for nuclear factor-1 (NF-1), GATA-2,
AP-1 /jun and acute phase reaction regulatory elements (APRE) (Benatti et
al., 1993; Inoue et al., 1989a,b; GronostajskiT987)].
1.4.4 Endothelin expression
Since the original isolation of ET-1 from porcine aortic endothelial cells
(Yanagisawa et al., 1988b), ET isoforms have been detected in a number of
tissues. Most studies have used immunological methods which can
detect ET and "big" ET isoforms in the femtomole range but cannot fully
characterize the identity of the ET isoform because of cross-reactivity of
the antibody with the different ET isoforms. Qualitative data regarding
gene expression has also been obtained with the use of Northern analysis,
RT-PCR and in situ hybridisation techniques (Baley et al., 1990; Economos
et al., 1992, O'Reilly et al., 1992; Pagotto et al., 1995; Pekonen et al., 1995).
Of the isoforms, ET-1 is the major form produced by all endothelial cell
types such as the umbilical vein (Inoue et al., 1989a,b), glomerulus
(Marsdon et al., 1991), aorta (Tokunaga et al., 1992), mesenteric artery
(Dohi et al., 1992), brain microvessel (Yoshimoto et al.,1990) and corpus
covernosum (Saenz de Tejada et al., 1991). Vascular smooth muscle cells
also express ET-1 mRNA and protein (Resing et al., 1990). ET-1 is also
present in a number of other cell types such as breast epithelium (Baley et
al., 1990), endometrial stromal glandular epithelial cells (Economos et al.,
1992a,b), keratinocytes (Imokawa et al., 1992), bone marrow mast cells and
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macrophages (Ehrenreich et al., 1992) and cardiomyocytes (Suzuki et al.,
1990). Equally, a number of tumour derived cells also express ET-1. These
include, endometrial carcinoma (Economos et al., 1992a,b), Hep-2
hepatocarcinoma and HeLa cells (Shichiri et al., 1991a,b), renal
adenocarcinoma (Tokito et al., 1991), MDA-MB-231, MCF-7, ZR-75-1
human epithelial breast cancer cells (Yamashita et al., 1993), mammary
carcinomas (Kusuhara et al., 1990; Patel et al., 1995), pancreatic tumour
samples (Nelson et al., 1995), SKOV-3, OVCA433, A2780 and BG-1 ovarian
carcinoma cells (Bagnato et al., 1995). In contrast ET-2 and ET-3 have not
been detected in either vascular endothelium or smooth muscle as
suggested by Northern analysis (Bloch et al., 1989a,b; Firth, 1992) but both
are expressed in human endometrium (O'Reilly et al., 1992). ET-2 has
also been shown to be expressed in human renal adenocarcinoma (Tokito
et al., 1991). At the tissue level, mRNA for ET-1 has been shown to be
present in all organs examined with lung being the predominant site
expressing ET-1 mRNA 5-fold higher than the large intestine and 15
times higher than other organs (Onda et al., 1990; Firth and Ratchlife
1992). ET-3 mRNA is also detected at higher levels in a number of
organs. Table 1.3 summarises the cell lines and tissues where ET peptides
have been shown to be expressed. Studies on the regulation of ET-1
expression indicate that in endothelial cells, levels of ET-1 mRNA were
increased after treatment with growth factors, cytokines and vasoactive
substances such as thrombin (Kurihara et al., 1989; Emori et al., 1992),
TGFfi (Kurihara et al., 1989; Yanagisawa and Masaki 1989), TNF-a
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Normal tissue/cell type Reference
breast epithelium Baley et al., 1990
cardiomyocytes Suzuki et al., 1990
endometrial stromal cells Economos et al., 1992a
glandular epithelial cells Economos et al., 1992b
1 bonemarrow Ehrenreich et al., 1992
1 mast cells Ehrenreich et al., 1992
macrophages Ehrenreich et al., 1992
keratinocytes Imokawa et al., 1992
Tumour-derived cells Reference
pulmonary squamous cell carcinoma Giaid et al., 1990
pancreatic tumour samples Kusuhara et al., 1990,
Nelson et al., 1995
I mammary carcinomas Kusuhara et al., 1990
Patel et al., 1995
Hep-2 hepatocarcinoma Scihiri et al., 1991a,b
HeLa cervical carcinoma cells Scihiri et al., 1991a,b
renal adenocarcinoma cells Tokito et al., 1991
endometrial carcinoma Economos et al., 1992a
human endometrial adenocarcinoma cells Pekonen et al., 1992
MDA-MB-231, MCF-7, ZR-75-1 human
breast epithelial cancer cells
Yamashita et al., 1993
SKOV-3, OVCA433, A2780, BG-1 human
I ovarian epithelial cancer cells
Bagnato et al., 1995
Table 13: List of the normal and malignant tissues and cell lines that have been shown to
express and/or secrete endothelin peptides.
27
(Lamas et al., 1992), interleukin-1 (Maemura et al., 1992), angiotensin II
(Dohi et al., 1992), bradykinin (Marsden at al., 1991) and insulin (in vitro)
(Oliver et al., 1991; Metsarine et al., 1994). ET mRNA levels were
increased in cells of the haemopoietic system (human macrophages)
following the addition to cultures of lipopolysacharides and phorbol
esters (Ehreneich et al., 1990); in human breast epithelial cells by
supplementing culture media with prolactin and in human breast cancer
cells by IL-6 and bombesin (Yamashita et al., 1993). In endometrial
stromal cells and cultured human avascular amniotic cells, EGF, IL-1 and
TNF-a all increased ET expression (Casey et al., 1991). Some of the factors
that have been shown to modulate the production of ETs are shown in
table 1.4. The concentrations of the mature peptides in circulating blood
of healthy individuals and patients with a variety of diseases have been
measured by radioimmunoassays specific for ET-1, ET-3 and big
endothelin (Kurihara et al., 1989). Results from such studies suggested
that the ET concentrations detected in samples from healthy individuals
were lower than those in samples from patients.
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System Modulator Effect Reference
endothelial cells thrombin t ET-1 mRNA Kurihara et
al.,1989
endothelial cells TGFfi T ET-1 mRNA Kurihara et
al.,1989
human breast




phorbol esters t ET-1 mRNA









T ET-1 Casey et al., 1991
endothelial cells bradykinin t ET-1 mRNA Marsden et al., 1991
endothelial cells insulin (in vitro) T ET-1 mRNA
Oliver et al., 1991
Metsarine et al.,
1994
1 endothelial cells angiotensin II T ET-1 mRNA Dohi et al., 1992
endothelial cells
INF
TNFa T ET-1 mRNA
Lamas et al., 1992
Maemura et al.,
1992




I breast cancer cell lines bombesin T ET-1 Schrey et al., 1992
I human epithelial
1 breast cancer cell lines
IL-6 TET-i Yamashita et al.,
1993
Table 1.4: List of molecules which have been shown to modulate the expression of
endothelin-1 in different cell types.
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1.4.5 Endothelin Converting Enzyme (ECE)
A number of enzymes have been proposed as endothelin converting
enzymes including chymotrypsin, several aspartic proteases (eg. pepsin,
Takaoka et al., 1990) and cathepsins D and E (Lees et al., 1990). The
conversion of "big" endothelins to active endothelin peptides requires
the cleavage of specific amino acid bonds. All the above mentioned
enzymes, successfully cleave either one but not all bonds or they cleave
more than the necessary bonds. Studies using macromolar
concentrations of Pr [(N-a-rhamnopyranosyl-oxyhydroxyphosphinyl)-
Leu-Trp], an inhibitor of the bacterial zinc protease, thermolysin, and zinc
peptidase E-24.11 demonstrated that they could inhibit exogenous "big"
ET concentrations both in vivo and in vitro. ECE may be structurally and
catalytically similar to E-24.11 (Turner et al., 1993). Although ECE can be
separated from E-24.11 by immunoaffinity chromatography or by
isoelectric focusing (Murphy et al., 1993; Corder et al., 1993) there is still
debate as to whether or not E-24.11 is an ECE. The identification of an ECE
peptide was initially reported by Ohraka et al (1990). The peptide was
membrane associated, inhibited by EDTA and EGTA chelators and
insensitive to other proteases. Separate studies described the
characterization of a membrane bound, Pr sensitive, thiorphan
insensitive ECE which was distinct from E-24.11 and pH sensitive (Okada
et al., 1990). Other studies reported similar findings describing a
phosphoramidon sensitive cytosolic ECE metalloprotease (Matsumura et
al., 1990, 1991). The lack of a specific assay which could combine
sensitivity and speed of detection has delayed the purification of the ECE
enzyme. The peptides initially purified were isolated from rat lung
(Takahashi et al., 1993) and porcine aortic endothelium (Ohnaka et al.,
1993). The rat enzyme was a 130,000 Mr protein (determined by SDS page)
compared to the 90,000-100,000 Mr E-24.11 protein while the porcine aortic
endothelium ECE was characterized as a 120,000 Mr protein (SDS page,
Ohnaka et al., 1993). Two more sources of ECE activity were the bovine
adrenal cortex (Mr 126,000) and transformed endothelial cell lines.
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Purified ECE from membrane preparations of bovine endothelium cell
line showed that ECE exists as a disulphide linked dimer with two 120,000
Mr subunits (Schmidt et al., 1994). Gel filtration of E-24.11 also revealed a
dimer formation which is maintained by non-covalent interactions.
1.4.6 Molecular cloning of ECE
After the purification of ECE a number of groups cloned and sequenced
the enzyme. ECE-1, which shows significant homology to E-24.11 and the
erythrocyte blood group antigen, is a highly glycosylated transmembrane
protein with a number of N-linked glycosylated sites and a highly
conserved Cys rich domain. The N-terminal region shows great
homology (>92%) between bovine, rat and human ECE enzymes (Schmidt
et al., 1994). Variations between the other two bovine ECE enzymes may
represent different isoforms. It is therefore possible that different
subunits of ECE exist differing in the length of their cytoplasmic domains,
possibly resulting from differential splicing. All ECE enzymes show a
>95% homology in their extracellular domain amino acid sequences.
ECEs are distributed broadly in a number of tissues such as the lungs, the
pancreas, the placenta, the ovary, the testis and the adrenal gland.
Endothelins are the only ECE substrates known so far. A number of
studies have suggested possible sensitivity differences for the conversion
of "big" ET-1 isoforms to the active peptides (Xu et al., 1994).
1.4.7 Endothelin receptors
Early ligand-binding studies using endothelins, suggested more than one
ET receptor subtype (Kloog et al., 1989). Data accumulated by ligand
binding and kinetic studies, chemical modifications of the receptors and
cloning and expression of the receptor proteins reached similar
conclusions. Two types of endothelin receptors have been identified so
far and have been named ETa-R (with higher affinity for ET-1 than ET-2
and lower affinity for ET-3) and ETb-R (with equal affinities for all
endothelin peptides). Both receptors have been cloned by different
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groups (ETa-R: Arai et al., 1990; Lin et al., 1991; Hosoda et al., 1992 and
ETb-R: Sakurai et al., 1990; Nakamuta et al., 1991; Ogawa et al., 1991).
Binding studies using 125I-ET radiolabeled ET's have identified high
affinity (Kd's in the nM range) binding sites in brain, heart, lung, kidneys,
liver, intestines, uterus, placenta, amnion and ovaries in the membranes
of either isolated cell types, or tissue sections. Such studies indicated the
co-existence and the differential distribution of ETa-R and ETb-R
subtypes. Binding characteristics of the two receptor types in terms of Kds
and Bmax values display significant variation between studies and can be
caused in different ways. Firstly, individual studies have used different
methods of tissue preparation including subcellular fractions or cell
lines. However, differences may still be observed even when the same
preparations were used, possibly due to alternative measuring techniques
(Lewy et al., 1992). Secondly, variations in buffer composition or pH and
the presence or absence of chelators such as Mg2+, Ca2+ or BSA have
proved important (Bolger etal., 1990; Maggi et al., 1991). Other critical
factors included differences in the purity of the preparations, variations in
the receptor concentration and in the ratio of the receptor to ligand and
production of artifacts as the result of ligand becoming trapped within the
cell when homogenate preparations were not used. Protection against
degradation of the ligand and/or the receptors by a number of
endogenous proteases required the presence of various protease
inhibitors in the assay. In different species, different receptor subtypes
may mediate the same function. In addition, differences between ET-R
subtypes have been observed between species (Fukuroda et al., 1994b).
Journeaux et al., (1994) demonstrated sex differences in the expression of
ET-R in rats, glyconeogenesis being mediated by ETa-R in males and by
ETb-R in females. Recently, a number of studies have suggested the
existence of two ETa-Rs and two ETb-Rs, one with pM Kd values and one
with nM Kd values in Rat-1, S3T3 fibroblasts (Ambar and Sokolovsky,
1993), and rat cerebellum (Sokolovsky et al., 1993). Two functionally
distinct ETa-R types were identified in rat mesangial cells (Simonson and
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1993), and rat cerebellum (Sokolovsky et al., 1993). Two functionally
distinct ETa-R types were identified in rat mesangial cells (Simonson and
Rooney, 1993) with Kds of 1.2 nM and 32 pM. Studies using the BQ123
ETa-R antagonist to examine its effects on the binding of ET-1 to receptors
in rat heart, have suggested that the inhibitory action of BQ123 was
competitive at the nM sites but non-competitive at the p M sites
(Sokolovsky et al., 1993), supporting the suggestion that BQ123 is an
allosteric antagonist acting through a secondary site. The possibilities that
these receptors can oscillate between the nM and pM affinity states, or
that they represent fully different receptor subtypes have to be
investigated. It has been suggested that although they represent two
subtypes of similar Mr polypeptides (45-47 KDa), the pM receptor sites
(ETbi-R) are not coupled to the phosphoinositide hydrolysis signal
transduction pathway while the nM sites (ETb2-R) are and therefore
induce the phospholipase C (PLC) activation (Mittler et al., 199). The
same hypothesis is supported by data from Sokolovsky et al., (1994) and
Shraga et al., (1994) which suggested that the pM sites are involved in the
signal transduction via cAMP and cGMP pathways. Karne et al., (1993)
demonstrated the presence of a third type of ET-R (ETc-R) in Xenopus
laevis with higher affinity for ET-3 and lower affinities for ET-1 and ET-2.
The existence of such a receptor subtype could explain the fact that ET-3
and not ET-1 or ET-2 has been shown to mediate cell proliferation in
wounded human umbilical vein endothelium. However, a study with
rat brain capillary endothelial cells detected an ETa-R type receptor
sensitive to BQ123 showing high affinity for ET-3 (Sokolovsky et al., 1994).
1.4.8 Endothelin antagonists
In order to investigate further the potential role of endothelins in normal
and pathological conditions, specific ET antagonists have been developed.
Many ET antagonists which have been identified were discovered by
screening natural products and compounds. The best example is BQ123, a
highly selective ETa-R antagonist, a cyclic ET-1 analogue pentapeptide
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common antagonists. Most can be divided into two groups according to
structure. The first group including derivatives of cyclic peptides (BQ123,
RES-701-1, TAK 044) and the second groups derivatives of linear
tripeptides (FR-139137, PD-151242, BQ788). The receptor antagonists bind
to the receptor with high affinity (1-25 nM) and thereby inhibit the effects
of ETs. Certain studies have shown that synergistic inhibition using
BQ123 and BQ788 (ETa-R and ETb-R receptor antagonists) was needed for
complete inhibition of the effects of ET-1 on the contraction of pulmonary
arteries (Fukuroda et al., 1994a). Alternatively, non-selective ET receptor
antagonists can produce simpler blockade (Clozel et al., 1994). Thus
antagonists such as Bosentan (RO-0203) can bind to both ETa-R and ETb-R
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Table 1.5: Structures and selectivities of the most common ET-receptor antagonists.
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1.4.9 Molecular cloning/characterization of the receptors
cDNA clones encoding the two different subtypes of endothelin receptors
have been isolated and characterised by a number of different groups.
Data analysis of such studies revealed that the two receptor polypeptides
have similar numbers of amino acid residues (415-442) and their
molecular weights were estimated to be between 46,900 and 49,630. The
homology between ETa-R and ETb-R in humans showed a 65% identity
and sequences of ETb-R between human, rat and bovine isoforms reached
85% homology. ETc-R in Xenopus laevis consists of 424 amino acid
residues with 47% and 52% homologies with ETa-R and ETb-R
respectively (Karne et al., 1993). It is not yet clear if this receptor
represents a variant of the two known types of ET receptors or a distinct
ETc-R. The same studies suggested that the amino acid sequences of ET
receptors contain seven hydrophobic areas, each consisting of 22-26 amino
acid residues which are separated by hydrophilic regions. This structure
description is comparable with the G-protein coupled receptor complexes
in which the polypeptide consists of seven transmembrane elements, an
extracellular N-terminal domain and a cytoplasmic COOH tail. The N-
terminus of all ET-R sequences contained a proline rich region although
there was clear indication of major differences between the amino acid
sequences of the two major ET-R subtypes. The N-terminus of ETa-R
consisted of 80 residues while that of ETb-R consisted of 101 residues with
a relatively limited homology. Further evidence as to the similarity of
the receptors with the G-protein coupled receptors family is the presence
of the Asp-Arg-Tyr triplet at residues 182-184 in ETa-R and at 198-200 in
ETb-R (Lin et al., 1991). Finally, the different subtypes of ET-R might be
due to alternative splicing of a single gene.
1.4.10 Kinetics of binding
The binding of ETs to specific ET receptors in various tissues has
demonstrated a very slow dissociation of the ligand from the receptor,
following binding. In some cases this process is almost irreversible and
36
dissociation rates vary between tissue types (Sokolovsky et al., 1994). The
phenomenon could be explained as a dissociation of the ligand from a
heterogeneous population of binding sites or in terms of a two step
isomerisation model (Sokolovsky et al.; 1989) with the dissociation rate
varying depending on the pre-incubation period of the ligand with the
receptors. Takasuka et al., (1994) suggested that the dissociation of ETb-R-
ligand complex was facilitated by proteolytic digestion during the signal
transduction process.
1.4.11 Endothelin receptors and signalling
i) Phospholipase C (PLC) signal transduction pathway
It has been suggested that phosphoinositide (PIP2) hydrolysis in human
tissue, rat heart myocytes and rat cerebellar slices is mediated via two
types of G-protein (a Gi or Go Pertussis toxin sensitive protein and a Gq
type protein). The same studies have demonstrated that higher
concentrations of endothelin are needed for stimulation of PLC activity
compared to concentrations used for ligand binding studies. A number of
reasons could account for this including the use of different experimental
conditions for different experiments, multiple receptor subtypes, coupling
of a limited number of receptors to PLC and existence of several different
receptor-ligand complexes (Sokolovsky 1995). A study using Chinese
hamster ovaries suggested that ETg-R can activate two different signal
transduction pathways depending on the concentration of ETs applied to
cells (Etoh et al., 1994). In rat messangial cells the stimulation of the PLC
pathway by ETs resulted in mobilization of intracellular Ca2+ ([Ca2+];)
concentration and activation of chloride channels (Iijima et al., 1991).
The activation of chloride channels can , in turn, result in CI- efflux and
further depolarization of the membrane. Such depolarization can cause
the activation of voltage-dependent Ca2+ channels and therefore the
increase in [Ca2+]j.
ii) Ca2+ Flux
In almost all systems, the binding of ETs to ET receptors results in Ca2+
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signalling which mediates a number of short-term effects such as
vasoconstriction (Gulati and Srimmal, 1992; Maiani, 1993). It has been
suggested that Ca2+ flux is mediated through two distinct mechanisms.
The first is the IP3 mechanism already discussed above, and the second is
through the activation of multiple types of Ca2+ channels. It has been
demonstrated that ETs can affect both voltage-operated and receptor-
operated Ca2+ channels (which can be opened as the result of the
involvement of second messengers). The addition of low doses of ET-1 in
a number of systems stimulated a monophasic [Ca2+]i increase which was
sustained, and the duration of which was pronounced with ET-1 and
ET-2.
iii) Phospholipase A2 (PLA2)
It has been reported that ETs stimulate PLA2 in a number of tissues.
Activation of PLA 2 lead to the release of arachidonic acid (AA) which was
subsequently metabolised to prostaglandins (PG), leukotrienes and
thromboxanes thought to act as second messengers mediating some of the
biological activities of ETs (Reynolds, 1990; Resink, 1989). The observed
release of arachidonic acid could be the result of two possible mechanisms
which include either the direct activation of PLA2 or the activation of an
indirect pathway acting through PLC and DAG which could also lead to
AA production. Studies have demonstrated the activation of PLC and
PLA2 in separate but parallel pathways (Schramek et al., 1994). Such
activation of PLA2 can occur following the binding of ETs to either ETa-R
or ETg-R receptors. The same studies have demonstrated the activation
of both PLA2 and cytosolic PLA2 by ET-1 binding to both such types of
receptors (Schramek et al., 1994). ET-1 activated PLA2 in a rapid manner
which was regulated at the post-translational level. ET-1 also activated
cytosolic PLA2 in a much slower manner (Schramek et al., 1993, 1994).
iv) Phospholipase D (PLD)
PLD is a phospholipase which hydrolyses phosphatidyl choline and
phosphatidyl ethanolamine (which constitute about 40% of all
phospholipids) producing phosphatidic acid (PA) and choline or
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phospholipids) producing phosphatidic acid (PA) and choline or
ethanolamine. Recently, PLD activation by growth factors,
neurotransmitters and hormones was shown to be a ubiquitous signal
transduction pathway in mammalian cells (Dennis et al., 1991). ET-1
activated both PKC-dependent and PKC-independent PLD activation in
Rat-1 fibroblasts (MacNulty et al., 1990). Similarly, PLD activation as a
result of ETs biding to ET-Rs has been demonstrated in C6-glioma cells,
Rat-1 cells and Swiss 3T3 fibroblasts, resulting in the production of DAG
and PA with a number of potential effects such as prolonged maintenance
of PKC activation. Brain is a rich source of PLD (Chalifour and Kanfer,
1980) as well as for ETa-R- PLD activation can result in increased choline
concentration and thus increased synthesis of acetylcholine in the brain.
In the same way, phosphatidyl ethanol can lead to brain specific PKC
activity as a substrate for phosphatidyl serine (Nishizuka et al., 1988).
v) Na+/H+ exchange
The regulation of Na+/H+exchange has been linked with the binding of
hormones, growth factors and other agents, to different receptors
(Simonson, 1993). ETs were shown to activate Na+/H+ exchange in the
brain (Vigne et al., 1991) through receptors with equal affinity for ET-1
and ET-3 and via a PKC independent mechanism. High ET (nM)
concentrations may also result in the phosphorylation of Na+/H+
antiporter through a PKC activation (Simonson et al., 1989) while low ET
concentrations (pM) regulate Na+/H+ exchange through a PKC-
independent pathway (Kraker et al., 1990).
vi) cAMP/cGMP production
ETs regulate the production of cAMP in a number of systems. In some
tissues such as in brain capillary endothelial cells, ETs activate cAMP
formation (Ladoux and Frelin 1991) while in other systems, as in rat
cardiac myocytes, they inhibit cAMP formation (Hilal et al., 1992). The
effects of ETs are seen simultaneously on the PIP 2 hydrolysis and cAMP
levels. Studies on the intracellular signal transduction pathways of ETa-
R and ETb-R in Chinese hamster ovary cells (Aramori and Nakanishi,
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but cAMP formation was regulated by ETa-R and cAMP inhibition was
regulated by ETb-R. However, such conclusions are not in accordance
with studies in other systems and such diversity of results might shed
light on the complexity of the signalling pathways involved. Sokolovsky
et al., (1994) demonstrated that ET-1 at pM concentrations induces cAMP
formation in a dose-dependent manner while ET-1 concentrations
between 10-HM and 10 7M resulted in a dose-dependent inhibition of
cAMP formation, reaching basal levels at KHM ET-1. Such results could
be explained by the presence of both main types of receptors (ETa-R
activation of cAMP and ETb-R inhibition of cAMP) or by the possibility of
a very fast desensitization process for the receptors as already
demonstrated in rat myometrium (Khac et al., 1994; Cyr et al., 1993).
cGMP synthesis is also stimulated by growth factors, hormones and
neurotransmitters in various systems. Such stimulation can be mediated
by nitric oxide (NO) binding to guanylyl cyclase which in turn stimulates
the synthesis of cGMP (Moncada et al., 1991). In a number of tissues, ET-1
and ET-3 can mediate cGMP signalling at low doses as well as
vasodilation caused by NO (Taniguchi et al., 1994). Increased stimulation
of cGMP has been observed after the addition of ET-1 and SRTX-b at
picomolar concentrations while when added at higher concentrations
these same peptides caused a dose-dependent inhibition of cGMP.
However, ET-3 and SRTX-c addition at picomolar concentrations did not
stimulate cGMP formation while such effects were observed after the
addition of the peptides at nanomolar or higher concentrations. These
results suggest that the majority of the receptors are of the ETb-R type
while only a minority of the receptors are of the ETa-R type and that the
latter are responsible for the cGMP production. Further studies
demonstrated that ET-1 and ET-3 activate cGMP formation through NO
production and via a PT-sensitive G-protein(s) while SRTXs act via a
different pathway which does not involve PT-sensitive G-protein(s).
Therefore, ETs and SRTXs seem to bind to the same receptors and may
produce the same second messengers but through different signalling
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pathways.
viii) Signal transduction in the nucleus
ETs have also been shown to act through second messengers in order to
activate MAP kinases and induce expression of genes such as c-fos, c-myc
and c-jun (Simonson 1993). In Chinese hamster ovary cells, (Tabuchi et
al., 1994) ETa-R and ETb-R differentially activated the c-fos gene.










AA: arachidonic acid AC: adenylate cyclase
cAMP: cyclic adenyl monophosphate cGMP: cyclic guanyl monophosphate
DAG: diacyl glycerol E.R: endoplasmic reticulum
G: G-protein GC: guanine cyclase
IP3: Inositol 1, 4, 5 tris-phosphate LT: leukotrienes
LX: lipoxin PA: phospatidic acid
PC: phosphatidyl choline PGE2: Prostaglandin E2
PGI2: Prostaglandin I2 PIP2: phosphatidyl Inositol4,5 bis-
phosphate
PKC: Protein kinase C PLA2: phospholipase A2
PLC: phospholipase C PLD: phospholipase D
ROC: Receptor operated Ca2+ channel TX2: Thromboxane 2
VOC: voltage operated Ca2+ channel
Figure 13: Diagrammatic representation of the cell signalling pathways activated by
endothelin.
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1.4.12 Endothelins and ovarian cancer
The role of endothelins in the ovaries and ovarian cancer has not yet
been investigated in depth. The granulosa cells of the porcine ovary
secrete (Kamada et al., 1991,1993) and human follicular fluids (Schiff et al.,
1993) contain detectable amounts of immunoreactive ET-1. Human
ovarian cancer cell lines SKOV-3, OVCA-433, A2780 and BG-1 produce
substantial amounts of ET-1 (detectable by radioimmunoassay) (Bagnato
et al., 1995). Even more limited information is available regarding the
presence of ET-R in normal and malignant ovarian cells. In porcine
ovarian granulosa cells, a single, high affinity (Kd: 0.59 pM) receptor type
has been found, which has equal affinities for ET-1 and ET-3 (Kamada et
al., 1991), suggesting that it was the ETb-R subtype. In the ovarian
carcinoma cell lines SK-OV-3, OVCA-433 and A2780 binding studies using
radiolabeled ET-1 suggested the presence of a single type of high affinity
ETa-R. The addition of exogenous ET-1 to porcine granulosa cells
(Kamada et al., 1993) and the human ovarian cancer cells mentioned
above (Bagnato et al., 1995), resulted in a dose dependent stimulation of
growth, suggesting a possible mitogenic role for ET-1 in these systems.
Other effects such as increased [Ca2+]j and IP3 hydrolysis were observed as
the results of exogenous addition of ET-1 to the cells, suggesting that the
mitogenic effects were mediated by such changes.
1.4.13 Endothelins and breast cancer
The production of ET-1 from normal breast and breast cancer cells has
been investigated. Baley et al., (1990) suggested that normal epithelial
breast cells exhibited low constitutive expression of ET mRNA while
normal breast stromal cells showed no expression of the same peptide.
The production of ET-1 from breast cancer cells has been demonstrated in
a number of lines, including MCF-7, BT-20, ZR-75-1 and ZR-75-30
(Kusuhara et al., 1990), MDA-MB-231, T47D, MCF-7 (Patel and Schrey
1995), epithelial cancer lines. In a study of breast tissue samples
(Yamashita et al., 1991), it was shown that breast cancer tissue samples
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contained 15 times more ET-1 than normal breast tissue samples and 6
times more than benign breast tumours. In the same study it has been
shown that large amounts of ET-1 were present even at early stages of the
disease (stage I) but there was no association between ET-1 concentration
and prognostic factors such as tumour size, age of patients, and
involvement of lymph nodes and it was thus concluded that ET-1 may be
involved in the malignant transformation of breast ductal cells rather
than the growth of cancer cells. It was also suggested that hormone
dependent cell lines (MCF-7, T47D, ZR-75-1) produced up to 20 times
more ET-1 than hormone independent breast cancer cell lines (MDA-MB-
231, BT-20). In phyllodes tumours it has been shown that ET-1 is
produced in even higher levels than other types of breast tumours
(Yamashita et al., 1992). Two separate studies have suggested modulation
of the production of ET-1 from breast cancer cell lines by molecules such
as bombesin, Cortisol, oestrogen, TNF-a, IL-1, IL-6 and TGF-fi. Bombesin,
glucocorticoids and IL-6 have all been shown to stimulate the production
of ET-1 in different cell lines of breast cancer (Schrey et al., 1992;
Yamashita et al., 1993). In 1995, Patel and Schrey reported that human
cancer cell lines (MCF-7, T47D, MDA-MB-231) contain a
phosphoramidon-sensitive metalloproteinase which can process
exogenously added big ET-1 to ET-1 (Patel and Schrey 1995). In breast cell
lines and tissues, the presence of specific ET receptors has been associated
with fibroblasts. Other studies have shown that ET-Rs are not present on
the epithelial normal breast cells but associated with surrounding
fibroblasts (Baley et al., 1990). Exogenous addition of ET-1 to S3T3
fibroblasts (Kusuhara et al., 1989), breast fibroblasts (Schrey et al., 1992) and
other systems (Schichiri et al., 1991) produced mitogenic effects. ET-1
addition resulted in a modest increase in the incorporation of tritiated
thymidine into human breast fibroblasts but these effects were enhanced
with the addition of the peptide in the presence of IGF-1 (Schrey et al.,
1992). The role of endothelins in breast cancer is still not fully defined but
(i) increased production of the peptides from epithelial cancer cells
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compared to normal cancer cells, and (ii) the absence of ET receptors in
the epithelial cells but the presence of receptors in breast fibroblasts
suggest a possible paracrine role for endothelins.
1.5 Aims
The aims of the present study were focused on expanding the present
knowledge regarding the expression and roles for endothelins and their
receptors in ovarian and breast cancer. More precisely this study aimed
to:
i) measure the expression and secretion of endothelin by epithelial and
fibroblast cell lines derived from ovarian and breast carcinomas.
ii) determine the expression of specific endothelin receptors and their
binding characteristics in the same cell lines.
iii) monitor the effects of the exogenous addition of endothelin-1, -2 and -
3 on the growth of these cell lines in culture.
iv) investigate the effects of the co-culture of epithelial and fibroblast cell
lines on the growth of both cell types.
v) determine the expression of endothelins and endothelin receptors in a





(In this section material suppliers are listed by technique.)
2.1.1 Cell lines
i) Epithelial cancer cell lines
The human ovarian epithelial cancer cell lines PE04 and PE014 were
derived from the ascites of different patients (Langdon et al 1988). The
PE04 ascites was collected from a patient with a poorly differentiated
primary serous adenocarcinoma who had been previously treated with
chemotherapy while the PE014 ascites was collected from a patient with a
well differentiated primary serous adenocarcinoma prior to treatment.
ii) Fibroblastic cell lines
The human ovarian fibroblast cell lines (PE09F, PE012F, PE014F and
PE027F) were cultured from the ascites of patients with ovarian cancer
and the human breast fibroblastic cell lines (BRF1 and BRF2) were
obtained from patients with breast cancer. S3T3 mouse fibroblasts were
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RIA kit for the detection of Endothelin-1 - Peninsula
Trifluoroacetic acid - Sigma
2.1.4 Receptor binding assays









BQ123 (ETa receptor antagonist)
BQ788 (ETb receptor antagonist)
125I-ET-1
IgG immunoglobulin
IRL1038 ETb receptor antagonist
Polyethylene glycol
iii) Protein concentration assays
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2.1.4
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Other materials as described in section
2.1.6 RT-PCR
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2.1.7 Southern blotting
732P-ATP
DNA 5' end labelling system
N+ membrane
Probes (oligonucleotides)
- ICRF Claire Hall
- Gibco BRL
- ICRF Claire Hall
- Techne, Cambridge, UK
- Gibco BRL
- Amersham
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- Boehringer Mannheim,
East Sussex, UK




DPX synthetic mounting medium
Epithelial common antigen
ET-1 human monoclonal antibody
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Rabbit anti mouse biotinylated antibody - Dako limited
Tris buffered saline - Sigma
Xylene - Fisons













i) Growth of cell lines
The breast epithelial cancer cell lines MDA-MB-231, T47D, ZR-75-1, the
ovarian adenocarcinoma cell lines PE04, PE014 and the S3T3 mouse
fibroblast line were routinely cultured at 37°C in an atmosphere of 5%
CO2, 95% air (90% humidity) in Dulbecco's Modified Eagle Medium
(DMEM) containing phenol red pH indicator. The medium was
supplemented with 10% FCS (v/v), L-glutamine (2mM), penicillin (100
IU/ml) and streptomycin (100 pg/ml). The ovarian fibroblastic cell lines
PE012F, PE014F, PE027F were cultured under the same conditions, also
in DMEM containing L-glutamine, penicillin and streptomycin but
supplemented with 15% FCS. Breast cancer fibroblastic cell lines, code-
named BRF1 and BRF2, were routinely cultured in Alpha Modified Eagle
Medium (Alpha MEM) supplemented with 15% FCS and L-glutamine,
penicillin and streptomycin.
ii) Subculturing
Monolayers of all the cell lines were grown to confluence in 75 or 125 cm 2
flasks. Media were discarded and the cells were washed twice with
phosphate buffered saline (PBS) pH 7.3. Cells were then detached from
the plastic by incubating with trypsin (0.25% (w/v) in Gibco solution) /
versene (ImM EDTA in PBS, 0.5% (v/v) phenol red) solution (1:1) for 5-
15 min at 37°C. Following trypsinisation, 5 ml of media were added to the
flasks to neutralize the effect of trypsin and cells were collected in a
Universal container. A microlance 3 needle (0.8x40 mm, 21G for PE04,
MDA-MB-231, T47D, ZR-75-1, S3T3 and 1.1x40 mm, 19G for PE014,
PE012F, PE014F, PE027F, BRF1 and BRF2 cell lines) was used to syringe
cells and create single cell suspensions. Aliquots of cells were seeded into
new flasks. For routine culture, media were replenished every 3-4 days
and cells were passaged once a week.
iii) Preservation and resuscitation of cells from liquid nitrogen
Stocks of each cell line were created by growing cells to near confluence
(80-90%), trypsinising and collecting in a Universal container. An aliquot
(1 ml) of cell suspension was counted in the haemocytometer to estimate
total cell count. The remaining cells were washed with 5 ml of fresh
media containing serum and centrifuged at 1000 x g for 5 min. Aliquots
of the remaining pellet were re-suspended in ice cold 10% (v/v) dimethyl
sulphoxide (DMSO) in foetal calf serum (FCS) at a concentration of 5x106
cells/ml and transferred into cryotubes. Samples were kept at
-80°C for 24 h before being stored in liquid nitrogen for future use. Cells
were resuscitated by removing from the liquid nitrogen and, in order to
thaw rapidly, immersed in a 37°C warm water bath. Cells were then
washed with 5 ml of DMEM media containing FCS (percentage
depending on the cell line) and centrifuged at 1000 x g for 5 min. The cell
pellet was re-suspended in fresh media (5 ml) and transferred to a 25 cm2
flask. After 24 h in culture, cells usually had attached firmly to the surface
of the flask. Attached cells were washed with PBS and covered with fresh
media (5 ml).
2.2.2 Radioimmunoassay of conditioned media for endothelin
i) Preparation and collection of conditioned media
For the preparation of conditioned media for the radioimmunoassay,
each cell line was subcultured in 3 x 25 cm2 flasks and allowed to grow to
90% confluence in phenol red containing media supplemented with the
standard amount of serum. Cells were then washed twice with 5 ml of
pre-warmed PBS and incubated in 10 ml phenol red- and serum-free
DMEM supplemented with HITS (lOnM hydrocortisone, 5pg/ml insulin,
10pg/ml transferrin, 30nM sodium selenite). After 24h this was
removed, fresh media were added and cells were incubated for a further
72 h. The resulting conditioned media were collected and the cells in
each flask were trypsinised and counted.
*
ii) Extraction
Conditioned media collected from different cell lines were applied to C-18
cartridge columns which had been previously activated with 3 x 1ml
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methanol and washed with 3 x 1ml distilled H2O. The columns were
then left at room temperature for 60 min and the bound material was
eluted with 3 ml of 60 % acetonitrile, 0.1% trifluoroacetic acid (60% ACN,
0.1% TFA) and collected in glass tubes. The eluents were evaporated
down overnight using a Univap Uniscience centrifuge and stored at 4°C
until assayed,
iii) Radioimmunoassay
The presence of immunoreactive ET-1 in the conditioned media of
different cell lines was investigated using a commercially available
radioimmunoassay kit (Peninsula). Samples and standards in the RIA
were prepared in duplicate and each experiment was performed on 3
occasions. For the preparation of the standards in the radioimmunoassay,
100 pi of increasing concentrations (1, 2, 4, 8, 16, 32, 64, 128 pg/lOOpl) of
standard ET-1 were added (in duplicate) to 12 x 75 mm plastic tubes.
Three extra pairs of tubes were prepared TC-1 and 2 (total counts), NSB-1
and 2 (non-specific binding), TB-1 and 2 (total binding) with no RIA buffer
(TC tubes) and 200 pi of RIA buffer (NSB and TB tubes) respectively.
Samples of each conditioned media were diluted, 1:1, 1:2, 1:4 and 1:8 and
aliquots (100 pi) of these dilutions were added to the tubes in duplicate.
Primary rabbit anti ET-1 serum (100 pi) was added to TB and all standards
and samples. The tubes were mixed by vortexing, covered in foil and
incubated for 24 h at 4°C. At the end of the incubation period, 100 pi of
15,000 cpm 125I-ET-1 was added to all the tubes, mixed and incubated for a
further 24 h at 4°C. At the end of this second incubation period, goat anti-
rabbit IgG (100 pi) and normal rabbit serum (100 pi) were added to all
tubes. Samples were mixed by vortexing and incubated at room
temperature for 90 min. RIA buffer (500 pi) was then added to all tubes,
mixed and centrifuged at 1700 x g for 20 min at 4°C. The supernatant was
then aspirated from the tubes (apart from TC tubes) with an elongated,
fine point pastette and radioactivity in the tubes was counted using a
Cobra gamma counter. TB tubes demonstrated the "maximum" binding
of the assay while NSB tube accounted for the non-specific binding value
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in the assay. From the counts of the standards in the assay, a plot was
drawn of the %specific binding (%B/Bo) against the log of the standard
concentration of the ET-l-like peptide measured in the assay. From the
resulting sigmoid curve and with the use of the %B/Bo value obtained
for each sample in the assay, it was possible to calculate the concentration
of the ET-l-like peptide for each sample, by finding the intersection point
with the curve and then reading the corresponding X-axis value. Values
were multiplied by the dilution factor and mean values were obtained for
each individual sample.
2.2.3 Receptor binding assay
i) Preparation of cell membranes
Cells were grown to 70% confluence in 125 cm2 flasks in DMEM media
supplemented with 10% FCS and subsequently cultured in serum-free
DMEM media supplemented with HITS until fully confluent. Cells were
then trypsinised with 2ml of trypsin/versene mixture and collected by
centrifugation at 1,000 x g for 10 min at 4°C. The cell pellet was re-
suspended in buffer-1 (lOmM Tris/HCl, 1.5 mM EDTA, 1 mM
benzamidine, 0.002% soybean trypsin inhibitor, pH 7.4) sonicated using a
SONIPREP MSE sonicator and re-centrifuged at 1,000 x g for 5 min at 4°C.
The resulting supernatant was ultracentrifuged at 100,000 x g in a
Beckman TL 100 for 30 min at 4°C and the pellet re-suspended in 0.5 ml of
buffer-2 (50mM Tris/maleate, lOmM MgSC>4, ImM benzamidine, 0.002%
soybean trypsin inhibitor, pH 7.4). The "membrane" fractions were
passed through a pastette to disaggregate clumps, transferred into
cryotubes and stored at -80°C, until assayed. An aliquot (100 ml) of the
membrane preparation was stored for protein estimation at a later date.
ii) Binding assay
The binding assay was performed in 12 x 75 mm Pyrex borosilicate glass
tubes. Duplicate aliquots (2 x 100 pi) of membrane preparations were
incubated with 50pl of increasing concentrations of non radioactive ET-1
(final concentrations of: 50, 100, 200, 450, 950, 1450, 2950, 4950, 6950, 9950
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pM) added to 50|il of a fixed (50 pM) concentration of i25I-ET-l. The
radiolabeled and standard ET-1 were left for 10 min at 30° and a
membrane fraction (100 pi) was added to each tube. Samples were placed
in a shaking water bath for 90 min at 26°C; conditions found to be optimal
for this assay (results section). To terminate the reaction, tubes were
placed on ice and 0.5 ml of ice-cold 0.5% (w/v) immunoglobulin G (IgG)
was added to each tube, followed by 1 ml of 12.5% (w/v) polyethylene
glycol (PEG). Separation of the bound and free 125I-ET-1 was performed by
centrifugation at 3000 rpm for 15 min at 4°C using a swing out rotor on a
Beckman CPR centrifuge. After centrifugation, samples were placed on
ice and the supernatant, containing the free 125I-ET-1, was aspirated with a
fine-tip pastette and the remaining pellet, containing the bound 125I-ET-1,
was counted in a Packard Cobra Gamma Counter. The "total" cpm was
calculated using two tubes containing the same amount of labelled ET-1
(50 pM) but no membranes or standard ET-1. Non-specific binding (NSB)
was also calculated using lpM of standard ET-1 and was found to be less
than 10% of total binding.
iii) Receptor site concentration
The cpm value of 125I-ET-1 in each tube, was corrected by subtraction of
the value for the NSB and data were analyzed and plotted according to
the method described by Scatchard (Scatchard, 1949). For interpretation of
the data, the "Ligand" computer program (Biosoft) was used to determine
dissociation constant values (Kd) and x-axis intercept values (Bmax). The
same programme was used in the case where two components were
present in the graph, to fit, assign and calculate, the Kd and Bmax values.
iv) Binding inhibition experiments
For the binding inhibition experiments the same protocol as described
above was used. Aliquot of cell membrane samples (in triplicate) were
incubated at 26°C for 90 min with 125I-ET-1 (50pM), increasing
concentrations (10-13 to 10-6M) of ET-1, ET-3, BQ123 (ETa-R antagonist)
and BQ788 (ETb-R antagonist). At the end of the incubation period
specific binding was calculated as described previously. Non-specific
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binding was determined in the presence of lpM ET-1.
v) Protein concentration assays
A modified version of the Bradford assay (Bradford et al 1976) was used to
measure the protein concentration of the membrane preparation.
Aliquots (100 pi) of (i) BSA standards (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8
mg/ml), (ii) two BSA quality controls (0.4 and 0.8 mg/ml) (iii) the
membrane preparations which had been incubated with 2M NaOH (100
pi) for 1 h at 60°C and neutralised by the addition of 2M HC1 (100 pi), were
prepared. For each membrane preparation dilution sample (20 pi), BSA
standard, quality control sample, or simple buffer sample triplicate 12x75
mm glass tubes were prepared. The reagent solution was prepared by
diluting Bio-Rad Protein Dye Assay Reagent Concentrate 1:5 in distilled
water and filtering through Whatman Number One filter paper. This
solution was added (1 ml) to the last solution and mixed by vortexing.
Aliquots (200 pi) of each solution were pipetted into 96-flat bottomed well
microtitre plates and the optical densities (OD) of the solutions were read
in a Bio-Rad automatic plate reader at 595 nm. The protein concentration
of each sample was calculated by comparison of the sample's OD with
those on the standard curve.
2.2.4 Growth assays
i) Growth curves
Cells were plated in 24 well plates at a concentration of 2.5 x 104 cells/ml
and left to grow for 9 days in the conditions optimal for each cell line (see
section 2.2.10) or in 1% FCS. Quadruplicate wells were trypsinised and
counted on days 0, 2,4, 7, 9 and 11.
ii) Preparation of HITS nutrient
The preparation of HITS nutrient was performed in sterile conditions by
dissolving insulin (5 pg/ml) in 0.01M of NaOH/EtOH in a total volume
of 1L. To the resulting solution, hydrocortisone, transferin and sodium
selenite were added. The HITS stock solution was stored in aliquot (5 ml).
One aliquot was added to each 500 ml of media (final concentrations of
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nutrients: hydrocortisone 100 nM, insulin 5 |ig/ml, transferin 10|ig/ml,
and sodium selenite 30 nM).
iii) Effects of ETs on the growth of cell lines
The effects of the exogenous addition of ETs on the growth of different
cell lines were investigated as follows. The growth curves for the cell
lines were determined in DMEM + 10% FCS, DMEM + 15% FCS and in
Alpha MEM + 15% FCS (breast fibroblasts) and phenol red-free DMEM
+1% FCS and phenol red -free Alpha MEM + 1% FCS. For MDA-MB-231,
T47D, ZR-75-1, PE04, PE014, S3T3 cell lines, cells were harvested in mid-
log phase as mentioned before (see section 2.1.2) and sub-cultured in 24
well plates (0.5 ml/well) at a concentration of 5x104 cells/well (2.5x104
cells/well for MDA-MB-231, T47D, ZR-75-1 and PE04 cells), using an
Eppendorf multidispenser. Cells were cultured at such conditions for 24h
and were subsequently washed x2 with pre-warmed PBS (0.5 ml/well) and
incubated in phenol red-free DMEM + 1% FCS for a further 24h. Phenol
red-free DMEM was used because it has been shown (Berthois et al 1986)
that phenol red possesses weak oestrogenic activity. Fresh 1% FCS
+DMEM with or without concentrations of ETs ranging from 10-^M to 10-
13M were added to the cells (Day 0); cultures were incubated for 48h, at the
end of which period the same addition was performed (Day 2) and cells
were incubated for a final 24 h. Finally (Day 5), cells were washed twice
again with pre-warmed PBS, were trypsinised in 250|il trypsin/versene
mixture/well and counted in a Coulter counter. For PE012F, PE014F and
PE027F ovarian fibroblasts the same method was used but cells were
initially plated in 15% FCS DMEM instead of 10% FCS. In the case of
breast fibroblasts, cells were cultured in 6 well plates because of their
larger size and tendency to be contact inhibited. They were initially plated
in 2 ml of 15% FCS/Alpha MEM media, were washed in 2ml of pre-
warmed PBS and were trypsinised using 1 ml of trypsin/versene mixture.
ET additions and replenishment of the media were performed as before
and at the same time-points as for the other cell lines. Each set of
conditions was studied in quadruplicate and in some cases cells were
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counted on days 0, 2, 5, while in others, cells were counted only on day 5.
For the receptor antagonist experiments, the same protocol was used but
lOOnM of either BQ123 (ETa-R) or BQ788 (ETb-R) antagonists was added to
cells at the same time as ETs of fresh media,
iv) "Antisense" experiments
For the "antisense" experiments, specific "antisense" oligonucleotides
against ETa and ETb receptors mRNA were designed to block the
translation of these RNA molecules to proteins. Antisense
oligonucleotides were targetted to the start codon (methionine) within
the mRNA human ETa-R (Sakamoto et al., 1991) and ETb-R (Elshourbary
et al., 1993) sequence. "Sense" oligonucleotides for ETa and ETb mRNAs
as well as a "random" oligonucleotide were also designed to test the
specificity of the "antisense" and their sequences are shown in table 2.1.
PE04 and PE014 cells were seeded in 24 well plates at concentrations of 2.5
and 5X104 cells/well respectively and cultured in 10% FCS for 24h. Old
media were then replaced with serum free media (DMEM+HITS) and
after a further 24h, concentrations of 10 or 30|iM of "antisense", "sense"
and "random" oligonucleotides were added to cell cultures. After a
further 48h, fresh oligonucleotides were added and cells were cultured for
two days, at the end of which period they were trypsinised (as described
before) and counted using a Coulter Counter.






Table 2.1: Sequences and general information on oligonucleotides used in anti-sense
experiments.
v) Co-culture experiments
For the co-culture experiments, fibroblasts (PE012F and BRF1 cells) were
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seeded in wells of 24 well-plates (5xl04 cells/well) at standard serum (10%
and 15%, respectively) conditions, while epithelial cancer cells (PE014 and
T47D cells) were seeded (at 2.5xl04 cells/well in 10% serum) in 24 well-
plate inserts that were placed in separate wells. After 24h, epithelial cells,
contained in well inserts were transferred on top of fibroblasts cells and
were cultured together for 5 days in 1% serum in the presence or absence
of BQ123 or BQ788 ET-receptor antagonists (lOOnM). At the end of the
incubation period cells were trypsinised and counted using a Coulter
Counter.
vi) Coulter counting
At the end of the 5 day incubation period, media were removed from
each well, cells were subsequently washed in warmed PBS (0.5 ml/well)
and detached from the well by incubation with trypsin/versene mixture
(0.25 ml/well) at 37°C for a few minutes. Detachment of the cells from
the well was observed under the microscope and cells were passed
through a microlance 3 syringe (0.8x40 mm, 21G for PE04, MDA-MB-231,
T47D, ZR-75-1, S3T3 and 1.1x40 mm, 19G for PE014, PE012F, PE014F,
PE027F, BRF1 and BRF2) to obtain single cell suspension. An aliquot of
the cell suspension (200pl) was added to 0.9% NaCl (9.8 ml) and gently
mixed. Each suspension was counted 3 times using a 200|im diameter
probe in a ZF Coulter counter. In order to calculate number of cells /well
the mean value of the triplicate counts were multiplied by the dilution
factor (x 25 for the 24 well plates and x 100 for the 6 well plates).
2.2.5 RNA ISOLATION
i) Homogenisation of tumours
Tumour samples were removed from liquid nitrogen, placed in a Falcon
35 x 10 mm petri dish and sliced into small pieces, as rapidly as possible,
with a sterile surgical blade under sterile conditions. Pieces of tumour
were then placed into a homogenisation capsule of a MIKRO-
DISMEMBRATOR II homogeniser and homogenised for ten seconds or
until completely powdered. The tumour powder was subsequently
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removed from the capsule into a SARSTEDT (95 x 16.8 mm) centrifuge
tube using a pastette and TRI REAGENTTM was added to the tumour
preparation (1 ml per 50-100 mg of tissue). Tumour homogenates were
stored at -80°C before RNA extraction.
ii) RNA isolation from tumour homogenates
Homogenized samples were left for 5 min at room temperature to allow
the complete dissociation of nucleoprotein complexes. Chloroform
(0.2ml/lml) of TRI REAGENTTM) was added to each tube which was then
covered tightly, vigorously shaken for 15 s and left at room temperature
for 15 min. The resulting mixtures were centrifuged at 12,000 x g for 15
min at 4°C using a Sorvall RL-5B (DU POND) centrifuge. After
centrifugation, the mixture separated into three phases. The red-coloured
phenol-chloroform lower phase, contained the proteins, the white
interphase contained most of the DNA and the upper clear aqueous phase
contained the RNA. The clear aqueous RNA phase which constituted
60% of the total volume, was removed into new tubes. For precipitation
of RNA, isopropanol (0.5 ml/1 ml of TRI REAGENT™) was added to
each tube. At this point samples were dispensed into 1 ml eppendorf
tubes, left at room temperature for 10 min and subsequently centrifuged
at 12,000 x g for 10 min at 4°C using an Eppendorf centrifuge. At the end
of the centrifugation, the RNA precipitate formed a gel-like pellet on the
side and bottom of each eppendorf tube. The supernatant was removed
using an extended nose pastette and pellets were washed with 75%
ethanol (1 ml of 75% ethanol/ 1 ml of TRI REAGENTTM) by vortexing
and centrifuged at 7,500 x g for 5 min at 4°C (Eppendorf centrifuge). The
supernatant was removed with an extended nose pastette and the pellet
was dissolved in 40 pi of diethyl pyrocarbonate (DEPC) treated water. A
small aliquot was removed (5 pi) for concentration assessment and the
remaining RNA was stored at -80°C for future use.
iii) RNA isolation from cell lines
For the preparation of RNA from cell lines, cells were allowed to grow to
confluence using routine culture conditions in 75 cm2 flasks. Media were
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removed using a sterile 25 ml plastic pipette and TRI REAGENT ls (i
ml/10 cm2) was added to each flask in order to lyse the cells. The lysate
was passed through the pipette several times to allow complete lysis and
was transferred into a SARSTEDT (95 x 16.8 mm) test and centrifuge
tubes. For RNA isolation, the same protocol described above (section
2.2.5) was followed.
The yield and purity of the RNA preparation products were measured by
mixing the RNA preparations (5pl) with water (1295|il) and measuring
the light absorbance of the mixture at wavelengths of A 260 and A 280 in a
UNICAM UV/VIS spectrophotometer. Samples with very low yield (<5
pg) and/or low purity were discarded (purity = A260/A280 and the
acceptable values are 1.6-2.0).
2.2.6 RT-PCR
i) Selection of oligonucleotide primers
The human ET-1, ET-2, ET-3 DNA gene sequences as published by Bloch
et al 1989, 1991 were used in order to design specific primers for all 3
endothelin peptides with the assistance of the Gene Jockey program. The
primers used for ETa-R, ETg-R and fi-actin were originally designed by
Pekonen et al (1995). The sequences of all the primers are shown in table
2.2.
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For reverse transcription of the endothelins, their receptors and fi-actin, a
small aliquot of each RNA (5 pg) prepared from cell lines and tumour
samples was mixed with 1 pi oligo dT primer, 2 pi TaQ buffer (50 mM
KC1, 10 mM Tris, 0.1%TritonX-100), 2 pi of each deoxy-NTP (1 mM) and 4
pi MgCh (5 mM). The mixture was heated to 65°C for 5 min in a Techne
PHC-3 programable thermal cycler for the RNA to anneal to oligo-dT
primers. The mixture was then transferred onto ice for 2 min before
RNAsin (0.5 pi) and reverse transcriptase (RT) (0.5 pi) enzymes were
added to each tube. Samples were re-placed in the thermal cycler at 42°C
for 1 h to allow the first strand cDNA synthesis. This was followed by
incubation for lmin at 92°C to inactivate the RT enzyme.
iii) Preparation of the primers
All the PCR primer oligonucleotides were received in eppendorf tubes.
To each primer, 60 pi of sodium acetate (1 M), 80pl MgCl2 (25 nM), 60 pi of
dH20 and 600 pi of cold ethanol were added. The oligonucleotides were
left on dry ice for 15 min and centrifuged at maximum speed (15,000 rpm)
using an eppendorf centrifuge for 5 min. The supernatant was removed
using a pastette and pellets were washed in 1 ml of 80% cold ethanol.
Primers were mixed and re-centrifuged once again at maximum speed for
5 min. The ethanol was removed and pellets were re-suspended in 1 ml
of RNAse-free H2O and stored at -40°C. A small aliquot (10 pi) of each
primer was re-suspended in 990 pi of H2O.
iv) Polymerase chain reaction (PCR)
For the PCR reaction, 1 pg of reverse transcribed RNA product (4 pi) was
added to a total of 20 pi of PCR mixture containing 0.3 mM dNTP (0.6 pi),
10 pmol of each primer (0.6 pi) and 2.5 units of Taq polymerase (0.5 pi) in
buffer containing 1.875 mM MgCl2, 10 mM Tris, 50 mM KC1, 0.1% Triton
X-100 and RNAse free water. The reaction mixtures were set up in
Eppendorf tubes and mixed. A drop of light mineral oil was added to
each tube for the prevention of evaporation of the mixture. The PCR
reaction was a three step reaction incubating at 93°C (1 min), 57 or 60°C (1
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min) and 72°C (1 min); products were amplified for 32 cycles at the above
temperatures followed by a further 5 min run at 72°C. The products of
the reaction were visualised under UV light with the use of ethidium
bromide on a 1.4% agarose gel which ran for 90 min at 100V.
2.2.7 Southern Blotting
i) DNA Transfer
A photograph of the gel of the PCR products was taken and the position
of each band on the gel noted before immersing the gels in distilled water
for 30 min for destaining. Capillary action was used to transfer the DNA
from the gel onto a nylon membrane overnight using an alkaline transfer
(0.4 M NaOH). After the completion of the transfer the membrane was
air dried, sealed in a plastic bag and stored at 4°C until used. To check for
the complete transfer of the DNA on the membrane, the gel was re-
stained in ethidium bromide solution for 30 min and visualised under
UV light.
ii) Probe labelling
The oligonucleotides used for the probe labelling were designed using the
cDNA sequences of the 3 endothelin isoforms and the two receptor types
as published (table 2.3). The specific sequences were contained within the
section of the cDNA sequence of the selected primers used for the PCR
amplification. The oligonucleotides were end-labelled with y32? ATP in a
reaction mixture containing 20 ng of oligo, 3 units of T4 polynucleotide
kinase, in lx forward exchange buffer and 1.85 mBq of y32P ATP. The
mixture was mixed and incubated for 30 min at 37°C.






Table 23: Sequences of oligonucleotides used in Southern blot experiments.
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iii) Hybridisation and washing
Membranes were submerged in 6x saline sodium citrate (SSC). In order to
remove any air bubbles, the membranes were carefully rolled between
two pieces of nylon gauze. The membranes were then placed in
hybridisation oven tubes, immersed in hybridisation solution (5x SSc
containing 0.1% SDS, 0.1% sodium pyrophosphate, 0.05% BSA, 0.05%
polyvinyl pyrolidine, 0.05% ficol) and prehybridised for 30 min at 48°C.
The solution was poured off and 25 ml of hybridisation solution
containing the labelled oligonucleotide was added. The membranes were
left in this solution for 4h at 48°C after which period filters were rinsed
twice and washed four times at 48°C for 15 min in 4x SSC, 0.1% sodium
pyrophosphate. The filters were then sealed in plastic bags and
autoradiography was carried out at room temperature, where filters were
exposed for 30 min to 2h.
2.2.8 Immunohistochemistry
i) Tumour samples
Paraffin fixed sections of tumour samples were dewaxed in xylene for 10
min and washed in descending concentrations of ethanol before being
placed in 1% hydrogen peroxide for 15 min and washed in water. The
sections were then washed in Tris buffered saline (TBS) for 5 min and
were incubated in a moist environment with 20% FCS in TBS for 10 min.
Excess TBS /FCS was drained off and sections were covered with primary
human ET-1 (1: 200 dilution in water), ET-2 and ET-3 (1:400 dilution in
water) antibodies for 30 min at room temperature followed by 2x 5 min
washes with TBS. The sections were covered with avidin biotin
peroxidase (AB) complex dissolved in TBS for 20 min at room
temperature and washed as before. The sections were then covered in 1
mg/ml solution of 3,3' diaminobenzidine (DAB) containing 5% hydrogen
peroxide for 5 min at room temperature and washed in water. Finally,
the sections were counterstained lightly in haematoxylin, dehydrated in
alcohol, cleared in xylene and mounted in DPX under coverslips.
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ii) Multispot slides
For the preparation of the multispot slides from the ovarian fibroblast cell
lines, cell suspensions (20|il of 5x106 cells/ml) were added to each well on
the slides. Multiwells were left to dry overnight and then fixed in 1:1
acetone /methanol solution for 10 min. Fixed slides were left to air dry
and transferred to -20°C until used. Multispot slides were processed
further using the same protocol as the tumour samples, discussed above.
Four primary antibodies were added to the slides: monoclonal mouse
anti-human fibroblast (1:10 dilution), epidermal membrane antigen (1:40),
common leucocyte antigen (1:10) and human endothelin 1 (1:200).
2.2.9 Statistics
All the statistical analysis were based on paired t-test analysis of variant.
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Chapter 3: Cell lines and growth
The role of the endothelin family in ovarian and breast cancer was
studied using a number of cell lines as models. Two human ovarian
cancer (PE04 and PE014), three breast cancer (MDA-MB-231, T47D and
ZR-75-1), three human ovarian fibroblast (PE012F, PE014F and PE027F)
and two breast fibroblast (BRF1, BRF2) cell lines were used in this study.
The growth of these cell lines in varying serum conditions was first
established.
3.1 Ovarian cell lines
3.1.1 Ovarian epithelial cancer cell lines
The two cancer cell lines, PE04 and PE014, were routinely cultured in
10% serum and images of the cultures of these cells are shown in
photographs 3.1 and 3.2. The growth of these cells in DMEM culture
media supplemented with 10% (with phenol red) or 1% (without phenol
red) foetal calf serum (FCS) over an 11 day period is discussed below.
i) PE04 cells
PE04 cells were seeded at a concentration of 2.5x104 cells/well in 24 well
plates. Cells growing in 10% FCS DMEM progressively increased in
number over the culture period, reaching 50x104 cells/well at the end of
the 11 day incubation. In contrast, cells cultured in 1% FCS conditions
grew much more slowly and reached only 7.2x104 cells/well at the end of
the same period (figure 3.1).
ii) PE014 cells
PE014 cells were also seeded in 24 well plates at a concentration of 2.5xl04
cells/well and cultured in either 1% or 10% FCS conditions. At the end of
the 11 days incubation, cells had reached 23xl04 cells/well while cells in
1% FCS reached 7.5xl04 cells/well (figure 3.2). Comparing the growth of
the two ovarian cancer cell lines, it can be seen that PE04 cells grow faster
than PE014 cells in 10% serum, and that both cell lines grow much slower
but at comparable rates in 1% serum.
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Figure 3.1; Growth of PE04 ovarian epithelial cancer cells (shown on top) in culture media
containing 10% and 1% foetal calf serum (FCS) during an 11 day incubation period. Cells
were seeded in 24 well plates at a concentration of 2.5x104 cells/well in 15% serum
conditions. After 24h media fresh media supplemented with either 10% or 1% serum were
added in the cultures and cells were incubated for 10 days. Cells counts were obtained on
days 0. 2,5,7,9 and 11. Media were replenished once on day 5. Results represent mearctse
of quadruplicate values obtained from a representative of 3 experiments performed on
separate occasions.
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Figure 3.2: Growth of PE014 ovarian epithelial cancer cells (shown on top) in culture
media containing 10% and 1% foetal calf serum (FCS) during an 11 day incubation period.
Cells were seeded in 24 well plates at a concentration of 25xl04 cells/well in 15% serum
conditions. After 24h media fresh media supplemented with either 10% or 1% serum were
added in the cultures and cells were incubated for 10 days. Cells counts were obtained on
days 0.2,5,7,9 and 11. Media were replenished once on day 5. Results represent meartfcse
of quadruplicate values obtained from a representative of 3 experiments performed on
separate occasions.
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3.1.2 Ovarian fibroblast cell lines
3.1.2.1 Characterisation
The fibroblasts that were used in the experiments presented in this thesis
were derived from ascites of patients with ovarian cancer. The PE09F
and PE014F cells were derived from patients with adenocarcinoma while
PE012F and PE027F cells were derived from patients with serous
cystadenocarcinoma. Samples of ascites were recovered from liquid
nitrogen and seeded into tissue culture flasks. After 6 h, media (15%
FCS) were replaced. The fibroblasts which attach more rapidly to the
tissue culture plastics were thus selected and once the cultures were
established, multispot slides were prepared for immunohistochemistry in
order to compare the original ascites with the selected fibroblast culture.
The antibodies selected were: leucocyte common antigen, epithelial
membrane antigen, fibroblast antigen and ET-1 antibody (not used with
ascites). A number of dilutions were used in order to determine the
optimum antibody concentrations and controls (no primary antibody
addition) were included in each set of multispots. The ascites cell
population for the PE012F cell line consisted predominantly of leucocytes
(85%) and contained few fibroblasts (10%) and less epithelial cells (5%).
Multispots of the cultured cells stained with the same antibodies showed
that almost 99% of the cells were stained with the fibroblast antibody, and
very low staining with common leucocyte antigen , ET-1 and epithelial
membrane antigen, suggesting that the cultured cells were fibroblasts.
The other two cell lines (PE014F and PE027F) showed similar results.
Examples of the observed staining in the ascites and fibroblasts are shown






Figure 33: Multispot slides stained with leucocyte common antibody
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Figure 3.4: Multispot slides stained with epithelial membrane antigen.
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Figure 3.6: Multispot slides stained with ET-1 antibody.
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3.1.2.2 Growth
Several culture conditions using a variety of serum concentrations were
compared in order to decide optional conditions for the growth of these
cells. It was finally decided that ovarian fibroblast cell lines were growing
best when cultured in media supplemented with 15% FCS and images of
these cell lines are shown in photographs 3.7, 3.8 and 3.9 PE012F, PE014F
and PE027F cell lines appear to have a limited period of growth in cell
culture after which their rate of growth slows down and they
progressively become enlarged and die. In all the experiments performed
therefore, cells were used within the first three weeks of their growth.
i) PE012F
PE012F fibroblasts were seeded at a concentration of 2.5x104 cells/well in
24 well plates and cultured in 1% and 15% serum for 11 days. Cells
growing in 15% serum reached levels of 12xl04 cells/well while cells
cultured in 1% serum had a far lower rate of growth reaching 5.9xl04
cells/well (figure 3.7).
ii) PE014F
As with PE012F cells, PE014F fibroblasts were seeded at a concentration of
2.5xl04 cells/well. At the end of the 11 day incubation in 15% serum
numbers of cells had reached 11.7xl04 cells/well compared to 5.8xl04
cells/well for cells growing in 1% serum for the same period of time
(figure 3.8).
iii) PE027F
PE027F cells seeded at the same concentration as PE012F and PE014F
fibroblasts also exhibited higher growth rates when cultured in 15%
serum, reaching 12.7xl04 cells/well compared to 5.9xl04 cells/well when
cultured in 1% serum (figure 3.9).
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Figure 3.7: Growth of PE012F ovarian fibroblasts (shown on top) in culture media
containing 15% and 1% foetal calf serum (PCS) during an 11 day incubation period. Cells
were seeded in 24 well plates at a concentration of 2.5x104 cells/well in 15% serum
conditions. After 24h media fresh media supplemented with either 15% or 1% serum were
added in the cultures and cells were incubated for 10 days. Cells counts were obtained on
days 0.2,5,7,9 and 11. Media were replenished once on day 5. Results represent mean±se




Figure 3.8: Growth of PE014F ovarian fibroblasts (shown on top) in culture media
containing 15% and 1% foetal calf serum (FCS) during an 11 day incubation period. Cells
were seeded in 24 well plates at a concentration of 2.5x104 cells/well in 15% serum
conditions. After 24h media fresh media supplemented with either 15% or 1% serum were
added in the cultures and cells were incubated for 10 days. Cells counts were obtained on
days 0.2,5,7,9 and 11. Media were replenished once on day 5. Results represent mearttse




Figure 3.9: Growth of PE027F ovarian fibroblasts (shown on top) in culture media
containing 15% and 1% foetal calf serum (PCS) during an 11 day incubation period. Cells
were seeded in 24 well plates at a concentration of 2.5x104 cells/well in 15% serum
conditions. After 24h media fresh media supplemented with either 15% or 1% serum were
added in the cultures and cells were incubated for 10 days. Cells counts were obtained on
days 0. 2,5,7,9 and 11. Media were replenished once on day 5. Results represent mearttse
of quadruplicate values obtained from a representative of 3 experiments performed on
separate occasions.
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3.2 Breast cell lines
3.2.1 Breast epithelial cancer cell lines
The three breast carcinoma cell lines MDA-MB-231, T47D and ZR-75-1
were routinely cultured in DMEM culture medium with 10% serum.
Photographs and growth curves of the three cell lines are seen in figures
3.10 and 3.11 and 3.12.
i) MDA-MB-231
Cells were seeded in 24 well plates at a concentration of 2.5x104 cells/well
and cultured in 10% and 1% serum for 11 days. The rate of growth in 10%
serum was higher than in 1% serum and growth reached 55xl04
cells/well compared to 13xl04 cell/well (figure 3.10).
ii) T47D
As with MDA-MB-231 cells, T47D breast cancer cells showed better growth
in 10% serum conditions reaching 43xl04 cells/well compared to lOxlO4
cells/well when cultured in 1% serum conditions. Comparing the
growth rates of T47D cells with those of MDA-MB-231, it appeared that
T47D cells grow more slowly than MDA-MB-231 cells in both 10% and 1%
serum conditions (figure 3.11).
iii) ZR-75-1
ZR-75-1 cells were the slowest growing epithelial breast cancer cells of the
three cell lines used in the study. However, the same characteristics of
growth were observed with ZR-75-1 cells, with 10% serum conditions
allowing cells to grow to 16xl04 cells compared to 6xl04 cells/well in 1%
serum conditions (figure 3.12).
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Figure 3.10: Growth of MDA-MB-231 breast epithelial cancer cells (shown on top) in
culture media containing 10% and 1% foetal calf serum (FCS) during an 11 day incubation
period. Cells were seeded in 24 well plates at a concentration of 2.5xl04 cells/well in 15%
serum conditions. After 24h media fresh media supplemented with either 10% or 1% serum
were added in the cultures and cells were incubated for 10 days. Cells counts were obtained
on days 0. 2, 5, 7, 9 and 11. Media were replenished once on day 5. Results represent
meantse of quadruplicate values obtained from a representative of 3 experiments












Figure 3.11: Growth of T47D breast epithelial cancer cells (shown on top) in culture media
containing 10% and 1% foetal calf serum (PCS) during an 11 day incubation period. Cells
were seeded in 24 well plates at a concentration of 2.5x104 cells/well in 15% serum
conditions. After 24h media fresh media supplemented with either 10% or 1% serum were
added in the cultures and cells were incubated for 10 days. Cells counts were obtained on
days 0.2,5,7,9 and 11. Media were replenished once on day 5. Results represent mean±se




Figure 3.12: Growth of ZR-75-1 breast epithelial cancer cells (shown on top) in culture
media containing 10% and 1% foetal calf serum (FCS) during an 11 day incubation period.
Cells were seeded in 24 well plates at a concentration of 25xl04 cells/well in 15% serum
conditions. After 24h media fresh media supplemented with either 10% or 1% serum were
added in the cultures and cells were incubated for 10 days. Cells counts were obtained on
days 0. 2,5,7,9 and 11. Media were replenished once on day 5. Results represent mearctse
of quadruplicate values obtained from a representative of 3 experiments performed on
separate occasions.
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3.22 Breast fibroblast cell lines
The two breast fibroblast cell lines BRF1 and BRF2 were obtained by Peter
Mullen (ICRF Medical Oncology Unit, Edinburgh, personal
communication) and previously routinely cultured in Alpha MEM
culture medium supplemented with 15%. For these growth experiments,
cells were seeded in 24 well plates at 2.5xl04 cells/well in 15% serum
conditions. Cells were supplemented with fresh medium 24h after
seeding and allowed to grow in the same conditions or in 1% serum
conditions for 10 days. Photographs of the cell lines and growth curves
for the 11 day incubation period under both sets of conditions are shown
in figures 3.13 and 3.14.
i) BRF1
As shown in figure 3.13, BRF1 cells exhibited satisfactory growth under
both sets of conditions. However, in 15% serum, cells grew faster
reaching a cell number of 62x104 cells /well compared to 38x104 cells/well
when cultured in 1% serum for the same incubation period (figure 3.13).
ii) BRF2
The growth of the BRF2 cells was very similar to that of BRF-1 fibroblasts.
In media supplemented with 15% serum cell number reached 63xl04
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Figure 3.13: Growth of BRF1 breast fibroblasts (shown on top) in culture media containing
15% and 1% foetal calf serum (FCS) during an 11 day incubation period. Cells were seeded
in 24 well plates at a concentration of 2.5x10* cells/well in 15% serum conditions. After 24h
media fresh media supplemented with either 15% or 1% serum were added in the cultures
and cells were incubated for 10 days. Cells counts were obtained on days 0.2,5,7,9 and 11.
Media were replenished once on day 5. Results represent meartfcse of quadruplicate values
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Figure 3.14: Growth of BRF2 breast fibroblasts (shown on top) in culture media containing
15% and 1% foetal calf serum (FCS) during an 11 day incubation period. Cells were seeded
in 24 well plates at a concentration of 2.5x104 cells/well in 15% serum conditions. After 24h
media fresh media supplemented with either 15% or 1% serum were added in the cultures
and cells were incubated for 10 days. Cells counts were obtained on days 0.2,5,7,9 and 11.
Media were replenished once on day 5. Results represent meanise of quadruplicate values
obtained from a representative of 3 experiments performed on separate occasions.
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3.4. Discussion
Results presented in this chapter, show the growth characteristics of a
number of cell lines that were used as models in order to investigate the
role of endothelins in ovarian and breast cancer. A number of
experiments using the cell lines would need to be carried out at restricted
serum conditions and thus the growth of the cell lines was investigated
in full and restricted serum conditions. All the cell lines demonstrated
more rapid growth in 10-15% serum. However, even in 1%FCS all the
cell lines exhibited some growth during the 11 day incubation period and
indicated that these culture conditions can be used in experiments.
Additional results show the characterisation of the PE012F, PE014F and
PE027F cell lines which were shown to consist of more than 99%
fibroblasts.
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Chapter 4: Expression of endothelin
4.1 Secretion of endothelin by ovarian and breast carcinoma and fibroblast
cells
The following section describes the results of experiments designed to
assess if ovarian and breast carcinoma and fibroblastic cell lines secrete
ET-l-like peptide. The method used to determine such secretion is based
on an assay of conditioned media using a radioimmunoassay employing
an ET-1 specific primary antibody included in a commercially available
ET-1 detection radioimmunoassay kit (Peninsula).
4.1.1 Optimisation of extraction procedure
For the detection of ET-l-like material secreted by different cell lines,
conditioned media were collected and concentrated by extracting the
material through cartridge columns. Conditioned media (5ml) from two
ovarian (PE04, PE014) and three human breast epithelial cancer cell lines
(MDA-MB-231, T47D, ZR-75-1), three ovarian (PE012F, PE014F, PE027F)
and two breast fibroblast cell lines (BRF2, BRF1) as well as mouse S3T3
fibroblasts growing under serum-free conditions, were collected. After
collecting the conditioned media, the cells in each flask were trypsinised
off the plastic and counted using a coulter counter. Collected conditioned
media were extracted through CI8 cartridge columns and concentrated to
one tenth of their original volume by centrifugation under vacuum and
reconstitution in radioimmunoassay (RIA) buffer (500}il).
In order to determine the efficiency of the extraction method, duplicate
samples of diluted 125I-ET-1 (1975,1875 and 1934, 1963 cpm respectively) in
serum-free media were loaded onto a C-18 cartridge column and after 60
min at room temperature the bound material was eluted with either 60%
acetonitrile or 60% acetonitrile plus 0.1% tri-fluoro-acetic acid. At the end
of the extraction, 80% (mean value of two samples: 1597cpm) of
radiolabeled ET-1 eluted with 60% acetonitrile was recovered, while 96%
(mean value of two samples: 1897cpm) of 125I-ET-1 using 60% acetonitrile,
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0.1% tri-fluoro-acetic acid, was collected. Since the latter extraction
proved more efficient, the extractions of the conditioned media collected
from all the cell lines in culture were performed using 60% acetonitrile,
0.1% tri-fluoro-acetic acid for the elution of the material bound on the C-
18 cartridges.
4.1.2 Radioimmunoassay optimisation and specificity
Before the radioimmunoassay was routinely used to detect the level of
peptide secreted by different cell lines, several control experiments were
performed in order to optimise the method and determine its specificity.
The data sheet supplied with the radioimmunoassay kit suggested low
cross-reactivity of the ET-1 peptide with the isopeptides ET-2 and ET-3
(7%). To confirm these levels of cross-reactivity, serial dilutions of ET-2
and ET-3 (128, 64, 32, 16 and 8 pg), and ET-1 (128, 64,16, 4 and 1 pg), were
run through the assay and were compared to the serial dilutions of the
standard ET-1 included in the RIA kit (figure 4.1).
Figure 4.1 shows that ET-1, ET-2 and ET-3 compete with the radiolebelled
ET-1 in the radioimmunoassay. However, ET-1 dilutes in an almost
identical way with the standard peptide while the addition of ET-2 and
ET-3 give somewhat different results. The cross-reactivities of ET-2 and
ET-3 with the assay's standard ET-1 were estimated to be 14.4% and 8.3%
respectively, while ET-1 that had been obtained from different sources
behaved identically with the standard ET-1 included in the kit. Two
completely unrelated peptides [bombesin and interleukin-6 (IL-6)] were
also run through the assay and results suggested that no cross-reactivity of
standard ET-1 was detected with either bombesin or IL-6. Table 4.1 shows
the amounts of ET-1, ET-2 and ET-3 added in diluted samples of the
peptides in the assay in order to determine the level of cross-reactivity.
The results of immunoreactive ET-1-like material
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Figure 4.1: Graph shows the parallel dilution of standard ET-1 included in a125I-ET-l
radioimmunoassay kit with ET-1, ET-2, ET-3 obtained separately. Dilutions of two
unrelated peptides bombesin, and interleukin-6 showed little displacement and no
parallelism with standard ET-1. Graph is a typical example of 3 experiments performed
on separate occasions.
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Table: 4.1: Table of the cross reactivity of standard ET-1 included in the
radioimmunoassay kit with ET-1, ET-2 and ET-3 which had been obtained separately.
First row [ET added (pg)] represents the amount of ET added in pg in the assay, the second
row {ET-1 detected (pg)] represents the amount of ET-1-like material detected in each
sample after it has been run through the assay and row 3 represents the % cross-reactivity
of each of the samples with standard ET-1. The mean %cross-reactivity values±sd for
each ET with standard ET-1 are summarised in row 4. Results represent a typical of 3
experiments performed on separate occasions.
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detected in each sample and the % of cross-reactivity for each sample and
the mean % cross-reactivity for all dilutions are shown. Due to the
existence of cross-reactivities between the three ET isopeptides, the
material measured by this radioimmunoassay method was referred to as
"ET-l-like" material.
Because reports have suggested the presence of ET peptides in serum, all
the cell cultures used for the collection of conditioned media were
growing in culture media deprived of foetal calf serum and
supplemented with essential supplements (HITS, see section). To test the
presence of immunoreactive ET-1 in foetal calf serum and the media
enrichment (HITS) serial dilutions (neat, 1:1, 1:2, 1:4, 1:8) of the two were
assayed. Mean values of measurements obtained on separate occasions
suggested significant amounts of ET-l-like material present in serum
(0.22pM) while ET-l-like peptide was not detected in HITS supplemented
media. The limit of detection for ET-l-like material is <1 pg/tube (40 fM).
Finally, in order to test the variability of results due to error of the
available technology or handling of the materials, mean intra-assay and
inter-assay variations were calculated running an undiluted sample of
conditioned media on four separate occasions through the assay. The
inter- and intra-assay variations were found to be 5.5 and 6.8%
respectively.
4.1.3 Secretion of ET-l-like material by ovarian and breast cell lines
For the detection of ET-l-like material secreted by different cell lines, a
neat sample and serial dilutions (1:1, 1:2, 1:4, 1:8) of the collected
conditioned media were prepared using RIA buffer.
The samples were assayed and the obtained values for ET-l-like material
present in each sample (in pg) were corrected for the dilution factor.
Additional corrections were made for the number of cells in the tissue
culture flasks from which the conditioned media were derived. Secreted
amounts of ET-l-like material were expressed as fmol/106 cells/72h.
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Table (4.2) summarises the mean values (of quadruplicate experiments
performed on separate occasions) of immunoreactive ET-l-like material
detected in serial dilution samples of the conditioned media collected
from each cell line.
Concentrations of ET-l-like material secreted in the conditioned media by
PE04 and PE014 ovarian carcinoma cell lines were 1.7±0.42 (mean±sd)
and 17.5±7.6 (mean±sd) fmol/106 cells/72h respectively. The breast
epithelial cancer cell lines MDA-MB-231, T47D and ZR-75-1 cells secreted
14±3.6, 52±12.3 and 17.69±2.56 (mean±sd) fmol/106 cells/72h respectively.
Although all the epithelial carcinoma cell lines secreted measurable
amounts of immunoreactive ET-l-like material, none of the human
ovarian and breast or the mouse S3T3 fibroblasts secreted levels of the
peptide measurable by this method. All the conditioned media samples
collected by the ovarian and breast epithelial cancer cell lines, diluted in
parallel with standard ET-1 in the assay as shown in figures 4.2 and 4.3.
The release of ET-l-like material from all the ovarian and breast
epithelial cancer cell lines as a function of time over a 48h period was
determined by collecting and assaying conditioned media at different time
points (6,12, 24 and 48h). These results are shown in figure 4.4. Although
each cell line secreted different amounts of the peptide, the pattern of the
release as a function of time was similar for all the cell lines, i.e. seem to
increase linearly over the first 12 hours and plateauing thereafter.
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Production of immunoreactive ET-l-like material



































carcinoma 11.8513.0 2.810.73 3.4 1413.6
T47D
breast
carcinoma 77.94118.4 10.412.46 6.02 52112.3
ZR-75-1
breast
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Table 4.Table on the production of immunoreactive ET-l-like material in conditioned
media from ovarian and breast epithelial cancer cell lines and fibroblasts. Results are
presented as raw data (pg/tube) or normalised data taking into account the number of cells
from which the conditioned media were secreted (fmol/106 cells and pM). Results
represent mean values±sd of quadruplicate experiments performed on separate occasions.
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1:8 1:4 1:2 1:1
dilution
Figure 4.2: Parallel dilution of standard ET-1 with immunoreactive ET-l-like material
detected in diluted samples (1:1,1 -2,1:4,1:8) of the conditioned media of PE04 and PE014
ovarian epithelial cancer cell lines. Graph represents data typical of 3 experiments
performed on separate occasions
I i I i
1:8 1:4 1:2 1:1
dilution
Figure 43: Parallel dilution of standard ET-1 with immunoreactive ET-l-like material
detected in diluted samples (1:1, 1:2, 1:4, 1:8) of the conditioned media of MDA-MB-231,
T47D and ZR-75-1 breast epithelial cancer cell lines. Graph represents data typical of 3




Figure 4.4: Release of immunoreactive ET-l-like material from PE04 and PE014 ovarian
epithelial and MDA-MB-231, T47D and ZR-75-1 breast epithelial cancer cells growing
under serum-free conditions as a function of time. Conditioned media were collected at 6,
12, 24 and 48h. The results represent mean values±sd of 3 distinct conditioned media
collected on separate occasions.
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4.1.4 Modulation experiments
Endothelin is known to be regulated by several growth factors and
cytokines. In human breast cancer factors such as bombesin, insulin and
interleukin-6 (IL-6) have been shown to modulate ET-1 expression but no
such information is known about human ovarian cancer cell lines. In
order to confirm the observed effects in human breast cancer cell lines
and to investigate possible modulation effects in human ovarian cancer
cell lines, bombesin and IL-6 were added in the serum-free culture media
of the cell lines 24 h prior to the collection of the conditioned media. As
is shown in figures 4.5 and 4.6 such additions resulted in an increase in
basal secretion of ET-l-like material from all the epithelial cell lines. In
the ovarian epithelial cancer cell lines, PE014 cells show the greater
increase in ET-l-like secretion with the addition of bombesin (18 pM
compared to 4 pM control secretion) while in breast cancer cell lines T47D
cells show the greatest increase in secretion of ET-l-like peptide (62 pM
compared to 10 pM basal secretion). The percentage increase in ET-l-like
peptide secretion from all the cell lines as a result of the addition of
bombesin and IL-6 in the culture media is summarised in table 4.3. PE04
and PE014 human ovarian epithelial cancer cells showed a 40% and 400%
increase (respectively) in basal ET-l-like secretion as a result of the
addition of 100 nM bombesin for 24 h and a 38% and 310% increase
(respectively) with the addition of 200 ng/ml of IL-6 for the same time
period (24 h). Human breast epithelial cancer cell lines (MDA-MD-231,
T47D and ZR-75-1) also secreted increased (compared to control) levels of
ET-l-like material as the result of the addition of 0.1 |iM bombesin (52%,
496% and 57% respectively) or 200 ng/ml IL-6 (26%, 80% and 37%
respectively) in the culture media for 24 h. No effects of ET-l-like
material secretion were observed with the addition of bombesin or IL-6 in
the culture media of human ovarian and breast or mouse S3T3
fibroblasts. The addition of similar amounts of pure bombesin or IL-6 in























Figure 4.5: Immunoreactive ET-l-like material released from PE04 and PE014 cells
growing in serum-free media after 72h incubation alone (control) or in serum-free media
supplemented with bombesin (lOOnM) or interleukin-6 (IL-6, 200ng/ml) 24h prior to



























j <//// •£ £
MDA-MB-231 T47D ZR-75-1
Figure 4.6: Immunoreactive ET-l-like material released from MDA-MB-231, T47D and
ZR-75-1 cells growing in serum-free media after 72h incubation alone (control) or in serum-
free media supplemented with bombesin (lOOnM) or interleukin-6 (IL-6, 200ng/ml) 24h
prior to collection. Bars represent mean values±sd of 3 experiments performed on separate
occasions.
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Effect of the addition of bombesin and IL-6
on the secretion of ET-l-like material




PE04 ovarian carcinoma 140% 138%
PE014 ovarian carcinoma 500% 410%
MDA-MB-231 breast carcinoma 152% 126%
T47D breast carcinoma 620% 180%
ZR-75-1 breast carcinoma 157% 137% j
Table 43: Table of the effects of the incubation of bombesin (lOOnM) and interleukin-6 (IL-
6, 200ng/ml) for 24h in the culture of ovarian and breast epithelial cancer cells, regarding
the secretion of immunoreactive ET-l-like material from the cells into conditioned media
after a 72h incubation at serum-free conditions. Table represents data from a typical
example of 3 experiments performed on separate occasions.
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4.2 Discussion:
The results presented above show that ovarian (PE04 and PE014) and
breast (MDA-MB-231, T47D and ZR-75-1) cancer cell lines secrete
immunoreactive ET-l-like material and that levels of ET-1 secreted can be
modulated by bombesin and IL-6 peptides. However, as determined by
radioimmunoassay of conditioned media, neither ovarian (PE012F,
PE014F and PE027F) nor breast fibroblast cell lines (BRF1 and BRF2)
produce detectable amounts of the same peptide.
In this study, a commercially available ET-1-detection radioimmunoassay
kit was used in order to investigate the production of this peptide from
breast and ovarian cancer cell lines and fibroblasts. The specificity of the
radioimmunoassay was tested with the use of two unrelated peptides
(bombesin and IL-6) which failed to cross react with the assay while ET-1
which had been obtained separately from the kit demonstrated a 94.7%
cross reactivity with the standard ET-1 included in the assay. The cross-
reactivity of ET-1 with ET-2 and ET-3 isopeptides was also measured and
calculated as 14.4 and 8.2% respectively. The assay did not cross-react with
"big"-ET-l as suggested by the manufacturer. These levels of cross
reactivity suggest that what has been measured in the assay is mostly ET-1
because for ET-2 and ET-3 crossreactivities to account for these levels it
would mean that they are secreted at extremely high levels. However,
the possibility that ET-2 and ET-3 could account for a part of the detected
amount, could not be ruled out. Previous studies have demonstrated the
production of immunoreactive ET-1 in the nervous and cardiovascular
systems, pancreatic and colon carcinomas (Kusuhara et al., 1990, Suzuki et
al., 1989), pancreatic cancer cells (Oikawa et al., 1994), human breast cancer
tissues (Yamashita et al., 1993). In the case of ovarian cancer, only a single
report has previously been published and this suggested the production of
immunoreactive ET-1 from OVCA-433, A2780 and SKOV-3 ovarian
epithelial cancer cell lines (Bagnato et al.,1995). In breast cancer, a number
of reports have demonstrated the release of immunoreactive ET-1 from
MDA-MB-231, T47D, ZR-75-1 and MCF-7 breast epithelial cancer cell lines
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(Suzuki et al., 1989; Kusuhara et al., 1990, Schrey et al., 1992).
From the two ovarian cancer cell lines used in our study, PE014 cells
produced ten times the amount of immunoreactive ET-1 secreted by PE04
cells (17.5 and 1.7 fmol/106 cells for PE014 and PE04 cells respectively).
The amounts of ET-like peptide released by these two cell lines were
comparable to levels released from SK-OV-3 (61.2±5 fmol/106 cells)
OVCA-433 (75.2±4 fmol/106 cells) and A2780 (65±3.7 fmol/106 cells) cell
lines (Bagnato et al., 1995).
The breast epithelial cancer cell lines all produced significant amounts of
ET-l-like material with T47D cells producing the greatest amounts (52±12
fmol/106 cells) and MDA-MB-231 and ZR-75-1 cells producing lower
concentrations of ET-l-like peptide (14±3 and 17±7 fmol/106 cells). Values
of ET-l-like peptide released from the breast epithelial cell lines were
directly comparable to values mentioned in previous reports (46.4, 14 and
7.2 fmol/106 cells for T47D, MDA-MB-231 and ZR-75-1 cells respectively)
(Suzuki et al., 1989; Kusuhara et al., 1990; Schihiri et al., 1991; Schrey et al.,
1992). Such reports have also suggested that hormone-dependent breast
cancer cell lines (T47D,MCF-7, ZR-75-1) secreted up to twenty times the
amount of ET-1 secreted by hormone-independent cells (MDA-MB-231).
In the present study, although T47D cells produced higher levels of ET-1
than the rest of the cell lines, such a large difference in ET-1 production
was not observed (MDA-MB-231 and ZR-75-1 cells produced almost equal
amounts). Conditioned media collected from the human ovarian
(PE012F, PE014F and PE027F), breast (BRF1 and BRF2) and S3T3 mouse
fibroblasts were also measured by radioimmunoassay and results
suggested that no significant amounts of ET-l-like material were secreted
by these cells.
A number of peptides (bombesin, Cortisol, oestradiol, tamoxifen, TNF,
IFN-y, IL-lfi, IL-6, TGF-fi, and prolactin) have been used as possible
modulators of ET-1 production in breast cancer. Bombesin, Cortisol,
glucocorticoids, IL-6, have all been shown to stimulate ET-1 secretion in
breast cancer cell lines (T47D, ZR-75-1, MCF-7) (Schrey et al., 1992;
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Yamashita et al., 1993). The modulation of ET-1 production by these
factors has not been investigated in ovarian cancer cell lines.
In this study, addition of bombesin and IL-6 to ovarian and breast
epithelial cancer cells 24h prior to collection of conditioned media
resulted in a stimulation of immunoreactive ET-1-like material from the
cell lines.
Bombesin (lOOnM) stimulated ET-l-like material secretion by 40% and
400% in PE04 and PE014 ovarian epithelial cancer cells respectively while
addition of IL-6 (200ng/ml) to the same cell lines resulted in a 38% and
310% increase in basal ET-l-like secretion (in PE04 and PE014 cells
respectively). In breast epithelial cancer cells, bombesin stimulated an
increase of 52%, 496% and 57% in the secretion of immunoreactive ET-1
detected in conditioned media collected from MDA-MB-231, T47D and
ZR-75-1 cells respectively. These values are comparable to levels of
stimulation reported (580%) for T47D cells (Schrey et al., 1992). Addition
of IL-6 into the media of breast epithelial cancer cells also resulted in
stimulation of released ET-l-like material by 26%, 80% and 37% compared
to basal levels for MDA-MB-231, T47D and ZR-75-1 cells respectively.
Such effects are of similar magnitude to those reported in previous
studies with MCF-7 (206% increase) and ZR-75-1 (314% increase) cells
(Yamashita et al., 1993). The possibility of similar results due to the cross-
reactivity of bombesin and IL-6 with the ET-1 targeted antibody in the
radioimmunoassay, was excluded because the radioimmunoassay failed
to detect any ET-l-like material when serial dilutions of bombesin and IL-
6 were assayed (figure 4.1.2.1). The potential effect of bombesin and IL-6
on the production of ET-1 from ovarian and breast cancer cell lines was
investigated due to a number of observations regarding the presence and
roles of these peptides in these systems.
Both bombesin and ET-1 have been reported to be present in breast cyst
fluids and bombesin-related peptides have been identified at significantly
higher levels in cyst fluids from women with apocrine breast cysts (Lai et
al., 1990). Bombesin has also been shown to stimulate cellular signalling
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in breast (Patel and Schrey 1990) and ovarian (Christen et al., 1994) cell
lines, without being accompanied by mitogenic responses.
IL-6 has been detected in the systemic circulation of the local neoplastic
tissue in cancer patients and has been suggested to act as the major
systemic mediator of the early host response (acute phase response) to
infection and injury (Sehgal et al., 1988; Kishimoto et al., 1989; Bataile et.
Al., 1989). It has also been demonstrated that ET-1 plasma-levels are
elevated following acute physical stress situations (Miyauchi et al., 1989)
and interestingly, in the 5'-flanking region of the cloned
preproendothelin-1 gene, there exist sequences of the acute phase
reactant-regulatory elements which mediate the gene expression under
acute physical stress in vivo (Inoue et al., 1989). Breast cancer cell lines
like MCF-7 and ZR-75-1 have been shown to express high affinity IL-6
binding receptors, while ovarian cancer cell lines (OVCA) and ovarian
carcinomas have been shown to contain high levels of ET-1 (Offner et al.,
1995; Schroder et al., 1994) which can be regulated by other cytokines such
as IL-1, TNF-a and IFN-y (Offner et al., 1995). IL-6 levels are higher in
malignant compared to benign ovarian tumours (van-der Zee et al., 1995)
while the same difference has been observed with ET-1 in malignant
compared to benign breast tumours (Yamashita et al., 1991). In breast
cancer cells, IL-6 has also been associated with cellular morphology and it
has been suggested that IL-6 treated ZR-75-1 cells convert from an
epithelial to fibroblastoid shape followed by decreased cell association and
increased cell motility (Tamm et al., 1989, 1991). IL-6 has been the only
cytokine shown to cause the same conversion to ductal cell carcinoma
cells from epithelial to fibroblast phenotype. ET-1 has been shown to
induce an increase in the gene expression and synthesis of matrix
proteins such as fibronectin and type IV collagen and cell proliferation
through ETa-R in messangial cells (Gomez-Garre et al., 1996).
Combining these observations with the results discussed above it could be
suggested that bombesin and IL-6 could affect the production of ET-1 in an
autocrine or paracrine manner. Such interaction of bombesin and IL-6
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could result in increased levels of ET-1 in cancer cells with potential
mitogenic effects as well as possible effects on the motility and cell-cell
interaction through synergistic effects of ET-1 with IL-6.
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Chapter 5: ET receptor binding studies
5.1 Optimisation of the assay conditions
5.1.1 Validation of method
The assay method used for the binding experiments is described in detail
in section 2.2.3 of the methods. However a series of experiments were
performed initially in order to optimize the method in terms of
temperature, incubation period and specificity of the assay.
(i) Influence of temperature and incubation period on specific binding
Membrane preparation samples from PE014 cells were incubated with
125I-ET-1 labelled peptide (50pM) for up to 180 min at 4°, 26° and 37°C.
Triplicate samples were collected at 10, 30, 60, 90, 120 and 150 min from
experiments performed at all three temperatures and binding was
determined by y-counter. Non-specific binding was determined by
incubation of the same membrane preparation sample with 0.36nM of
125I-ET-1 in the presence of 100-fold (0.4pM) of non-labelled ET-1. At all 3
temperatures no binding was observed in the first 30 min of incubation
(figure 5.1). After that period, and until approximately 60 min of
incubation time, binding increased to maximum levels in the
experiments performed at 26° and 37°C with the latter temperature
showing the highest binding. Incubation at 4°C resulted in less but
continuously increasing binding reaching a maximum level at 120 min of
incubation before plateauing. At 26° and 37°C, there was a decrease in
binding between 60 and 120 min of incubation and binding reached a
plateau between 120 and 150 min of incubation. From the results of these
experiments, (demonstrated in figure 5.1) it was concluded that
incubation of the samples for 60 min at 26°C provided the optional
conditions for detection of the specific binding of 125I-ET-1 to membrane
preparation and these were therefore used for all the experiments.
(ii) Specificity of binding
The specificity of binding of 125I-ET-1 was tested on a membrane
preparation of PE014 cells incubated with various concentrations of non-
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radiolabelled related (ET-1) and unrelated peptides (bombesin and
insulin). The results, shown in figure 5.2, suggest that ET-1 displaced
approximately 70% of the binding while bombesin and insulin did not
displace any labelled ET-1.
5.2 Scatchard analysis
Membrane preparation fractions (100|il) were incubated with a standard
amount of 125I-ET-1 (50pM) and increasing concentrations of unlabelled
ET-1(50-9950 pM) for 90 min at 26°C. Scatchard analysis of the binding
data obtained from a membrane preparation of S3T3 mouse fibroblasts
was used as a positive control. Data obtained from that experiment
resulted in a curve, a typical example of which is shown in figure 5.3 The
graph suggested the presence of two binding sites and, in order to
interpret and plot the data, the"Ligand" binding program was used. The
intercept of the x-axis of the line on the left represents high affinity sites
and the intercept of the line on the right represents low affinity sites. The























Figure 5.1: Effect of varying time and temperature of incubation period on the binding of
125I-ET-1 (0.36nM) to PE014 cell membrane preparation for up to 180min at 4°, 26° and
37°C. Non specific binding was determined by the addition of 100-fold excess unlabelled
ET-1. Data represents mean values±sd of triplicate samples from a representative of 3










Concentration of competitor (nM)
Table 5.2: Specificity of binding of 125I-ET-1 to PE014 ovarian cancer cells. A fraction of
membrane preparation was incubated with 50pM of 125I-ET-1 in the presence or absence of
competing peptide (25, 50, 100, 150 and 400 nM) for 60 min at 26°C. Points represent
mean±se of triplicate samples from a representative of two experiments.
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5.2.1 Scatchard of binding in ovarian epithelial cancer and S3T3 cells
Membrane fractions of ovarian epithelial cancer cells were prepared from
PE04, PE014 and S3T3 (positive control) cell lines growing in phenol red-
free, serum-free DMEM culture media containing HITS (hydrocortisone,
insulin, transferrin and sodium selenite).
(i) S3T3 fibroblasts
The S3T3 fibroblasts were used as a positive control in this set of
experiments. Scatchard analysis (figure 5.3) indicated the presence of two
distinct binding sites. A higher affinity binding site with a dissociation
constant of 0.9 nM (Bmax: 0.49 pmol/mg of protein) and a lower affinity
binding site with a dissociation constant of 7.10 nM (Bmax: 1.68 pmol/mg
of protein).
(ii) PE04 cells
For PE04 cells (figure 5.4), the Scatchard analysis produced a plot which
suggested the presence of two distinct classes of receptor binding sites.
The higher affinity receptor site had a dissociation constant value of 0.065
nM (Bmax: 0.047 pmol/mg of protein), whereas the lower affinity receptor
site had a dissociation constant value of 0.49nM (Bmax: 0.23 pmol/mg of
protein).
(ill) PE014 cells
For the PE014 cell line, the Scatchard analysis indicated the presence of a
single class of lower affinity receptor binding site (figure 5.5) with a
dissociation constant value of 0.56 nM (Bmax: 0.31 pmol/mg of protein).
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ET-1 added (pM)
Figure 53: Saturation curve of the binding of 125I-ET-1 to S3T3 mouse fibroblasts.
Increasing concentrations of ET-1 were added to membranes prepared from cells in
duplicate in the presence (non-specific) or absence (total binding) unlabelled (lpM) ET-1.
Cells were incubated at 26°C for 60min. Scatchard analysis results were plotted with
values obtained by "LIGAND" computer program and represent a typical result of 3















Figure 5.4: Saturation curve of the binding of 125I-ET-1 to PE04 ovarian cancer cells.
Increasing concentrations of ET-1 were added to membranes prepared from cells in
duplicate in the presence (non-specific) or absence (total binding) unlabelled (lpM) ET-1.
Cells were incubated at 26°C for 60min. Scatchard analysis results were plotted with
values obtained by "LIGAND" computer program and represent a typical result of 3





Figure 5.5: Saturation curve of the binding of 125I-ET-1 to PE014 ovarian cancer cells.
Increasing concentrations of ET-1 were added to membranes prepared from cells in
duplicate in the presence (non-specific) or absence (total binding) unlabelled (lpM) ET-1.
Cells were incubated at 26°C for 60min. Scatchard analysis results were plotted with
values obtained by "LIGAND" computer program and represent a typical result of 3
experiments performed on separate occasions.
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5.2.2 Scatchard analysis of binding in human breast epithelial cancer cells
Membrane fractions of two breast epithelial cancer cell lines, T47D and
MDA-MB-231, were prepared and used in binding experiments. Results
shown in figure 5.6 demonstrate the background level of binding of 1251-
ET-1 with membrane preparations from the two breast cancer cell lines,
suggesting the absence of ET receptors in MDA-MB-231 and T47D cells.
5.3 Binding inhibition experiments
For the binding inhibition studies, cell membrane samples (lOOpl) were
incubated with 125I-ET-1 (50pM) and increasing concentrations (lOpM to
lpM) of ET-1, ET-3, BQ123 (ETA-R antagonist) and BQ788 (ETB-R
antagonist). Samples were incubated at 26°C for 90 min and counted in a
y-counter. Non specific binding was determined in the presence of l(iM
ET-1.
5.3.1 Ovarian cancer cells
Membrane preparations of PE04 and PE014 cell lines were used in
binding inhibition experiments in order to determine the specific receptor
subtype expressed in these cells.
(i) PE04 cells
A typical experiment using membrane preparations from PE04 cells is
shown in figure 5.7. The half maximal inhibitory concentrations for ET-1,
ET-3, BQ123 and BQ788 were 0.04, 3, 0.2 and >1000 nM respectively. These
results suggested the predominant expression of ETA-R in these cells.
However, a small inhibition of 125i-ET-l binding in the presence of BQ788
(ETb-R) antagonist suggested the expression of a limited amount of ETB
receptors in PE04 cells.
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Table 5.6: Binding (cpm) of ET-1 to membrane preparations of MDA-MB-231 and T47D
breast cancer cells. Membrane samples were incubated with increasing concentrations of
125JET-1 (50,100, 250, 500,1000, 2000,4000 and lOOOOpM ) at 26°C for 60 min. Figure shows
results of a representative of two experiments performed on separate occasions.
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Figure 5.7: Inhibition of specific 125I-ET-1 binding in PE04 ovarian cancer cell membrane
preparations by ET-1, ET-3, BQ123 (ET^-R antagonist) and BQ788 (ETg-R antagonist).
Cell membranes were incubated at 37°C for 60min with 50pM 125I-ET-1 in the presence or
absence of the above peptides at the concentration indicated. Graph presents results of a
representative of 3 experiments performed on separate occasions. Binding of 125I-ET-1 is
expressed as the percentage of the specific binding in the absence of unlabelled peptide.
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(ii) PE014 cells
For PE014 cells, (figure 5.8) half maximal inhibitory concentrations for
ET-1, ET-3, BQ123 and BQ788 were 0.17, 10, 0.85 and >1000 nM
respectively. Although as in PE04 cells, the maximal inhibitory
concentration of BQ788 antagonist was >1000 nM, there was no change in
the pattern of the effect even at very high concentrations. Therefore, and
in contrast to what was observed in PE04 cells, results suggest the
expression of ETa-R only in PE014 cells.
5.3.2 Ovarian fibroblasts
Membrane fractions from PE012F fibroblasts were prepared for binding
experiments. The limited growth of these cells precluded Scatchard
analysis however, sufficient numbers were available for binding
inhibition studies. As shown in figure 5.9, half maximal inhibitory
concentrations for ET-1, ET-3, BQ123 and BQ788 were 3, 20,140 and 500nM
respectively. These results suggest the expression of both ETa-R and ETb-
R in PE012F ovarian fibroblasts.
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Figure 5.8: Inhibition of specific 125I-ET-1 binding in PE014 ovarian cancer cell membrane
preparations by ET-1, ET-3, BQ123 (ET^-R antagonist) and BQ788 (ETb-R antagonist).
Cell membranes were incubated at 37°C for 60min with 50pM 125I-ET-1 in the presence or
absence of the above peptides at the concentration indicated. Graph presents results of a
representative of 3 experiments performed on separate occasions. Binding of 125I-ET-1 is
expressed as the percentage of the specific binding in the absence of unlabelled peptide.
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Figure 5.9: Inhibition of specific 125I-ET-1 binding in PE012F ovarian fibroblast membrane
preparations by ET-1, ET-3, BQ123 (ETa-R antagonist) and BQ788 (ETb-R antagonist).
Cell membranes were incubated at 37°C for 60min with 50pM 125I-ET-1 in the presence or
absence of the above peptides at the concentration indicated. Graph presents results of a
representative of 3 experiments performed on separate occasions. Binding of 125I-ET-1 is
expressed as the percentage of the specific binding in the absence of unlabelled peptide.
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5.33 Breast fibroblasts
As with PE012F cells, BRF1 cells were cultured in order to prepare
membranes for use in binding inhibition experiments. As shown in
figure 5.10, ET-1 and ET-3 and both antagonists inhibited the 125I-ET-1
specific binding. Half maximal inhibitory concentrations were 2.5nM for
ET-1, 7nM for ET-3, lOOnM for BQ123 and 900nM BQ788. Results suggest
the expression of both ETa-R and ETb-R in BRF1 breast fibroblasts.
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Figure 5.10: Inhibition of specific 125I-ET-1 binding in BRF1 breast fibroblast membrane
preparations by ET-1, ET-3, BQ123 (ETa-R antagonist) and BQ788 (ETb-R antagonist).
Cell membranes were incubated at 37°C for 60min with 50pM 125I-ET-1 in the presence or
absence of the above peptides at the concentration indicated. Graph presents results of a
representative of 3 experiments performed on separate occasions. Binding of 125I-ET-1 is
expressed as the percentage of the specific binding in the absence of unlabelled peptide.
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5.4 Discussion
Results presented in this chapter suggest that while breast epithelial
cancer cell lines MDA-MB-231, T47D and ZR-75-1 do not bind 125I-ET-1,
ovarian epithelial cancer cell lines PE04 and PE014 as well as ovarian
(PE012F) and breast (BRF1) fibroblasts bind endothelin with high affinity
consistent with the presence of ET-receptors.
In this study, i25I-ET-l exhibited specific binding with membrane
preparations of both PE04 and PE014 ovarian epithelial cancer cells.
Results from PE014 cells, suggested the presence of a single type of
receptor binding site (Kd: 0.56nM, Bmax: 0.31pmol/mg of protein) while
studies on PE04 cells suggested the presence of two distinct binding sites,
a lower affinity binding site (Kd: 0.49nM, Bmax: 0.23pmol/mg of protein)
similar to the one seen in PE014 cells, and a higher affinity binding site
(Kd: 0.065nM, Bmax: 0.047pmol/mg protein).
As has already been suggested (Kenakin et al., 1992; Huggins, 1993) the
identification of the specific type of receptors present in a system could
not be entirely based on binding data due to the similarities of Kd's for the
two major types of ET receptors. There are also suggestions about the
presence of two subtypes with Kd's of the pM and nM range for each of
the ETa and ETg receptors (Ambar and Sokolovsky., 1993; Simonson and
Rooney., 1993). Reports on a third type of endothelin receptor ETc with a
proposed rank order of affinity of ET-3>ET-1 added further complication
(Karne et al., 1993). Therefore, and unless in situations where tissues
represent pure sources of receptors subtype (e.g. rat aorta, for ETa-R,
Huggins at al., 1993), binding inhibition curves could provide further
information when carefully analysed.
The nature of the receptors expressed on the surface of both cell lines was
investigated in competition experiments where ET-1, ET-3, BQ123 (ETa-R
antagonist) and BQ788 (ETb-R antagonist) were competing with 125I-ET-1
for binding to membrane preparations from both cell lines. For PE04
cells, specific 125I-ET-1 binding to membrane preparations was inhibited by
the presence of increased concentrations of BQ123 antagonist and to a
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lesser extent by addition of ET-3. The addition of increased concentrations
of BQ788 had a small effect at very high concentrations. For PE014 cells,
125I-ET-1 binding was inhibited by increasing BQ123 concentrations and
less affected by ET-3 addition but was not affected at all by the addition of
BQ788 antagonist.
A single study by Bagnato et al. (1995) on 3 ovarian epithelial cancer cell
lines (SKOV-3, A2780 and OVCA-433) has suggested the expression a
single type of ET receptor with Kd values of 0.15, 0.03 and 0.02 nM
respectively and specific binding was blocked with the addition of BQ123
suggesting that receptors were of the ETa-R type.
Combining the results from this study it could be suggested that PE014
cells express a single type of receptors (Kd: 0.56nM) which can be blocked
with BQ123 antagonist and therefore is of the ETa-R type. For PE04 cells
however, two receptor binding sites have been observed. One with a Kd
of 0.49nM very similar to that seen with PE014 cells and a second higher
affinity binding site (Kd: 0.065 nM). This higher affinity binding site could
represent higher affinity ETa also seen in S3T3 cells (Ambar and
Sokolovsky 1992), or high affinity ETb receptors. Analysing the results of
the binding inhibition experiments for PE04 it can be suggested that the
major type of receptors expressed is that of ETa-R type because of the
inhibition of binding seen with the addition of BQ123. However, the
small inhibition of 125I-ET-1 binding in the presence of BQ788 might
suggest the presence of a limited amount of ETb receptors.
Binding inhibition experiments using membrane preparations of PE012F
ovarian fibroblast cell lines, showed that 125I-ET-1 binding could be
inhibited with the addition of increasing concentrations of ET-3, BQ123
and BQ788 suggesting the presence of both ETa-R and ETb-R in these cells.
In breast cancer, studies have suggested the absence of ET receptors in the
epithelial cancer cell lines and the specific binding of 125I-ET-1 to ET
receptors in breast fibroblasts (Kd of 0.09nM), (Baley et al., 1990).
However, there exist no further information regarding the type of ET
receptors expressed in these cells.
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In our study, 125I-ET-1 showed no specific binding to membrane
preparations from MDA-MB-231, T47D and ZR-75-1 cells which is
consistent with the absence of ET receptors in breast epithelial cancer cells.
However, binding inhibition experiments have suggested the presence of
such receptors in breast fibroblasts. In BRF1 cells, increasing
concentrations of ET-3, BQ123 and BQ788 all inhibited the binding of 125I-
ET-1 suggesting the expression of both types of ET receptors in these cells.
In summary, results shown in this chapter have suggested the expression
of specific ET receptors in ovarian epithelial and ovarian and breast
fibroblast cell lines. Combining these results with the production of
immunoreactive ET-l-like material (as measured by radioimmunoassay)
from ovarian and breast cancer cell lines it could be suggested that in the
ovarian system endothelins secreted by the cancer cells can bind to
receptors expressed in both cancer and fibroblast cells. Therefore ETs can
exert their effects in an autocrine and/or paracrine fashion. In the breast
system however, ET-l-like material secreted by breast cancer cells could
bind specific ET receptors expressed in breast fibroblast cells and therefore
exert their effects in a paracrine manner.
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Chapter 6: Effect of endothelin on the growth of ovarian and breast
epithelial cancer and fibroblast cell lines
To investigate the effects of ETs on the growth of human ovarian and
breast epithelial cancer and fibroblast cell lines, ETs were added
exogenously to the culture media of cell lines at a range of concentrations
(10-6 to 1(H3 M). Cells were grown in media supplemented with 1% FCS
and were exposed to ETs for 5 days. Cell numbers were compared to those
of cells grown in identical conditions and for the same incubation period
without being exposed to ETs.
6.1. Effect of exogenous ET addition on the growth of human ovarian
epithelial cancer cell lines
The effects of endothelins (ET-1, ET-2 and ET-3) on the growth of ovarian
cancer cells were investigated by adding ETs to cultures of two human
ovarian cancer cell lines, PE04 and PE014. Results shown in figures and
tables represent values from one of three experiments which produced
similar results. All concentrations described below as having growth
effects produced statistically significant differences from control culture
without the addition of endothelins.
(i) Effects of ET-1
As shown in figure 6.1, concentrations of ET-1 between 10-n and 1(H0M
added to PE04 cells resulted in an increasing growth stimulatory effect
reaching greater effects at KH°M (153% control growth) while the degree
of stimulation progressively decreased at concentrations of 10*9,10-8, lO7
and 10-6M of ET-1.
In PE014 cells, a similar pattern of effects was detected (figure 6.1).
Increasing effects were seen between concentrations of 1CH3 and 10-10M,
maximum stimulation of growth was observed at 10*9M (154% control
growth) and decreasing effects at 10-8,10-7 and 10-6M of added ET-1.
Table 6.1 summarises the effects of ET-1 addition between 1(H3 and KHM









control 13 12 11 10 9 8 7 6
ET-1 added (-logM)
Figure 6.1: Effects of the exogenous addition of ET-1 on PE04 and PE014 ovarian cancer cell
lines growing in 1% serum conditions for a 5 day period. Graph shows results from a
representative of 3 experiments performed on separate occasions (bars: meartfcse).
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Table 6.1. The effects of exogenous endothelin-1, added at concentrations of 1(H3 to 106M,
on the growth of PE04 and PE014 ovarian carcinoma cells expressed as % control cell
number (5.2xl04±1432 and 4.1xl04±1011 for PE04 and PE014 respectively). Each value
represents mean ± se of three experiments performed on separate occasions (* values
represent statistical significance, p<0.05).
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(ii) Effect ofET-2
The effect of the addition of ET-2 on the growth of PE04 and PE014 cells is
shown in figure 6.2.
In PE04 cells, addition of ET-2 at concentrations between 10-9 and 10-7M
resulted in an increase in control growth. Stimulation of growth reached
maximum effects between 10-8 and 10-7M (120% control growth). A
lower effect was observed at lO^M of added ET-2.
In PE014 cells, ET-2 stimulated growth, and effects were increased with
10-12M, 10nM and 10*10M of added ET-1, maximum effects occurring with
10-9M (133%); thereafter effects with 10-8M, 10-7M and 10-6M
concentrations produced decreasing responses.
Details on the % control growth of PE04 and PE014 cells with the
addition of ET-2 are presented in table 6.2.
(iii) Effect of ET-3
As shown in figure 6.3, results of the exogenous addition of ET-3 at
concentrations of 1CH3 to 10*6M did not have significant effects on the
growth of PE04 and PE014 cells in culture. Table 6.3 summarises all the





Figure 6.2: Effects of the exogenous addition of ET-2 on PE04 and PE014 ovarian cancer cell
lines growing in 1% serum conditions for a 5 day period. Graph shows results from a
representative of 3 experiments performed on separate occasions (bars: mean+se).





















±se 1.9 2.2 4.3 3.6 1.9 3.1 5 4.8





99 107 113 113 133 131 127 115
I 1 ±se 2 3.4 4.7 3.1 2.9 5.5 3.2 4.3
Table 6.2. The effects of exogenous endothelin-2, added at concentrations of 10"13 to 10"6M,
on the growth of PE04 and PE014 ovarian carcinoma cells expressed as % control cell
number (5.4x104+3024 and 3.79xl04±4014 for PE04 and PE014 respectively. Each value
represents mean ± sd of three experiments performed on separate occasions (* values












Figure 63: Effects of the exogenous addition of ET-3 on PE04 and PE014 ovarian cancer cell
lines growing in 1% serum conditions for a 5 day period. Graph shows results from a
representative of 3 experiments performed on separate occasions (bars: mean±se).
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Table 63. The effects of exogenous endothelin-3, added at concentrations of Kb13 to 10-6M,
on the growth of PE04 and PE014 ovarian carcinoma cells expressed as % control cell
number (5.1xl04±2017 and 5.4xl04±1001 for PE04 and PE014 respectively). Each value
represents mean ± se of three experiments performed on separate occasions (* values
represent statistical significance, p<0.05).
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6.2 Effect of exogenous ET addition on the growth of human ovarian
fibroblasts
The growth stimulatory effects of ETs on human ovarian fibroblasts were
investigated with the exogenous addition of ETs to PE012F, PE014F and
PE027F cell lines. Results shown below comprise values obtained from a
representative of 3 experiments performed on separate occasions and
concentrations of ETs discussed as having effects on growth of the cell
lines represent statistically significant differences compared to controls,
(i) Effect of ET-1
Figure 6.4 diagrammatically presents the effects of ET-1 addition on the
growth of ovarian fibroblast cell lines.
In PE012F ovarian fibroblasts, stimulatory effects were detected at
concentrations of 10-12M to 10-9M of ET-1 (figure 6.4). Increasing
stimulatory effects were seen at concentrations of 10-12M and 10-HM,
maximum effects were observed at 10-iOM (161%) and progressively lower
effects at 10*9M and 10*6M. Exogenous additions of ET-1 at concentrations
of 10-13, io-8 and 10-7M had no significant effect on the growth of the cells.
In PE014F cells, growth stimulatory effects of the exogenous ET-1 addition
were detected at a wider range of concentrations compared to PE012F
(figure 6.4). Addition of ET-1 at concentrations between 10"13 and 10-n M
resulted in increasing growth stimulatory effects reaching maximum
levels at 10-i°M (164% control cell number) while addition of 10-9, io-8
and 10-7M resulted in decreasing stimulatory effects.
In PE027F fibroblasts (figure 6.4) the addition of ET-1 between 10-13 and
10*6M exerted growth stimulatory effects. The pattern of effects was
similar to PE012F and PE014F fibroblasts with increasing stimulation of
growth seen between concentrations of 10-13 and 10-i°M, maximum
effects at 10-i°M (166%) and decreasing growth stimulatory effects between
10-9M and 10-6M of added ET-1.

























control 13 12 11 10 9 8 7 6
ET-1 added (-logM)
Figure 6.4: Effects of the exogenous addition of ET-1 on PE012F, PE014F and PE027F
ovarian fibroblasts growing in 1 % serum conditions for a 5 day period. Graph shows results
from a representative of 3 experiments performed on separate occasions (bars: mean±se).
Effect of ET-1 on the growth of ovarian fibroblast cell lines
added
Cell ET 13 12 11 10 9 8 7 6
line (-logM)
P % » » » » *




F Ise 5.3 7.9 11.2 6.5 12.4 10.5 4.8 2.9
P %control * » » » » * *
E
O
growth 116 123 137 164 155 150 128 111
1
4 Ise 7.6 9 12.6 9.9 11.5 15.5 7.6 9.3
F
P % * » » » » » * *
I E control 123 132 133 166 161 159 129 123
growth
1 2l F? Ise 6.5 6.9 8.4 4.3 12.3 14.6 4.5 5.3
Table 6.4. The effects of exogenous endothelin-1, added at concentrations of lO13 to 10"6M,
on the growth of PE012F, PE014F and PE027F ovarian fibroblast cell lines expressed as %
control cell number (4.3x10*12432, 4.2x10*13387, 3.8x10*13102 for PE012F, PE014F and
PE027F respectively). Each value represents mean 1 sd of three experiments performed on
separate occasions (* values represent statistical significance, p<0.05).
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(ii) Effect of ET-2
The effects of ET-2 addition on the growth of ovarian fibroblast cell lines
are shown in figure 6.5.
In PE012F cells, exogenous ET-2 addition stimulated growth at
concentrations between 10-12 and 10-6M. Increasing effect were observed
between 10-12 and 10-8M, maximum effects were reached with the
addition of KHM (199% control growth), while higher concentrations of
added ET-2 (10-7 and 1(HM) resulted in decreasing stimulatory effects.
In the same figure it can be observed that ET-2 addition to PE014F
fibroblast cells had similar effects to those observed in PE012F fibroblasts;
stimulatory effects were observed between concentrations of 10-12 to 10-6
M. Increasing effects were observed between concentrations of 10-12 and
10-iOM, maximum effects with 10-9M (160% control growth) and
decreasing effects with 10-8,10-7 and 10-6M.
In PE027F cells, stimulatory effects were seen between concentrations of
IO-13 and 10-7M (figure 6.5). Increasing levels of growth stimulation were
detected between 10-13 and 10-iOM of ET-2, maximum effects with the
addition of 10"9M (164% control growth) and decreasing stimulation of
growth with 10-8 and 10-7M ET-2 addition.
Table 6.5 summarises the effects of ET-2 on all 3 cell lines expressed as
%control cell number.
(iii) Effect of ET-3
The effects of ET-3 on the growth of ovarian fibroblast cell lines were also
investigated and are shown in figure 6.6.
In PE012F cells, stimulation of growth was observed with the addition of
ET-3 at concentrations between 10-12 and 10*6M. More precisely,
concentrations between 10-12 and 10-iOM resulted in increasing
stimulation of growth (maximum effect seen at 10-iOM was 175% control
cell number). Decreasing effects were observed between concentrations of
lO*9 and 10-6M.
In the same figure, stimulatory effects were seen for PE014F cells at
concentrations between 10-12 and 10-7M. Within this range of
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concentrations, increasing stimulatory effects were observed at 10-12,10-n
and 10-i°M, maximum effects at 10-9M (153% control growth) and
decreasing effects at lO8 and 10-7M.
In PE027F fibroblasts, growth stimulatory effects were observed between
concentrations of 10-12 and 10-7M of exogenous ET-3 (figure 6.5). The
pattern of the effects was similar to that observed in PE012F and PE027F
fibroblasts with increasing stimulatory effects between 10-12 and 10-i°M,
maximum effects at 10-9 and 10-8M (158% and 159% control growth,
respectively) and decreasing stimulatory effects at 10-7 and lO^M.
Table 6.6 summarises all the results of the effects of ET-3 in ovarian

















control 13 12 11 10 9 8
ET-2 added (-logM)
Figure 6.5: Effects of the exogenous addition of ET-2 on PE012F, PE014F and PE027F
ovarian fibroblast cell lines growing in 1% serum conditions for a 5 day period. Graph
shows results from a representative of 3 experiments performed on separate occasions (bars:
mean±se).
Effect of ET-2 on the growth of ovarian fibroblast cell lines
added
Cell ET 13 12 11 10 9 8 7 6
line (-logM)
P % * * * * * * *
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Table 6.5. The effects of exogenous endothelin-2, added at concentrations of lO13 to 106M,
on the growth of PE012F, PE014F and PE027F ovarian fibroblast cell lines expressed as %
control cell number (4.1x10*12034, 4.2xl04±3057, 3.9x10*13092 for PE012F, PE014F and
PE027F respectively). Each value represents mean ± se of three experiments performed on










control 13 12 11 10 9 8 7 6
ET-3 added (-logM)
Figure 6.6: Effects of the exogenous addition of ET-3 on PE012F, PE014F and PE027F
ovarian fibroblast cell lines growing in 1% serum conditions for a 5 day period. Graph
shows results from a representative of 3 experiments performed on separate occasions (bars:
mean±se).
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Table 6.6. The effects of exogenous endothelin-3, added at concentrations of lO13 to 106M,
on the growth of PE012F, PE014F and PE027F ovarian fibroblast cell lines expressed as %
control cell number (4.9xl04±1994, 4.8xl04±2397, 3.8xl0*±1095 for PE012F, PE014F and
PE027F respectively). Each value represents mean ± se of three experiments performed on





6.3 Effect of exogenous ET addition on growth of human breast epithelial
cancer cell lines.
The effects of the exogenous addition of ETs were investigated in the
culture of three human breast epithelial cancer cell lines MDA-MB-231,
T47D and ZR-75-1. Results discussed below are representative values
from one of 3 experiments performed on separate occasions and with
similar results.
(i) Effects of ET-1
The effects of ET-1 addition on the growth of breast cancer cell lines are
shown in figure 6.7. For all three breast epithelial cancer cell lines in
culture, addition of ET-1 at a range of concentrations (1(H3 to lO6 M) had
no effect on the growth of the cells, since no significant difference in cell
numbers was detected between treated and control cells.
(ii) Effects ofET-2
Figure 6.8 diagrammatically presents the effect of ET-2 addition on the
growth of MDA-MB-231, T47D and ZR-75-1 cells. As with the addition of
ET-1, the exogenous addition of ET-2 and ET-3 did not change the number
of cells at the end of 5 days incubation period for the treated compared to
control cells.
(iii) Effects of ET-3
Addition of ET-3 to the culture of the 3 breast cancer cell lines at a range of
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Figure 6.7: Effects of the exogenous addition of ET-1 on MDA-MB-231, T47D and ZR-75-1
breast cancer cell lines growing in 1% serum conditions for a 5 day period. Graph shows












ZR-75-1r _ i m c.k. is







control 13 12 11 10 9 8 7 6
ET-2 added (-logM)
Figure 6.8: Effects of the exogenous addition of ET-1 on MDA-MB-231, T47D and ZR-75-1
breast cancer cell lines growing in 1% serum conditions for a 5 day period. Graph shows













control 13 12 11 10 9 8 7 6
ET-3 added (-logM)
Figure 6.9: Effects of the exogenous addition of ET-1 on MDA-MB-231, T47D and ZR-75-1
breast cancer cell lines growing in 1% serum conditions for a 5 day period. Graph shows
results from a representative of 3 experiments performed on separate occasions (bars:
mean±se).
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6.4 Effect of the exogenous ET addition on growth of human breast
fibroblasts
The growth stimulatory effects of ETs on human breast fibroblasts were
investigated with the exogenous addition of ETs to BRF1 and BRF2
human breast fibroblast cell lines. Values shown in figures and tables
were obtained from a representative of 3 experiments performed on
separate occasions.
(i) Effects of ET-1
The effects of ET-1 addition at concentrations between 10-13 and lO^M on
the growth of BRF1 and BRF2 breast fibroblasts are shown in figure 6.10.
In BRF1 cells, addition of ET-1 resulted in a stimulation of growth at
concentrations between 10*12 and 10-8M. This stimulation followed the
same "bell-shaped" pattern, seen with the ovarian cancer cells, with
increasing levels of stimulation at 10-12 and 10-n of ET-1, maximum
effects at 10-i°M (145% control cell number) and lower effects at 10-9,10"8,
10-7 and 10-6M. All the concentrations of ET-1 mentioned above produced
statistically significant effects on growth apart from 10-7M.
In BRF2 cells, stimulation of growth as a result of the addition of
exogenous ET-1 was seen only at concentrations between 10-i°M and
10-8M with maximum stimulatory effect seen at 10-i°M (152% compared
to controls) (figure 6.10). At concentrations between 10"13M to 10-HM and
10-8 to 10-6M no stimulatory effects were detected.
Table 6.7 summarises the results of ET-1 addition on the growth of BRF1
and BRF2 fibroblasts from a representative of three experiments expressed
as % control cell number
(ii) Effects ofET-2
Results of the addition of ET-2 to BRF1 and BRF2 cells in terms of growth
are shown in figure 6.1. In the case of BRF1 cells, ET-2 addition between
10*13 and 10-i°M resulted in increasing stimulation of growth. Maximum
growth stimulation (161% control growth) was detected with the addition








control 13 12 11 10 9 8
ET-1 added (-logM)
Figure 6.10: Effects of the exogenous addition of ET-1 on BRF1 and BRF2 breast fibroblast
cell lines growing in 1% serum conditions for a 5 day period. Graph shows results from a
representative of 3 experiments performed on separate occasions (bars: mearctse).
Effect of ET-1 on the growth of breast fibroblast cell lines
added
CeH ET 13 12 11 10 9 8 7 6
1 line (-logM)
B % * * * * »
R control 95 115 120 145 132 127 103 98
F growth
1
±se 2.9 23.6 17.3 12.7 18.5 3.7 11.7 5.26
B % * • »
R control 101 105 108 152 145 119 107 101
F growth
2
±se 9.7 7.2 10 14.2 13.7 8.6 7.7 7.6
Table 6.7. The effects of exogenous endothelin-1, added at concentrations of 1CH3 to 10"6M,
on the growth of BRF1 and BRF2 breast fibroblast cell lines expressed as % control cell
number (2.9xl04±496 and 3.0xl04±2147 for BRF1 and BRF2 respectively). Each value
represents mean ± se of three experiments performed on separate occasions (* values








control 13 12 11 10 9 8 7 6
ET-2 added (-logM)
Figure 6.11: Effects of the exogenous addition of ET-2 on BRF1 and BRF2 breast fibroblast
cell lines growing in 1% serum conditions for a 5 day period. Graph shows results from a
representative of 3 experiments performed on separate occasions (bars: mean±se).
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Table 6.8: The effects of exogenous endothelin-2, added at concentrations of 1(H3 to 106M,
on the growth of BRF1 and BRF2 breast fibroblast cell lines expressed as % control cell
number (3.0xl04±3314 and 2.7x10412159 for BRF1 and BRF2 respectively). Each value
represents mean ± se of three experiments performed on separate occasions (* values
represent statistical significance, p<0.05).
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At concentrations between 10-9 and 10-6M the effects were decreasing.
In BRF2 cells, increasing stimulatory effects were detected at
concentrations of 10-12 and 10-n M with the maximum effects seen, as in
BRF1 cells, at 10-i°M (154% control growth) of added ET-2 and lower
effects at 10-9, lO"8-10-7 and lO^M.
Table 6.8 shows the effects of stimulation of growth (as % control cell
number) for all the concentrations of ET-2 in BRF1 and BRF2 cells,
(iii) Effects of ET-3
The effects of ET-3 addition to BRF1 and BRF2 cells are shown in figure
6.12.
In BRF1 cells a small, almost equal, stimulation of growth was observed
with the addition of ET-3 across the range of concentrations (IO13 to lO-6
M). At concentrations between 1(H3M and 10-HM, a decrease in the effect
was observed. Maximum effect was observed at 10"10M (119% of control
growth) and at higher concentrations (10-9 to 1(HM) the effects were
decreased and comparable to each other.
In BRF2 breast fibroblasts, added concentrations of ET-3 between 1(H2 to
10-7M resulted in an increased cell growth. The levels of growth
stimulation were lower than stimulation with ET-1 or ET-2 at the same
concentrations and followed the same "bell-shaped" pattern increasing
between 10-12M to 10-9M (maximum effect at 10-9M showing a 26%
increase in control cell number) and dropping with the addition of 10 8
and 10-7M of ET-3 added respectively.
Table 6.19 summarises the effects of ET-3 addition at concentrations


























Figure 6.12: Effects of the exogenous addition of ET-3 on BRF1 and BRF2 breast fibroblast
cell lines growing in 1% serum conditions for a 5 day period. Graph shows results from a
representative of 3 experiments performed on separate occasions (bars: mean+se).
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97 107 111 123 126 121 107 94
2
±se 10.1 4.8 9.5 9.4 4.9 4.9 4.6 4.5
Table 6.9. The effects of exogenous endothelin-3, added at concentrations of lO13 to 10-6M,
on the growth of BRF1 and BRF2 breast fibroblast cell lines expressed as % control cell
number (3.9x104+1899 and 2.6xl04±2875 for BRF1 and BRF2 cell lines respectively) . Each
value represents mean ± se of three experiments performed on separate occasions (* values
represent statistical significance, p<0.05).
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6.5 Discussion
Evidence presented elsewhere in this thesis suggests that epithelial cancer
cell lines but not fibroblasts produce significant amounts of ET-l-like
material and that ovarian epithelial cancer and ovarian and breast
fibroblast cell lines express specific ET-receptors. In this chapter we have
shown that exogenous addition of ETs has been shown to affect the
growth of these cell lines.
Thus, exogenous addition of ETs to PE04 and PE014 cells produced
significant stimulatory effects on the growth of both ovarian carcinoma
cell lines. The effect of exogenous ET-1 addition was concentration
dependent with the maximum effects shown at 10-10M for PE04 and at
10-9M for PE014 cells. The minimum ET-1 concentration necessary to
produce significant increase in cell number in both PE04 and PE014 was
10-12M. This concentration is higher that the circulating ET-1
concentration in humans (10"13M) (Huggins, 1993) but 100 times less than
the concentration (10-i°M) reported to produce mitogenesis in fibroblasts
and messangial cells (Huggins, 1993). Furthermore, exogenous addition
of ET-1 between 1(H0 and 10-7M (maximum effect with 10-7M) stimulated
thymidine incorporation in SK-OV-3 and cell growth (in cell numbers) in
OVCA 433 cells (Bagnato et al., 1995). In the present study, ET-2 also
stimulated an increase in cell numbers in a concentration dependent
manner but quantitative differences were evident between the cell lines,
PE014 cells appearing more sensitive. Thus, 10~8M was necessary to
stimulate maximum effects (20% increase in cell growth) in PE04 cells
compared to 10-9M needed to produce maximum effects in PE014 cells.
The effects of ET-1 and ET-2 on both ovarian epithelial cancer cell lines
show a biphasic nature with a smaller effect being seen at higher
exogenous concentrations (10-7M) than lower exogenous concentrations
(10-9M) of the peptide added to the cells. Such "bell shaped" effects on
growth have been observed with the peptides and could be explained by
the downregulation of endothelin receptors by the addition of high
concentrations of ET-1. Indeed such effects have been described in
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described in endothelial and smooth muscle cells which secrete ET-l-like
material and also express endothelin receptors on their membranes
(Clozel et al., 1993). Exogenous addition of ET-3 did not result in any
significant mitogenic response in either of the ovarian cell lines and at
any concentration (1(H3 to lCHM) tested. These results on the effects of
ETs on the growth PE04 and PE014 ovarian cancer cell lines support the
observations of the binding experiments (chapter 5) which suggested that
the cell lines express ETa-R subtypes which are shown to have very low
affinity for ET-3 (which would then have no effect on their growth), high
affinity for ET-2 and highest of ET-1.
The exogenous addition of ETs to PE012F, PE014F and PE027F ovarian
fibroblasts produced significant stimulatory effects on the growth. The
addition of ET-1 exerted mitogenic effects between concentrations of 10-13
to 10-6 (10-12 to lO-9 for PE027F cells) with the maximum effect seen at
10-iom in all 3 cell lines. ET-2 addition also had similar stimulatory
effects at concentrations between 10-12 and 10-7 in all cell lines with
maximum influences being seen at IO-9 M (PE012F and PE014F) and 10-
10M (PE027F). In contrast to ovarian epithelial cancer cell lines,
exogenous addition of ET-3 between IO-12 and 10-6M had the same growth
stimulatory effects in all 3 fibroblast cell lines as ET-1 and ET-2, maximum
effects were observed at 10-9M (PE012F, PE014F) and 10"8M (PE027F). The
magnitudes of the effects seen with each endothelin were similar in all
cell lines. These observations suggest that these effects were mediated at
least in part through ETg receptors although results from binding
experiments showed the expression of both types of ET-Rs.
The addition of exogenous ETs to MDA-MB-231, T47D and ZR-75-1 cells
did not have any effects on the growth of the three breast epithelial cancer
cell lines in culture, a result is in accordance with the absence of ET
receptors on the cells (chapter 5). Other studies have also reported the
absence of ET receptors in breast epithelial and cancer cell lines (Baley et
al., 1990).
Exogenous addition of ETs however had significant effects on the growth
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of BRF1 and BRF2 breast fibroblast cell lines. Addition of ET-1 exerted a
mitogenic effect on both cell lines at concentrations of 10-12 and 10-7M
with maximum stimulation observed at ICHOM. Addition of ET-2 to
BRF1 cells showed even greater effects than ET-1 at the same range of
concentrations and with maximum effects at 1(H° and 10*9M. In BRF2
cells, ET-2 had very similar effects to ET-1 with maximum growth
stimulation at 10-iOM but smaller than the effect seen with ET-1. ET-3
addition also affected growth of the cells in both cell lines. In BRF1 cells,
the effects were not as substantial as with ET-1 and ET-2 but were still
significant between concentrations of 1(H3 to lO-^M and 10*10 to 10-6M.
Maximum effects were observed at 10-iOM. In BRF2 cells effects were
observed between 10-11 and 10-7M with maximum stimulation of growth
at 10"10 and 10-9M. The results suggested that BRF2 cells were more
sensitive to ET-3 than BRF1 cells. As with ovarian fibroblast cell lines the
above results would suggest that effects of ETs are mediated at least
partially through ETb-R subtypes. Results from binding experiments
have suggested that these cell lines express both ETa-R and ETb-R
subtypes (chapter 5) and it is thus possible that ETs exert their mitogenic
effects through both receptor subtypes. Reports on breast fibroblasts have
suggested the expression of ET receptors in these cells without presenting
data regarding the type of receptors (Baley et al., 1990).
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Chapter 7: Effects of endothelin receptor antagonists on the growth of
ovarian and breast epithelial cancer cells and fibroblasts.
The effects of the three endothelin subtypes on the growth of different cell
types were described in chapter 6. In order to help determine the specific
ET receptor subtypes involved in the growth of ovarian and breast
epithelial cancer cell lines and fibroblasts, two endothelin receptor specific
antagonists (BQ123, ETa-R antagonist) and (BQ788, ETb-R antagonist)
were used. To ascertain whether the ET-receptor antagonists exert any
effects on the growth of the cell lines experiments using BQ123 and BQ788
in the culture of the cell lines in the absence of exogenous ET-1 were
carried out. Such experiments would also demonstrate the ability of these
antagonists to block possible effects on growth as a result of the
endogenous production of endothelin (already demonstrated in chapter
4) from PE04 and PE014 ovarian epithelial cancer cells.
7.1 Ovarian epithelial cancer cells
7.1.1 PE04 cells
The effects of the two endothelin receptor antagonists on the growth of
PE04 cells are illustrated in figure 7.1.
In this cell line, addition of the antagonists BQ123 or BQ788 at lOOnM in
the absence of exogenous ET-1 did not significantly affect the growth of
the cells. Addition of 10-9M ET-1 to the culture of PE04 cells in the
absence of any ET receptor antagonists resulted in a 50% increase in cell
number compared to controls (150% control cell number). However, the
addition of lOOnM of BQ123 (ETa-R antagonist) in the presence of 10-9M
ET-1 resulted in 90% inhibition of the ET-1 induced growth suggesting the
expression of ETa receptors in PE04 cells and their involvement in the
growth stimulation of the cells as a result of exogenous ET-1 addition.
The addition of lOOnM of BQ788 (ETb-R antagonist) in the presence of 10-9
M ET-1, significantly blocked (60%) the ET-l-induced growth. Although
the extent of this inhibition was not as substantial as that produced by the
ETa-R antagonist, it was still significant suggesting the presence of ETb
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receptors which partially mediate the ET-1 induced stimulation of growth
in PE04 cells.
7.12 PE014 cells
The effects of the ET antagonists BQ123 and BQ788 on the growth of
PE014 cells in the presence or absence of exogenous ET-1 are described in
figure 7.2.
In contrast with PE04 cells, the addition of lOOnM of BQ123 (ETa-R
antagonist) in the absence of exogenous ET-1, resulted in significant
inhibition of control growth. Such effect suggests inhibition of an effect
on the growth of PE014 cells caused by endogenous ET-1. Addition of
lOOnM of BQ788 (ETb-R antagonist) in the absence of exogenous ET-1 had
no effect on the growth of PE014 cells. Exogenous ET-1 at 10-9M and in
the absence of ET-R antagonists, stimulated growth to 170% compared to
control cell number. However, 10-9M ET-1 in the presence of lOOnM
BQ123 resulted in no stimulation of growth suggesting that the receptors
present in PE014 cells are of the ETa-R type and mediate the growth
stimulatory effects of ET-1. Addition of 10-9M of ET-1 in the presence of
lOOnM of BQ788 antagonist resulted in no inhibition of growth compared
to growth with ET-1 alone, suggesting that ETb receptors are either not
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Figure 7.1: Growth of PE04 ovarian epithelial cancer cells in culture, in the absence
(control), or presence of: BQ123 ETa-R antagonist (lOOnM), BQ788 ETb-R antagonist
(lOOnM), ET-1 (InM), ET-1 (InM) + BQ123 (lOOnM) and ET- l(lnM) + BQ788 (lOOnM).
Growth is shown as cell number at the end of a 5 days incubation and results representmean
values of three experiments performed on separate occasions (*) represents statistical
significance (p<0.05) compared to ET-1 while (•) represents statistical significance
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Figure 7.2: Growth of PE014 ovarian epithelial cancer cells in culture, in the absence
(control), or presence of: BQ123 ETa-R antagonist (lOOnM), BQ788 ETb-R antagonist
(lOOnM), ET-1 (InM), ET-1 (InM) + BQ123 (lOOnM) and ET- l(lnM) + BQ788 (lOOnM).
Growth is shown as cell number at the end of a 5 days incubation and results represent mean
values of three experiments performed on separate occasions (*) represents statistical
significance (p<0.05) compared to ET-1 while (•) represents statistical significance
(p<0.05) compared to control.
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7.2 Ovarian fibroblasts
PE012F ovarian fibroblasts were used in order to detect the effects of ET-R
antagonists on the growth of ovarian fibroblasts in the presence or
absence of exogenous ET-1 (figure 7.3).
Neither of the two ET-R antagonists had any effect on the growth of
PE012F cells in the absence of exogenous ET-1 while 10-9M of ET-1 alone,
stimulated the growth of the cells by 40% relative to the control cell
number. The addition of lOOnM of BQ123 (ETa-R antagonist) in the
presence of 10*9M, partially blocked the growth stimulatory effect of ET-1
resulting in an increase of 16% of cell number compared to control. Such
an effect suggested the expression of ETa-R subtypes in PE012F cells and
the involvement of such receptors in the stimulation of growth of
PE012F cells by ET-1. The addition of lOOnM of BQ788 ETb-R antagonist to
PE012F cells in the presence of ET-1 also resulted in partial blockage of
the stimulation seen with 10-9M ET-1 in the absence of antagonists,
showing an increase of 15% compared to control cell number. These
results suggested that both types of ET receptors are expressed in ovarian
fibroblasts and that they mediate the growth stimulatory effects of ET-1.
7.3 Breast fibroblasts
To identify the receptor subtype(s) mediating the growth stimulatory
effects of exogenous ET-1 in breast fibroblasts in culture, the effects of the
two ET-R antagonists BQ123 and BQ788 were investigated in BRF1 breast
fibroblast cell line (figure 7.4). Incubation of BRF1 cells with lOOnM of
either BQ123 or BQ788 antagonist had no significant effect on the growth
of the cells compared to controls. Incubation of BRF1 cells with 10-9M of
ET-1 in the absence of receptor antagonists resulted in 170% control cell
number while lOOnM of BQ123 in the presence of 10-9M of ET-1 resulted
in a reduced effect of ET-1 (125% of control cell number) on the growth of
the same cells. Similar results were seen after the incubation of cells with
lOOnM of BQ788 and 10"9M of ET-1 which also reduced the growth
stimulatory effect of ET-1 to 113% control cell number. Finally incubation
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of BRF1 cells with 10 -9M of ET-1 and both receptor antagonists (lOOnM of
each) completely blocked the effect of ET-1 suggesting, as with PE012F
ovarian fibroblasts, the involvement of both receptor subtypes in
mediating the growth stimulatory effects of ET-1.
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Figure 73: Growth of PE012F ovarian fibroblast cells in culture, in the absence (control), or
presence of: BQ123 ETa-R antagonist (lOOnM), BQ788 ETb-R antagonist (lOOnM), ET-1
(InM), ET-1 (InM) + BQ123 (lOOnM), ET-1 (InM) + BQ123 (lOOnM) and ET-1 (lnM)+BQ123
(lOOnM) + BQ788 (lOOnM). Growth is shown as cell number at the end of a 5 days
incubation and results represent mean values of three experiments performed on separate
occasions ((*) represents statistical significance (p<0.005) compared to ET-1 while (•)
represents statistical significance (p<0.005) compared to control.
Cell number
Figure 7.4: Growth of BRF1 breast fibroblast cells in culture, in the absence (control), or
presence of: BQ123 ETa-R antagonist (lOOnM), BQ788 ETg-R antagonist (lOOnM), ET-1
(InM), ET-1 (InM) + BQ123 (lOOnM), ET-1 (InM) + BQ123 (lOOnM) and ET-1 (lnM)+BQ123
(lOOnM) + BQ788 (lOOnM). Growth is shown as cell number at the end of a 5 days
incubation and results represent mean values of three experiments performed on separate
occasions (*) represents statistical significance (p<0.005) compared to ET-1 while (•)
represents statistical significance (p<0.005) compared to control.
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7.4 Discussion
The results presented in this chapter suggest that ET-receptor antagonists
can be used in order to inhibit growth stimulatory effects (in terms of cell
number) observed with the exogenous addition of ETs into the cultures of
different cell lines, thus providing additional information regarding the
subtypes of ET receptors mediating such effects.
A single report (Bagnato et al., 1995) using the same ET-R antagonists in
order to block growth stimulatory effects of ET-1 on OVCA 433 cells
showed that such effects were mediated by ETa-R subtypes and could be
blocked with the addition of BQ123 but not with the BQ788 antagonist.
In this study, results regarding the ovarian cancer cell lines, and the use of
BQ123 receptor antagonist suggested that ET-1 exerted its mitogenic effects
through ETa-R in both cell lines. In the case of PE04 cells only, a partial
blockage of this effect was observed with the addition of BQ788 antagonist,
suggesting the possible presence and involvement of ETb receptors in the
growth of these cells.
These results are in accordance with previous reports (Bagnato et al., 1995)
and are consistent with the observations of the ligand binding
experiments (chapter 5) which suggested the expression of ETa receptors
in both cell lines and the possibility of the presence of a small number of
ETb receptors in PE04 cells.
Results from PE012F ovarian fibroblasts have suggested that both
receptor antagonists could partially block the growth stimulatory effect
exerted on these cell lines by ET-1 thus suggesting the involvement of
both ETa-R and ETb-R in the growth control of these fibroblasts. The
consistent (non-significant) larger effect produced with the addition of
BQ788 could account for differences in the number of the two receptor
types expressed in PE012F cells but could also account for the different
degree of involvement of each receptor subtype in the growth of these
cells.
In BRF1 breast fibroblasts the use of either BQ123 or BQ788 antagonists
specifically blocked the effect of ET-1 on growth suggesting that both
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receptor subtypes mediate such effects. The same (consistent but not
statistically significant) observation, as in PE012F cells, was made in BRF1
fibroblasts, in which BQ788 antagonist blocked the effect of ET-1 more
effectively than BQ123 antagonist. The expression and involvement of
the ETb receptor subtype on the growth of ovarian and breast fibroblasts
cells could also explain the mitogenic effects observed with the addition
of ET-3 in the culture of these cells as suggested in chapter 6.
In conclusion, the growth stimulatory effects observed with the addition
of ET-1 in PE04 and PE014 ovarian cancer cells in culture are consistent
with mediation by the ETa-R subtype but in the case of PE04 cells with
the ETb-R subtype also. In ovarian and breast fibroblasts similar growth
stimulatory effects of ET-1 could be mediated by both receptor subtypes.
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Chapter 8: Co-culture experiments
To determine the effects of paracrine influences on the growth of
epithelial and fibroblast cell types in ovarian and breast cancer, co-culture
experiments were designed using tissue culture inserts in 24 well plates as
shown in figure 8.1.
Figure 8.1: Schematic representation of the co-culture experiments. Fibroblasts were
seeded at the bottom of 24 well plates and epithelial cells at the bottom of well inserts
placed in separate wells and left for 24h in serum containing conditions (10% for PE014,
T47D and 15% for PE012F and BRF1 cell lines). The inserts were then placed on top of the
wells containing the fibroblasts and cultured together for 5 days in 1% serum conditions.
The porous membrane at the bottom of the inserts allowed exchange of factors between the
two cell types. At the end of the 5 day period inserts were separated, and cell counts from
both populations were calculated using a Coulter counter.
The involvement of possible endogenous secretion of ETs from either
epithelial and fibroblast cells and their effects on the growth of both were
determined in the absence or presence of ET receptor antagonists.
Epithelial cells and fibroblasts were seeded separately from each other in
serum (10% and 15% respectively) containing media and then co-cultured
in restricted serum conditions (1%). At the end of a 5 day incubation
period, cells were trypsinised and cell numbers were determined by
coulter counter. Results (in cell number) of each of the two cell types in
culture in the absence or presence of ET-receptor antagonists were
compared to results of epithelial and fibroblast cells growing separately.
8.1 Co-culture of ovarian epithelial cancer cells and fibroblasts
For the co-culture experiments with ovarian cells, PE014 epithelial and
PE012F fibroblastic cell lines were used. The results of these experiments
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are summarised in figures, 8.2 and 8.3 and are discussed in detail below.
After a 5 days incubation period, PE014 cells growing in co-culture with
PE012F ovarian fibroblasts reached a significantly higher cell number
(35% increase) compared to PE014 cells growing separately. Similarly to
the epithelial cells, the number of PE012F cells in co-culture with PE014
cells was significantly greater (37% increase) than that of PE012F
fibroblasts growing alone, suggesting functioning paracrine systems
affecting the growth of both epithelial and fibroblast cell types.
With PE014 cells, BQ123 significantly reduced (13%) the cell number
compared to co-culture with no antagonist. However, the cell number of
PE014 cells in the presence of BQ123 remained significantly higher (17%)
than that of PE014 cells growing alone, suggesting the involvement of
ETs and ETa-R on the growth of these cells. Addition of the BQ788 ETb-R
antagonist into the co-culture of PE014 resulted in no significant
difference in their growth compared to controls.
The addition of BQ123 to PE012F fibroblasts in co-culture significantly
reduced (14%) their growth compared to PE012F cell number in the
absence of the antagonist. Cell number of PE012F cells in the presence of
BQ123 was still significantly higher (18%) than that of cells growing in
isolation. Additionally, the BQ788 ETb-R antagonist significantly reduced
(15%) the growth of PE012F fibroblasts. However, as with BQ123 cells
growing in the presence of BQ788 reached significantly higher numbers
(18%) compared to fibroblasts growing in isolation.
Table 8.1 summarises the results and the statistical analysis from the
experiments described above.
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Figure 8*2: Growth (in cell number) of PE014 ovarian epithelial cells growing in isolation
(control) or in co-culture, in the absence (cc) or presence of BQ123 (ETA-R) or BQ788 (ETB-
R) antagonists at the end of a 5 day incubation period. Asterisks (*) and points (•)
represent values that reach statistically significant cell numbers compared to co-cultured
and control cells respectively. Graphs shows mean values! standard error (se) of a
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Figure 83: Growth (in cell number) of PE012F ovarian fibroblasts growing in isolation
(control) or in co-culture, in the absence (cc) or presence of BQ123 (ETA-R) or BQ788 (ETB-
R) antagonists at the end of a 5 day incubation period. Asterisks (*) and points (•)
represent values that reach statistically significant cell numbers compared to co-cultured
and control cells respectively. Graphs shows mean values! standard error (se) of a
representative of 3 experiments performed on separate occasions.
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Cell conditions number compared to compared to








1 1157621 0.038 0.004
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Table 8.1: Table summarises numbers of PE014 ovarian epithelial and PE012F fibroblast
cells growing in co-culture (cc) or in isolation, in the presence or absence of BQ123 (ETA-R)
or BQ788 (ETB-R) antagonists and the statistical significance (p value) compared numbers
of cells in isolation (control) or in co-culture (co-cultured). The asterisk (*) signifies values
that reach statistical significance and results represent mean valuesistandard error (se) of
a representative of three experiments performed on separate occasions.
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8.2 Co-culture of breast epithelial cancer cells and fibroblasts
T47D breast epithelial cancer cells have been shown to secrete significant
amounts of immunoreactive ET-l-like material as described in chapter 4
while their growth is not affected by exogenous addition of ET-1, 2 or 3
due to the lack of expression of ET-receptors as described in chapters 6 and
5 respectively. In contrast, BRF1 breast fibroblasts have been shown not to
secrete ET-like peptide (chapter 4), to express both types of ET receptors
(chapter 5) while their growth can be stimulated by all 3 ETs (chapter 6).
T47D and BRF1 cell lines were used in order to study the paracrine role of
ETs on the growth of breast epithelial and fibroblast cells in co-culture.
The results are shown in figures 8.4 and 8.5 and are described in greater
detail below.
T47D cells growing in co-culture with BRF1 fibroblasts grew to
significantly higher (15%) numbers compared to T47D cells growing in
isolation. Even greater stimulation (31%) of growth was detected in BRF1
cells in co-culture compared with fibroblasts growing separately,
suggesting paracrine growth controls between the epithelial and fibroblast
cells.
The addition of BQ123 (lOOnM) or BQ788 (lOOnM) antagonists into the co-
culture of the cells had no effect on the growth of T47D epithelial cells.
However, the growth of BRF1 breast fibroblasts was inhibited by 12% (not
quite statistically significant) and 16% with the addition of BQ123 and
BQ788 antagonists (respectively) compared to cells growing in the absence
of antagonists and in co-culture with T47D cells.
Table 8.2 describes the results and the statistical analysis of the
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Figure 8.4: Growth (in cell number) of T47D breast epithelial cells growing in isolation
(control) or in co-culture, in the absence (cc) or presence of BQ123 (ETA-R) or BQ788 (ETB-
R) antagonists at the end of a 5 day incubation period. Asterisks (*) and points (•)
represent values that reach statistically significant cell numbers compared to co-cultured
and control cells respectively. Graphs shows mean values! standard error (se) of a
representative of 3 experiments performed on separate occasions.
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Figure 8.5: Growth (in cell number) of BRF1 breast fibroblasts growing in isolation (control)
or in co-culture, in the absence (cc) or presence of BQ123 (ETA-R) or BQ788 (ETB-R)
antagonists at the end of a 5 day incubation period. Asterisks (*) and points (•) represent
values that reach statistically significant cell numbers compared to co-cultured and control
cells respectively. Graphs shows mean values! standard error (se) of a representative of 3





























































Table 8.2: Table summarises numbers of T47D breast epithelial and BRF1 fibroblast cells
growing in co-culture (cc) or in isolation, in the presence or absence of BQ123 (ETA-R) or
BQ788 (ETB-R) antagonists and the statistical significance (p value) compared numbers of
cells in isolation (control) or in co-culture (co-cultured). The asterisk (*) signifies values
that reach statistical significance and results represent mean values±standard error (se) of
a representative of 3 experiments performed on separate occasions.
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8.3 Discussion:
As shown in the previous chapters, the ovarian (PE04 and PE014) and
breast (MDA-MB-231, T47D and ZR-75-1) epithelial cancer cell lines, all
secrete significant amounts of endothelin-l-like material. PE04 and
PE014 cells, ovarian (PE012F, PE014F and PE027F) and breast (BRF1 and
BRF2) fibroblast cell lines all express endothelin receptors and respond to
exogenous endothelins in terms of growth. Therefore, the involvement
of endothelins in a paracrine regulation of growth is possible.
In this study, such involvement of endothelins was investigated with the
addition of specific ET-receptor antagonists in the media of epithelial
cancer cells and fibroblasts in co-culture. Numbers of cancer cells and
fibroblasts in the presence or absence of ET-receptor antagonists in co-
culture were compared to numbers of cells growing in isolation.
Although the differences in cell number could be accounted for by the
effects of other factors, the inclusion of ET-receptor antagonists enabled
the detection of possible effects on growth due to endothelins.
Experiments involving PE014 ovarian epithelial cells and PE012F
fibroblasts suggested that both cell types, grew significantly faster in co-
culture than when growing separately. These results illustrated the
influence of factors released, acting in a paracrine manner, on the growth
of both cell types. The addition of BQ123 (ETa-R) antagonist to the media
of PE014 and PE012F cells in co-culture resulted in a partial but
significant blockade of growth suggesting that ETa receptors and therefore
endothelins were involved in the paracrine regulation of growth. The
fact that the antagonist blocked only a proportion of the effect suggested
that other factors were also involved. The addition of BQ788 (ETb-R)
antagonist to the culture media of PE012F cells resulted in a significant
reduction of growth compared to cells in co-culture in the absence of the
antagonist but had no effect on the growth of PE014 cells suggesting the
involvement of ETb receptors in the regulation of growth in PE012F
fibroblasts but not in the PE014 epithelial cancer cells.
In previous chapters it has been concluded that PE014 cells produce
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significant amounts of ET-l-like material and express at least one type of
ET receptor (ETa-R) while PE012F fibroblasts do not produce any ET-l-
like material but do express possibly both types of ET receptors(ETA-R and
ETb-R). According to the results analysed above both cell types grow
faster when in co-culture suggesting paracrine interactions which affect
their growth. The use of ET-receptor antagonists in the culture media of
both cell lines suggested that these paracrine interactions in addition to
the autocrine interactions demonstrated in chapter 7 affecting cell growth
do involve ET-l-like material secreted by PE014 cells and ET receptors
expressed in both PE014 cells (ETa-R) and PE012F fibroblasts (ETa-R and
ETb-R).
Co-culture experiments using T47D breast epithelial and BRF1 fibroblast
cell lines also demonstrated the growth stimulatory effects exerted by
factors acting in a paracrine fashion. Both cell lines grew faster when in
co-culture than when growing in isolation although that difference was
not significant in the case of T47D cells. The addition of BQ123 (ETa-R)
antagonist in the culture media of T47D cells in co-culture had no effect
on their growth suggesting that ETa receptors have no role in the growth
of these cells. However, addition of BQ123 into the media of BRF1 cells
resulted in a consistent although not quite statistically significant
inhibition of growth suggesting a possible involvement of ETa receptors
in the growth of these cells.
Addition of BQ788 (ETb-R) antagonists to the culture of T47D cells failed
to exert any effect on growth, while the same antagonist had a significant
inhibitory effect on the growth of BRF1 cells in co-culture.
The previous experiments demonstrated that T47D cells produce
significant amounts of ET-l-like material (able to bind to both ETa and
ETb receptors) while they do not express ET receptors while BRF1 cells do
not produce any detectable amounts of ET-l-like material but seem to
express both types of ET receptors. As shown in this chapter both cell
lines grow faster in co-culture than in isolation suggesting paracrine
interactions which in the case of T47D cells do not involve endothelins
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since their growth is not affected by ET-R antagonists while in the case of
BRF1 cells, such interactions involve ETs produced by T47D cells and
acting through ETb and possibly ETa types of receptors.
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Chapter 9: The use of antisense oligonucleotide technology to investigate
the autocrine role of ETs in the growth of ovarian cancer cell
lines
Specific "antisense"oligonucleotide sequences were designed to target the
mRNAs of both endothelin receptors and were added into cultures of
PE04 and PE014 cells in order to inhibit the effects of possible autocrine
production of ETs on the growth of these cell lines. "Sense" and
"random" oligonucleotide controls were also synthesised and their effects
compared with the antisense sequence.
For both cell lines, the oligonucleotides were added at concentrations of
10 and 30(iM (as described in the methods section). With PE04 cells, as
shown in figure 9.1, the addition of "antisense", "sense' or "random"
oligonucleotides for either ETa-R or ETb-R had no effect on the growth of
these cells. With PE014 cells however (figure 9.2), the addition of
"antisense" for ETa-R produced significant inhibitions at both
concentrations. Addition of "sense", and "random" had no effects at
either 10 or 30|iM suggesting that the effects were specific. The addition of
ETb-R "antisense" or "sense" produced no effects compared to control









Figure 9.1: Effects of the use of "antisense" (AS), "sense" (S) and "random" (R)
oligonucleotides for ET^-R and ETg-R at concentrations of 10 and 30pM on the growth of
PE04 cells after a 7 day incubation period in serum free media. Day zero counts for the
controls were 30128±519 cells. Results shown are mearcfcse values from a representative of 3






























Figure 92: Effects of the use of "antisense" (AS), "sense" (S) and "random" (R)
oligonucleotides for ETa-R and ETb-R at concentrations of 10 and 30pM on the growth of
PE014 cells after a 7 day incubation period in serum free media. Asterisk (*) represents
statistical significance (p<0.05) compared to control values. Day zero counts for the
controls were 29758±875 cells. Results shown are meanise values from a representative of 3
experiments performed on separate occasions.
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9.2 Discussion
In the previous chapters, it has been shown that PE04 and PE014 cells
secrete significant amounts of ET-l-like material, that they express ET
receptors, are growth responsive to exogenous ET addition and that this
effect can be blocked with the addition of specific receptor antagonists. In
this chapter we have investigated the possible effect of the endogenous ET
on the growth of the same cell lines by studying the impact of "antisense"
oligonucleotides for both ET receptors in order to block the production of
ET receptors. The use of antisense oligonucleotides against the ET-
receptors and not against ET-peptides was preferred. The reasoning
behind such decision was the problems of different affinities of the two
receptor types for the ET-peptides, and the fact that by using the
antagonists selected, more information would be revealed regarding the
receptor types involved and results would be directly comparable with the
results of the co-culture experiments. Results shown in this chapter
represent the first data of the use of antisense technology for endothelin
receptors and only the second set of data of antisense technology in
ovarian cancer. In the previous study, antisense oligonucleotides were
used against the IGF receptor (Resnicoff et al., 1993).
The results showed no effects on the growth of PE04 cells suggesting that
either the amount of ET secreted does not have any effect on their growth
or that the number of receptors expressed is low and therefore the
receptor signalling is not sufficient, or that the effects of "antisense" were
not sufficient to block the autocrine effect. However, previous
experiments (chapter 6) have illustrated that exogenous addition of ETs
can stimulate growth responses, suggesting that the number of receptors
expressed is sufficient for the effect to be detected.
For PE014 cells, it was shown that the use of "antisense" inhibition of the
ETa-R resulted in a 58-63% decrease in cell number suggesting the
involvement of this receptor type in the autocrine regulation of growth
from ETs. The growth of PE014 cells was not affected by the addition of
antisense for the ETb-R, and these observations are consistent with
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indications that ETb receptors are not expressed in PE014 cells. "Sense"
and "random" oligonucleotides had no effect on the growth of the same
cells suggesting that the effects seen with ETa-R antisense were genuine
and specific. Fully defined conditions serum-free culture conditions
(HITS) were used so that the only source of endothelin was from the cells
themselves.
Comparing RIA results for the two cell lines (chapter 4) PE014 cells were
shown to produce 10 times the amount of ET-l-like material compared to
PE04 cells and such difference might explain an increased dependancy for
PE014 on an ET/ET-R autocrine loop (dilutions of HITS
radioimmunoassayed showed no measurable ET-l-like material).
In summary, the results presented above suggest that in PE014 (but not
PE04) ovarian cancer cells an autocrine system of regulation of growth is
functional, and mediated by the ETa receptor expressed in these cells.
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Chapter 10: Expression of ET peptides and receptors using the Reverse
Transcriptase Polymerase Chain Reaction method
To help establish the isoform of endothelin (produced by the cell lines
used for radioimmunoassay experiments (chapter 4), the type of ET-
receptors, and to determine whether the same peptides are expressed in
tumour samples as in model systems, the expression of the 3 endothelin
peptides and the ET receptor types at the RNA level in ovarian and breast
cancer cell lines, fibroblasts and primary tumour samples, was
investigated using RT-PCR technology (primers sequences shown on page
62). Throughout the experiments described below, fi-actin was used as a
positive control and negative controls constituted of RNA samples that
were not taken through the RT step but were amplified for 30 cycles in a
PCR reaction with the appropriate primers. Further controls were
performed in some of the experiments using specific oligonucleotides
designed for probe labelling (Southern blotting, as described on page 64 of
the methods).
10.1 Expression of mRNA for ET peptides and receptors in ovarian and
breast cancer cell lines
10.1.1 Expression of ET peptides and receptors in ovarian cancer cell lines
RNA preparations from PE04 and PE014 cell lines were used to
investigate the expression of ET1, ET-2, ET-3 peptides and ETa and ETb
receptors (lanes 1 and 2 for PE04 and PE014 respectively). Results (figure
10.1) suggested the presence of single mRNA bands for ET-1, ET-3, ETa-R
and ETb-R at the predicted sizes (582, 493, 368 and 530bp respectively), fi-
actin bands of the predicted size (262bp) were also seen in PE04 and PE014
cell lines. Negative controls (lane 3 for PE04 in ET-1,2,3 and for PE014 in
ET-Rs and fi-actin) produced no bands. Southern blotting experiments,
using ET-1 and ETa-R oligonucleotides, showed that the relevant bands
observed in PCR gel represent ET-1, and ETa-R (figure 10.2).
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Figure 10.1: RT-PCR products of ET-1, ET-2, ET-3, ETa-R, ETb-R and 6-actin in PE04 and
PE014 ovarian cancer cell lines. Lane L: lOObp DNA marker; lane 1: PE04 cells; lane 2:
PE014 cells; lane 3: negative control samples (not through RT step). The predicted sizes






Figure 10.2: Southern blotting photographs of RNA bands in PE04 and PE014 cellsdetected with RT-PCR and labelled with specific oligonucleotides against ET-1 and ETaRbands.
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10.1.2 Expression of ET peptides and receptors in ovarian fibroblast cell
lines
RNA from the ovarian fibroblast cell lines PE09F, PE012F, PE014F and
PE027F were prepared and used for RT-PCR. Results (figure 10.3)
suggested the expression of mRNA for ET-1, ET-3 (not in PE027F) ETa-R
(not in PE09F) and ETB-R (lanes 1, 2, 3,4, for PE012F, PE014F, PE027F and
PE09F respectively) while no ET-2 mRNA was expressed. A fi-actin band
was observed (262bp) in all cell lines while negative controls (PE012F for
ET-1 and ET-2; PE014F for ET-3; PE027F for ETA-R and PE09F for ETB-R
and fi-actin) showed no bands.
10.1.3 Expression of ET peptides and receptors in breast cancer cell lines
The expression of ET-1, 2, 3 and ETA-R, ETB-R mRNA in breast cancer cell
lines was investigated using RNA preparations from four cell lines (MCF-
7, MDA-MB-231, T47D and ZR-75-1). Results shown in figure 10.4
suggested the expression of mRNA in the form of single bands for ET-1
and ET-3 (at 582 and 493bp respectively) in all four cell lines (lanes 1, 2, 3,4
for MCF-7, MDA-MB-231, T47D and ZR-75-1 cells respectively) apart from
ET-3 in T47D cells, and the absence of mRNA for ET-2, ETA and ETB
receptors in the same cell lines. Positive controls showed single band for
fi-actin (at the predicted size of 262bp) in MDA-MB-231, T47D and ZR-75-1
(but not in MCF-7 cells although bands were observed for ETs). Figure
10.5 shows results for fi-actin expression in MDA-MB-231, T47D and ZR-
75-1 cells from samples that have not been through the RT step (lanes 1, 2
and 3, respectively) and of identical samples that have been through the
RT step (lanes 5, 6 and 7, respectively). A specific fi-actin band at 262bp
was seen in all positive control and not in negative control samples.
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L 1 2 3451 23451 2345
ET-1 ET-2 ET-3
6oo bp—
2 3 4 5
6-actin
Figure 10.3: Photograph of an agarose gel of 30 cycle PCR products of PE09F, PE012F,
PE014F and PE027F ovarian fibroblasts. Lane L: lOObp DNA marker; lane 1: PE09F cells;
lane 2: PE012F cells; lane 3: PE014F cells; lane 4: PE027F cells; line 5: negative control
samples (not through RT step). The predicted sizes were: ET-1: 582 bp, ET-2: 197 bp, ET-3:
493bp, ETa-R: 368bp, ETB-R: 530bp, fi-actin: 262bp.
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ETb-R B-actin
Figure 10.4: Photograph of an agarose gel of 30 cycle PCR products of MCF-7, MDA-MB-
231, T47D and ZR-75-1 breast cancer cell lines. Lane L: lOObp DNA marker; lane 1: MCF-7
cells; lane 2: MDA-MB-231 cells; lane 3: T47D cells; lane 4: ZR-75-1 cells. The predicted




L 1 2 3 4 5 6 7
6 -actin
Figure 10.5: Photograph of an agarose gel of 30 cycle PCR products of MCF-7, MDA-MB-
231, T47D and ZR-75-1 breast cancer cell lines. Lane L: lOObp DNA marker; lane 1: MDA-
MB-231 cells; lane 2: T47D cells; lane 3: ZR-75-1 cells; lane 4: MDA-MB-231 (different
sample); lane 5: MDA-MB-231 cells (no RT step); lane 6: T47D cells (no RT step); lane 7:
ZR-75-1 cells (no RT step);. The predicted size for 6-actin: 262bp.
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10.1.4 Expression of ET peptides and receptors in breast fibroblast cell lines
Figure 10.6 shows the expression of ET peptides and ET receptors in RNA
preparations of BRF1 and BRF2 breast fibroblasts. From the three ET
peptides only ET-1 mRNA was expressed as a single band at the predicted
size of 582bp (lanes 2 and 3 for BRF1 and BRF2 respectively). Single bands
for both ETa (368bp) and ETb (530bp) receptors were also detected in both
cell lines (lanes 1 and 2 for BRF1 and BRF2 respectively). Negative
controls were used in lanes 1 and 4 (for BRF1 and BRF2 respectively) for
ET-1, ET-2 and ET-3 RNA samples only, which had not been through the
RT step. No bands were detected in these lanes.
10.2 Expression of mRNA for ET peptides and receptors in ovarian and
breast primary tumours
10.2.1 Ovarian primary tumours
Samples obtained from ten ovarian primary tumours were used to
prepare RNA and to detect the expression of ET peptides and receptors.
Results shown in figure 10.7 demonstrate the expression of ET-1 mRNA
from all samples (ET-1 lanes, from 1 to 10), that of ET-2 from 6 out of 10
samples (ET-2 lanes; 2, 3, 4, 5, 8, 9) and ET-3 mRNA from 9 out of 10
samples (ET-3 lanes, from 1 to 10 apart from 2). Southern blotting
experiments using the same gel and oligonucleotides for ET-1 and ET-3
both showed hybridisation of 10 bands for ET-1 and ET-3 at the exact
positions shown on the PCR photograph (figure 10.8). Regarding the
expression of mRNA of the two ET-receptor types, a single band was seen
at 368bp for ETa-R in all 10 samples (ETa-R lanes, from 1 to 10), and for
ETg-R (at 530bp) in only 2 out of 10 samples (lanes: 7, 9) (figure 10.9).
Southern blotting experiments using labelled probing oligonucleotides
for ETa-R showed that all ten bands were bound to radiolabeled probes
and represent ETa-R mRNA while with radiolabeled probes for ETb-R 6
bands appeared suggesting that although only 2 samples produced clearly
visible bands in the PCR photograph, 4 more (samples 2, 4, 6 and 8) appear
to express ETb-R mRNA (figure 10.10).
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ET-1 ET-2 ET-3
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ETa-R etb-r
Figtire 10.6: Photograph of an agarose gel of 30 cycle PCR products of BRF1 and BRF2
breast fibroblasts, (top) Lane L: lOObp DNA marker; lane 1: negative control BRF1 (no RT
step); lane 2: BRF1; lane 3: BRF2; lane 4: negative control, BRF2 (no RT step), (bottom) lane
1: BRF1 cells; lane 2: BRFlcells. The predicted sizes were: ET-1: 582 bp, ET-2: 197 bp, ET-3:




Figure 10.7: Photograph of an agarose gel of 30 cycle PCR products of 10 primary ovarian
tumour samples, (top) Lane L: lOObp DNA marker; lanes 1-10 tumour samples 1-10. The









Figure 10.8: Southern blotting photograph showing the hybridisation of mRNA bandsfrom 10 primary ovarian cancer samples detected by RT-PCR with specificoligonucleotides against ET-1, ET-2 and ET-3.
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ETB-R (3-actin
Figure 10.9: Photograph of an agarose gel of 30 cycle PCR products of 10 primary ovarian
tumour samples, (top) Lane L: lOObp DNA marker; lanes 1-10 tumour samples 1-10. The





Figure 10.10: Southern blotting photograph showing the hybridisation of mRNA bands
from 10 primary ovarian cancer samples detected by RT-PCR with specificoligonucleotides designed against ETa-R and ETb-R.
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A positive control band at 262bp for fi-actin was observed in all 10
samples. Figure 10.11 shows the expression of ETa-R mRNA in the
identical RNA samples from the same 10 primary tumours, that had (top)
and had not (bottom) been through the RT step.
10.2.2 Breast primary tumours
Samples which were obtained from 20 primary breast tumours, were used
to prepare RNA and to detect the expression of ET-1, -2 and -3 peptides
and ETa-R, ETb-R receptors. Figures 10.12 and 10.13 illustrate the
expression of mRNA for ET-1 from all 20 tumours while 12 out of 20
expressed mRNA for ET-2 (lanes 1, 2, 3, 5, 6 and 7 in figure 10.12 and lanes
1, 2, 3, 8, 9 and 10 in figure 10.13) and 16 out of 20 mRNA for ET-3 (lanes 2,
4, 5, 6, 7, 9 in figure 10.12 and all 10 in figure 10.13). Southern blotting
experiments were performed using radiolabeled probes for ET-1, ET-2
and ET-3 for the same 10 tumour samples shown in figure 10.12 (figure
10.14). These have shown ten bands in identical positions with ET-1, 7
bands for ET-2 (six of which were at identical positions with the ET-2
bands in the PCR gel and a band for sample 8) and 6 bands for ET-3 at the
same positions as seen in figure 10.12. Figures 10.15 and 10.16 illustrate
the results of the expression of ETa and ETb receptors in the same 20
tumour samples. Results demonstrate the expression of ETa-R and ETb-R
from all 20 primary tumours. Figure 10.17 shows the results of probe
labelling using radiolabeled ETa-R and ETb-R oligonucleotides which
showed that all the bands shown in figure 10.15 represent ETa-R and ETb-
R mRNA. In figure 10.16 (ETB-Ra) samples from the same primary
tumours were tested as negative controls for the expression of ETb-R
without passing through the RT-step (ETB-Ra) and no bands were
detected suggesting that RNA samples were not contaminated by DNA.
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eta-r
l 1 234 56789 10 11
ETa-r
Figure 10.11: Photograph of an agarose gel of 30 cycle PCR products of 10 primary ovarian
tumour samples, (top) Lane L: lOObp DNA marker; lanes 1-10 tumour samples 1-10.
(bottom) same as top but samples have not been through the RT step (negative controls).
The predicted sizes were: ET^-R: 368 bp.
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Figure 10.12: Photograph of an agarose gel of 30 cycle PCR products of 10 primary breast
tumour samples, (top) Lane L: lOObp DNA marker; lanes 1-10 tumour samples 1-10. The
predicted sizes were: ET-1: 582 bp, ET-2: 197 bp, ET-3: 493bp.
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Figure 10.13: Photograph of an agarose gel of 30 cycle PCR products of 10 primary breast
tumour samples, (top) Lane L: lOObp DNA marker; lanes 1-10 tumour samples 11-20. The







Figure 10.14: Southern blotting photograph showing the hybridisation of mRNA bands
from 10 primary breast cancer samples detected by RT-PCR with specific oligonucleotides







Figure 10.15: Photograph of an agarose gel of 30 cycle PCR products of 10 primary breast
tumour samples, (top) Lane L: lOObp DNA marker; lanes 1-10 tumour samples 1-10. The
predicted sizes were: ETa-R: 368 bp, ETg-R: 530 bp, C-actin: 262bp.
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Figure 10.16: Photograph of an agarose gel of 30 cycle PCR products of 10 primary breast
tumour samples, (top) Lane L: lOObp DNA marker; lanes 1-10 tumour samples 11-20 (ETg-
Ra; same samples but not taken through the RT step). The predicted sizes were: ET^-R: 368








Figure 10.17: Southern blotting photograph showing the hybridisation of mRNA bands
from 10 primary breast cancer samples detected by RT-PCR with specific oligonucleotides
designed against ETa-R and ETb-R.
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10.2.3 Expression of ET peptides and receptors in normal breast samples
Three histologically proven normal breast samples were used to test ET
peptide and receptor expression and to compare results with expression in
breast cancer samples. Figure 10.18 shows the expression of ET-1 in all 3
samples, that of ET-2 and ET-3 in 2 samples (lanes: 1, 2 for each). In the
same figure, mRNAs for both ET-receptors and fi-actin were shown to be
expressed in all 3 samples. Negative controls (lane 4; sample 1 for ET-1
and ET-2, sample 2 for ET-3 and ETa-R and sample 3 for ETb-R and fi-
actin) did not show any bands.
Table 10.1 summarises the results of the expression of ETs and ET-
receptors presented in this chapter.
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Figure 10.18: Photograph of an agarose gel of 30 cycle PCR products of 3 histologically
proven normal breast samples. Lane L: lOObp DNA marker; lanes 1-3 samples 1-3; lane 4:
negative control (not through the RT step). The predicted sizes were: ET-1: 582 bp, ET-2:
197 bp, ET-3: 493bp, ETa-R: 368 bp, ETg-R: 530 bp, C-actin: 262bp.
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mRNA source et-1 et-2 et-3 eta-r ETB-r
ovarian cancer cells 2/2 0/2 2/2 2/2 2/2
ovarian fibroblasts 3/4 0/4 0/4 3/4 4/4
breast cancer cells 4/4 0/4 3/4 0/4 3/4
breast fibroblasts 2/2 0/2 0/2 2/2 2/2
ovarian tumours 10/10 6/10 9/10 10/10 2/10
breast tumours 20/20 12/20 16/20 20/20 20/20
normal breast 3/3 2/3 2/3 3/3 3/3
Table 10.1: Summary of the results of the expression of ET-1, ET-2, ET-3, ETa-R and ETg-R




Results presented in this chapter show the mRNA expression for ET-1,
ET-2 and ET-3 peptides and the two ET-receptors (ETa-R and ETg-R) in
ovarian and breast cancer cells and fibroblasts as well as from 10 ovarian,
20 breast primary tumour samples and 3 normal breast samples.
RT-PCR technology using RNA from PE04 and PE014 ovarian cancer cell
lines demonstrated the expression of mRNA for ET-1 and ET-3 in these
cell lines. These results are consistent with observations in chapter 4
where it was concluded that the same cell lines secrete immunoreactive
ET-l-like material. Because mRNA for ET-3 was detected by RT-PCR and
the cross-reactivity of ET-3 with the radioimmunoassay used for ET-1
detection, was calculated to be 8.3% it is possible that ET-3 could account
for part of the ET-l-like material detected by RIA assuming that the
detected mRNA was translated into protein. RT-PCR also detected the
expression of mRNA for both ET receptor subtypes in these two cell lines.
Such results would be inconsistent with the conclusions stated in
previous chapters which suggested that PE014 cells, express the ETa-R
type. However, for PE04 cells results shown in previous chapters
suggested the expression of ETa-R and the possible expression of a small
amount of ETb-R which would be consistent with the expression of
mRNA for both receptors.
Results from the RT-PCR experiments using RNA from 4 ovarian
fibroblast cell lines suggested the expression of mRNA for ET-1 and ET-3.
Such results are in contrast with data from the radioimmunoassay study
(chapter 4) in which conditioned media from 3 of these cell lines (PE012F,
PE014F and PE027F) did not appear to contain ET-l-like material.
However, the detection of ET-l-like peptide would only be possible if the
mRNA was translated into protein and it may be that levels of ET were
below the level of sensitivity in the assay.
RT-PCR analysis also demonstrated the expression of mRNA for both
types of receptors in PE012F, PE014F and PE027F fibroblast cell lines
(except for ETa-R in PE09F). These results would be in accordance with
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the expression of ETa and ETb receptors in all these cell lines reported in
previous chapters.
Results from the breast cancer cell lines suggested the expression of
mRNA for ET-1 and ET-3 in all 4 cancer cell lines (except for ET-3 mRNA
in T47D cells). Results from the radioimmunoassay experiments using
conditioned media from MDA-MB-231, T47D and ZR-75-1 but not MCF-7
cells suggested the expression of ET-1-like material by all 3 cancer cell
lines which is consistent with what is observed at the RNA level. The
cross-reactivity of ET-3 with the RIA assay could mean that a component
of the ET-l-like material is ET-3. Results from RT-PCR also suggested
that none of those 4 breast cancer cell lines expressed mRNA for ET-
receptors which is consistent with the results presented in previous
chapters.
Breast fibroblast cell lines BRF1 and BRF2 were shown to express mRNA
for ET-1 but not ET-2 or ET-3. The expression of ET-1 mRNA is in
contrast with the absence of ET-l-like material from conditioned media of
both cell lines (chapter 4) which might suggest that the RNA detected is
not translated into protein. However, the expression of mRNA for both
ETa-R and ETb-R were in accordance with results from the binding
experiments and growth results analysed in previous chapters.
RT-PCR analysis suggested the expression of ET-1 (in 10/10), ET-2 (in
6/10), ET-3 (in 9/10), ETa-R (in 10/10) and ETb-R (in 10/10) in primary
ovarian tumour samples. Since the tumours consist of mainly epithelial
cells then these results are in accordance with those observed in the
ovarian cancer cell lines.
Results from primary breast tumour samples showed the expression of
mRNA for all 3 ET-peptides (in 20/20, 12/20 and 16/20 for ET-1, ET-2 and
ET-3 respectively) and both ET-receptors (in all 20 samples). Although the
mRNA expression for ET peptides was seen in breast cancer cell lines no
detection of mRNA for receptors was detected. This could be explained by
the possible presence of fibroblasts within the tumour samples.
The use of normal breast samples for the detection of ET-peptide and
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receptor suggested that the presence of mRNA for ET-1, -2 and -3 and both
ET-receptors. Therefore no difference in terms of expression was
observed between normal and cancer samples. However, results are
consistent with the suggestion that differences are quantitative and breast
cancer cell lines secrete higher amounts of ET-1 than either benign or
normal breast cells (Yamashita et al., 1991).
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Chapter 11: Expression of ETs in ovarian and breast primary tumour
samples as detected by immunohistochemistry
The expression of ETs in ovarian and breast cancer tumours was
investigated using paraffin-fixed sections from 15 ovarian and 15 breast
primary tumour samples. Details regarding the methodology and the
antibodies used are described in section 2.2.8.
11.1 ET expression in ovarian tumours
i) ET-1
The results on the expression of ET-1, ET-2 and ET-3 in ovarian primary
tumour samples are summarised in table 11.1.
ET-1 expression was investigated in 15 primary tumour samples and in
both tumour and stromal areas. Four tumour samples exhibited negative
staining both in tumour and stromal compartments. From the 11
tumour samples that stained positively for ET-1 expression in the tumour
areas, two were strongly positive, five were weakly positive and 4 samples
showed borderline staining. Stromal ET-1 staining was observed in 6 of
the 15 samples and its intensity was lower or similar to levels observed in
the tumour areas. Staining was generally diffuse, mostly cytoplasmic and
occasionally granular. A typical section stained positively for ET-1 is
shown in figure 11.1.
ii) ET-2 and ET-3
The expression patterns of ET-2 and ET-3 were investigated in 7 primary
ovarian tumour samples. Positive staining was diffuse and mainly
cytoplasmic. ET-2 expression was observed in the tumour compartment
in 5 of the 7 samples, and staining was weakly positive in 3 and
borderline in the other 2 samples. Only one of the samples showed
borderline staining in the stromal areas. ET-3 expression was positive in
the tumour areas of 5 primary tumour samples, 2 of which exhibited
weak staining and 3 borderline staining. ET-3 staining in the stromal




ET-1 ET-2 ET-3 negative control
tumour stroma tumour stroma tumour stroma tumour stroma
HOV 1 + ± + - + - - -
HOV2 + - ND ND ND ND - -
HOV3 + - ND ND ND ND - -
HOV4 ++ - - - ± - - -
HOV5 + - + - ± - - -
HOV6 ± + - - - - - -
HOV7 ± ± ± ± + ± - -
J HOV8 ++ ++ + - - - - -
[ HOV9 - - ND ND ND ND - -
|HOV10 ± ± ND ND ND ND - -
HOV11 + ± ± - ± ± - -
HOV 12 ± - ND ND ND ND - -
HOV13 - - ND ND ND ND - -
HOV14 - - ND ND ND ND - -
HOV15 - - ND ND ND ND -
Table 11.1: Results of the expression of ET-1, -2 and -3 from ovarian primary tumour
samples (HOV). Intensity of staining is expressed as: strong positive (++), weak positive
(+), borderline (±) and negativef-) (ND: not done).
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Figure 11.1s Positive staining of an ovarian primary tumour section with ET-1 antibody.
1%
Examples of positive staining for ET-2 and ET-3 are shown in figures 11.2
and 11.3.
Sections which were treated with tris-buffer instead of ET antibodies
(negative controls) were stained negatively as shown in figure 11.4.
11.2 ET expression in breast tumours
Table 11.2 summarises the results of the expression of ET-1, ET-2 and ET-3
in breast primary tumours.
i) ET-1
The expression of ET-1 in the tumour and stromal areas of 15 primary
breast tumour samples was investigated.
Two tumour samples stained negatively in both tumour and stromal
areas. ET-1 was detected in the tumour areas of 13 of the 15 tumours, 5 of
which stained strongly positive, 5 others weakly positive while 3 samples
exhibited borderline staining. Weak ET-1 staining in the stromal areas
was observed in one sample, borderline staining in 4 samples and no
positive staining in the rest of the samples. An example of positive ET-1
staining is shown in figure 11.5.
ii) ET-2 and ET-3
The expression of ET-2 and ET-3 was investigated in 6 primary breast
tumour samples. Two breast tumour samples exhibited weak staining
for both ET-2 and ET-3 in the tumour but not in the stromal areas and a
third sample showed borderline staining for ET-3 in the tumour area.
Examples for ET-2 and ET-3 positive staining are shown in figures 11.6
and 11.7 respectively.
Control samples (treated with tris-buffer instead of ETs) exhibited no
positive staining.
197
• •- g&t J
>. «%■«. a* %« ■ a*
**, , - 'A «» » » ,' J
* - ^ -
,*. :4 sii <w * • - ■ * . •
.' * •' . ■ ■ , • *, *
'%•-»% *' «h _/ /-•#** ,%• *** x <'j
*
c'1 ■*"*'» : 4 * - " J» * » k ■
v<VV.t-. _ . ;V»* «.• j ... ,v ' '• • >• v.?& * *-? • i , - -'
ro v ' ' ■
•• ' «' *
. •
,. I
\ v ♦' . '
' "IV* * < "' •-• •» *' •"•*#■ •' sv"
■
. •
••••-v: •-<•.- ' 1 • j,**V.«*!**■£. -/ >V
*
#4






« » # 4»<*;












"% . • -A»
'* , *.
• -




Figure 11.2: Positive staining of an ovarian primary tumour section with ET-2 antibody.
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Figure 113: Positive staining of an ovarian primary tumour section with ET-3 antibody.
199
Figure 11.4: Absence of staining of an ovarian primary tumour (tris buffer used as negative
control).
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| Sample ET-1 ET-2 ET-3 negative controltumour stroma tumour stroma tumour stroma tumour stroma
BC1 + - + - + - - -
BC2 ++ + ND ND ND ND - -
BC3 ± - - - - - - -
BC4 ± ± ND ND ND ND - -
BC5 - - - - - - - -
BC6 ++ ± ND ND ND ND - -
BC7 ++ ± ND ND ND ND - -
BC8 ++ - ND ND ND ND - -
BC9 + - ND ND ND ND - -
BC10 + - + - + - - -
BC11 ++ ± ND ND ND ND - -
BC12 ± - - - - - - -
1 6013 - - ND ND ND ND - -
| BC14 + - - - ± - - -
| BC15 + - ND ND ND ND - -
Table 11.2: Results of the expression of ET-1, -2 and -3 from breast primary tumour samples
(BC). Intensity of staining is expressed as: strong positive (++), weak positive (+),
borderline (±) and negativef-) (ND: not done).
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Figure 113: Positive staining of an breast primary tumour section with ET-1 antibody.
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Figure 11.6: Positive staining of an breast primary tumour section with ET-2 antibody.
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Figure 11.7: Positive staining of an breast primary tumour section with ET-3 antibody.
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11.3 Discussion
The expression of ETs in ovarian and breast primary tumour samples was
investigated immunohistochemically using commercially available ET-1,
ET-2 and ET-3 antibodies who according to our radioimmunoassay
studies show small crossreactivities with the other ET peptides.
In ovarian tumours, ET-1 was detected in the tumour areas of the
majority of samples (11/15) while some stromal staining was observed in
6 of the same 11 samples. ET-2 and ET-3 weak and borderline staining
appeared in 5/7 tumour samples and only in the tumour areas (with the
exception of borderline staining in 1 sample for both ET-2 and ET-3).
Radioimmunoassay data (chapter 4) for ovarian cancer and fibroblast cell
lines suggested the expression of ET-l-like material from cancer cells but
not fibroblasts. Results presented in this chapter seem to be in accordance,
showing that most of the staining was observed in the epithelial areas of
the samples with generally more diffuse staining in the stromal areas.
Thus the weak staining observed in the stromal areas of these samples
could represent ET peptides which originated in cancer cells and have
been transported to stromal areas. As described in previous chapters,
receptors for ETs are expressed in both ovarian epithelial and fibroblast
cells and both cell types in vivo may therefore be under ET regulation.
In breast tumours, ET-1 expression was observed in the epithelial
components of the majority of samples (13/15) while predominantly
borderline staining was observed in the stromal compartments of 5/15
samples. ET-2 and ET-3 expression was observed in 2 and 3 (respectively)
of the 6 samples tested. These results suggest that ETs are mainly
expressed in breast tumour compared to stromal cells and these
observations are in accordance with previously published data (Baley et
al., 1990). RIA results presented earlier in this thesis, also indicated the
production of significant amounts of ET-l-like material from epithelial
breast cancer cells but not fibroblasts (chapter 4). Baley et al., (1990) have
also suggested that ET receptors are expressed in breast fibroblasts but not
in epithelial tumour cells. Binding experiments shown in chapter 5
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their biological effects, the peptides need to interact with the fibroblasts.
Such a phenomenon could explain (as in ovarian primary tumour
samples), the generally weaker staining in the stromal areas of some
breast tumour samples.
Five of the HOV samples that were used in this immunohistochemistry
study (HOV 1, 4, 5, 7 and 11) came from the same tumour as samples used
for the RT-PCR experiments. Immunohistochemistry data showed that
5/5 samples stained positively for ET-1,4/5 for ET-2 and 5/5 for ET-3. PCR
data showed that the same 5 samples all expressed ET-1 ET-2 and ET-3
mRNA.
Results from five of the BC samples used for immunohistochemistry
(BC1, 3, 5, 10 and 14) regarding the expression can be compared with
results of the PCR experiments since samples from the same primary
tumours were used. In this chapter it was shown that 4/5 stained
positively for ET-1, 2/5 for ET-2 and 3/5 for ET-3. RT-PCR data showed
that 5/5 expressed ET-1 mRNA, 3/5 ET-2 mRNA (the same as in
immunohistochemistry plus BC14) and 5/ 5 samples expressed ET-3.
For some of the primary tumour samples, mRNA was detected for a
paticular ET peptide but no staining was observed with
immunohistochemistry. Since there were no HOV or BC tumour
samples which stained positively for any of the ET peptides but showed
no expression of mRNA, it is possible that the mRNA observed was not
translated into protein. However, such results could also be explained by
the very high sensitivity of the PCR method.
These data show that results from the two methods were consistent
(accounting for the fact that one shows expression in terms of mRNA and
the other in terms of protein).
In general, and despite the restricted number of tumour samples used
(which did not allow detailed analysis and correlation of tumour types
with expression of the peptides) and the absence of proven commercially
available ET-receptor antibodies, results presented above represent the
first data suggesting the expression of ET-1, ET-2 and ET-3 in ovarian
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first data suggesting the expression of ET-1, ET-2 and ET-3 in ovarian
tumours and the restricted expression of ET-2 and ET-3 in breast primary
tumours.
However, results obtained by these studies should be handled with
caution due to the fact that the specificity of the human monoclonal ET-1,
ET-2 and ET-3 antibodies was not tested and that the negative control
used in these experiments was tris buffer. Other confirmatory studies
should have been undertaken. These include employing negative
controls such as cheking the positivity of blood samples from the same
species as the antibodies were raised against but from animals that had
not been immunised with the antibody and checking the specificity of the
antibodies by western blot analysis.
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Chapter 12: Conclusions
In the previous chapters of this thesis, data on the expression of the ETs,
their receptors and their effects on the growth of ovarian and breast
cancer have been presented and discussed. In this final chapter an
attempt has been made to combine these results and provide models of
these ET in these two diseases.
12.1 Endothelins in ovarian cancer
The basic aim of this study was to determine whether ETs play a role on
the growth of ovarian and breast cancer. Growth regulation of cells by a
particular peptide requires: a) the presence of sufficient concentrations of
the peptide, b) the presence of cellular receptors to mediate the effects of
the peptide and c) an effect on growth (generally mitogenesis) following
the binding of the peptide to receptors.
In this study it has been shown that the PE014 and PE04 ovarian
carcinoma cell lines express mRNA for ET-1 and ET-3 and secrete ET-1
like peptide. ET receptors are expressed in both these cell lines at the
mRNA and protein levels and these appear to be functional in so far as
addition of both ET-1 or ET-2 are mitogenic to these two cell lines. The
concentrations of ET-l-like peptide produced by PE014 cells are 10-fold
greater than the concentration produced by PE04 cells and are predicted to
be growth stimulatory in that exogenous addition of picomolar levels
stimulated growth of PE014 cells. It is feasible therefore that an autocrine
growth stimulatory loop is present in PE014 cells but not necessarily in
the PE04 line. Consistent with this hypothesis, interruption of the loop
at the receptor level (ETa-R) either by use of a receptor blocking
antagonist (BQ123) or an antisense oligonucleotide (inhibiting the
synthesis of the receptor) produced growth inhibition of cells growing in a
serum-free environment and in which the only source of endothelin
cells themselves. Such effects were not observed in the PE04 cell line
consistent with a lower level of production being insufficient to produce
mitogenesis.
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Experiments with ovarian fibroblast cell lines indicated that these cells
produce ET-1 mRNA but not detectable levels of protein. However these
cells do possess ET receptors as detected at both the mRNA and protein
levels and were growth stimulated by all 3 ET isoforms. To examine the
interaction of these 2 cell types, a co-culture model was used. The results
obtained suggested that the endothelins secreted by the epithelial cancer
cells produced growth stimulation in the fibroblasts and these effects
could be partially blocked by ET receptor antagonists. These data indicate
that in addition to autocrine control, paracrine regulation may also apply.
In support of the view that these models are relevant to growth
regulation in primary tumours, RT-PCR and immunohistochemical
studies of a series of primary tumours indicated the expression of all 3
forms of ET in the majority of primary together with both forms of
receptors as detected by RT-PCR.
A single report has previously been published on the role of ETs in
ovarian cancer (Bagnato et al., 1995). These investigators demonstrated
the expression of immunoreactive ET-1 by ovarian carcinoma cell lines,
expression of ET-receptors and growth stimulation by ET-1 supporting the
findings described in this study.
Combining these results, a potential model of the effect of ETs on the
growth of ovarian cancer has been proposed (figure 12.1). According to
this, ET peptides secreted by the epithelial cancer cells can act through an
autocrine system and stimulate the growth of the cancer cells while the
same peptides acting through an alternative or additional paracrine
system also stimulate the growth of surrounding fibroblasts. Since it was
demonstrated that other molecules (bombesin, IL-6) stimulate the
production of ETs from cancer cells (chapter 4) and that ETs in co-culture
experiments accounted for a partial stimulation of the growth of cancer
cells and fibroblasts, it is almost certain that other factors modulate the









Figure 12.1: A diagrammatic representation of the suggested model of the involvement of
ETs on the growth of ovarian cancer cells and fibroblasts. ETs which are shown to be
secreted exclusively by the epithelial cells, can bind to both ETa-R and ETb-R ET-
receptors on fibroblasts and exert mitogenic effects through a paracrine system of action
and such effects can be blocked using specific ET-receptor antagonists (BQ123 for ETa-R and
BQ788 for ETg-R). However, ET peptides released by cancer cells can bind ETa-R and
possibly ETb-R expressed by the same cells and therefore exert mitogenic effects through
an autocrine system of action. Such effects were also blocked with the addition of BQ123
and ETa-R antisense [(+): stimulation, (-): inhibition)].
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12.2 Endothelins in breast cancer
Results presented in the previous chapters of this thesis have shown that
MDA-MB-231, T47D and ZR-75-1 breast cancer cells express mRNA for
ET-1 and ET-3 and produce immunoreactive ET-l-like peptide. Regarding
the expression of ET receptors, RT-PCR and ligand binding experiments
have shown that no ET-receptor mRNA or peptide was expressed in these
cell lines. Consistent with the absence of ET-receptors, exogenous
addition of ET peptides had no effect on the growth of these cells.
Therefore, and in comparison to what can be observed in ovarian cancer,
no autocrine control of growth can be in place in breast cancer cells.
Breast fibroblast cell lines BRF1 and BRF2 were shown to express mRNA
for ET-1 and not for ET-2 and ET-3, but no ET-l-like protein was detected
in the conditioned media of such cells. RT-PCR and ligand binding
assays demonstrated the expression of mRNA and protein for ET
receptors by breast fibroblasts.
The exogenous addition of ET-1, ET-2 and ET-3 to breast fibroblasts
resulted in activation of growth suggesting that in addition to what has
already been suggested for ET-1 (by other studies), ET-2 and ET-3 peptides
can also stimulate the growth of breast fibroblasts. Consistent with these
results, addition of ET-receptor antagonists (BQ123 for ETa-R and BQ788
for ETg-R) blocked partially the mitogenic effects of ET peptides. The
levels of ET-l-like peptide secreted by the breast cancer cells were
comparable to the levels of exogenous ET-1 that produced mitogenic
effects on breast fibroblasts consistent with a possible regulation of growth
of fibroblasts by cancer cells in breast cancer. Experiments with these two
types of cells in co-culture have shown that both cell types grow faster in
such environment compared to growth in isolation. The use of specific
ET receptor antagonists, showed data consistent with the involvement of
ETs in paracrine regulation of growth.
RT-PCR data using primary breast tumour and normal samples suggested
the expression of ET-1, ET-2, ET-3 and ET-receptor mRNA and
immunohistochemistry data on primary tumour samples suggested the
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presence of mostly ET-1 and in some cases ET-2 and ET-3 in epithelial but
not stromal areas of the tumours.
Previously reported data have demonstrated the production of ET-1 from
breast cancer cell lines and primary tumours and that ET-1 release was
higher in tumour compared to normal and borderline breast cells
(Kusuhara et al., 1990; Yamashita et al., 1991). The production of ET-1
from breast cancer cell lines has been shown to be modulated by several
factors including bombesin, glucocorticoids (Schrey et al., 1992) and IL-6
(Yamashita et al., 1993a). Studies on ET-receptors have suggested that
they are expressed in breast fibroblasts but not in epithelial cells (Baley et
al., 1990; Patel et al., 1995) while ET-1 has been shown to exert mitogenic
effects on breast fibroblasts (Patel et al., 1995).
Results discussed in this study and those reported before are consistent
with a paracrine regulation of growth by endothelins secreted by the
epithelial cancer cells and having mitogenic effects on breast fibroblasts.












Figure 12Jh A diagrammatic representation of the suggested model of the involvement of
ETs on the growth of breast cancer cells and fibroblasts. ETs which are shown to be secreted
exclusively by the epithelial cells, can bind to both ETa-R and ETb-R ET-receptors on
fibroblasts and exert mitogenic effects through a paracrine system of action. Such effects
can be blocked using specific ET-receptor antagonists (BQ123 for ETa-R and BQ788 for ETb-




Experiments described in this thesis provide information regarding only
the growth effects of endothelins and the expression and secretion of
major components of the mechanisms proposed (release of ETs, ET-
receptor expression) due to the restricted time available. Future work on
the same theme could investigate the possible differences in the role of
each of the three ET peptides and their receptors. The possible interactive
role of different peptides and growth factors (insulin, TGF-fi, IGF-I and
IGF-II) which may influence the secretion and mitogenic effects of ETs
and the signalling mechanisms by which such pathways are activated
could be further investigated in both systems following suggestions that
some of these factors play a role in the accumulation (TGF-fi), secretion
(bombesin, IL-6), metabolism (prostaglandin E2) and paracrine interaction
(IGF-I, IGF-II) of endothelins in other systems (Schrey et al., 1992, 1995;
Yamashita et al., 1993). The expression of "big" endothelins and the
presence and action of endothelin converting enzyme (ECE) which may
regulate the tissue ET levels by processing "big" ETs to active peptides is
another area which requires further investigation and has been suggested
in breast cancer cell lines (Patel and Schrey., 1995). Further studies could
have been focused on the activation of PLC, PLD, PLA2 and MAP-kinase
signalling pathways activated by ETs and the activation of proto-
oncogenes such as c-fos, c-myc and c-jun already suggested by previous
studies (Simonson et al., 1993; Tabuchi et al., 1994). Finally, the
suggestions of a possible role for ETs in angiogenesis of ovarian and breast
tumours and their possible interactions with adhesion molecules could
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